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ABSTRACT 
Intramuscular gene transfer of Apolipoprotein E (ApoE) to 
reverse hyperlipidaemia and atherosclerosis in ApoE- 
deficient mice
Plasma ApoE has multiple atheroprotective actions, including clearance o f cholesterol- 
rich remnant lipoproteins, and is an attractive gene therapy candidate to treat 
atherosclerosis. Here, I focus on the single intramuscular injection o f an ApoE- 
expressing vector, non-viral DNA (plasmid) or adeno-associated virus (AAV), as a safe 
and effective treatment to alleviate hypercholesterolaemia and atherosclerosis in ApoE- 
deficient (ApoE ") mice. Firstly, I constructed expression plasmids harbouring human 
ApoE3 cDNA, driven by two muscle-specific (CK6 and C512) and one ubiquitous 
(CAG) promoter. The CAG-driven plasmid was injected into tibialis anterior muscles, 
pre-treated with hyaluronidase, o f young A poE " mice and, provided the injection site 
was electropulsed, gave strong local expression o f ApoE3 protein at 1 week 
(13.38±7.46jig ApoE3 per muscle). This amount was much greater than the CK6- and 
C512-driven plasmids (0.61±0.38 and 0.45±0.38/ig, respectively), but in all mice 
plasma ApoE3 levels were below the detection limit (<15ng/ml) and did not ameliorate 
the hyperlipidaemia. Next, I generated both single-stranded (ss) and self- 
complementary (sc) AAV2/7 vectors. At 1, 2 and 4 weeks, ApoE was readily measured 
in the plasma o f A poE '' mice injected with the ssAAV2/7.CAG vector, reaching levels 
o f 1.4/xg/ml, whereas plasma ApoE was again undetected after administration o f the 
CAG-driven plasmid . By contrast, both ssAAV2/7 and scAAV2/7 vectors driven by 
the muscle-specific promoters performed poorly and ApoE could not be detected in 
plasma. Therefore, for my final experiment I pseudotyped the ssAAV2.CAG.ApoE3 
vector with the robust serotypes 8 and 9, and directly compared their efficiency with 
ssAAV2/7.CAG.ApoE3 in A poE " mice. After 1 week plasma ApoE had reached 
2jig/ml in ssAAV2/7 and ssAAV2/8-treated animals, and persisted at l-2pg/m l 
throughout the 13 week study, whereas the ssAAV2/9 vector was less effective and 
gave only 0.5pg ApoE/ml. Disappointingly, however, these concentrations o f plasma 
ApoE were still insufficient to have hypolipidaemic effects or to inhibit plaque 
development in the brachiocephalic artery. In conclusion, although electropulsation 
enhanced plasmid-mediated transgene expression from skeletal muscle, rAAV was a 
more efficient gene transfer vector and modest additional optimisation should provide 
therapeutic levels o f ApoE3 in plasma.
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Chapter 1:
General Introduction
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1 GENERAL INTRODUCTION
1.1 Epidem iology o f  cardiovascular disease
The prevalence of cardiovascular disease (CVD) is increasing in developing countries 
and Eastern Europe and the incidence of obesity and diabetes is rising in the Western 
world; CVD has, therefore, been predicted to be the leading cause of death globally 
within the next 15 years [1]. In the UK, CVD accounted for around 216,000 deaths in 
2004, half of which were caused by coronary heart disease (CHD) and a quarter from 
stroke, making it the main cause of mortality. Although death rates from CHD and 
stroke have been falling since the late 1970s, the decline has not been as fast as that in 
other Western countries and the UK has, thus, one of the highest CVD death rates 
among developed countries (Coronary Heart Disease statistics, BHF, 2006).
Reip<ratc*y dfcea*«
13% Injurtai and poisoning
AJI odwr causes 16%
Coronary heart disease 
21%Other CVD 8%
Stroke8%
Figure 1-1. Causes of death in men in 2004 (Coronary Heart Disease statistics, 
BHF, 2006)
1.2 A therosclerosis
Atherosclerosis, the principle cause of CHD and stroke in the Western world, has 
multiple genetic and environmental contributions, such as age, gender, smoking, 
hypertension, diabetes, stress and high cholesterol. These risk factors cause injury to 
the endothelial lining of the arterial wall and what follows is an inflammatory response 
involving T lymphocytes, monocytes, cytokines and chemokines. The normal 
homeostatic properties of the endothelium are altered leading to changes in the
15
permeability of the arterial wall and increased expression of cell surface adhesion 
molecules and cytokine production [2].
Adhesion o f circulating leukocytes to the endothelium is one of the earliest steps in 
atherogenesis, suggesting the involvement of an immune process [3]. Low-density 
lipoprotein (LDL) undergoes oxidative modifications in the intima which stimulates 
endothelial cells to produce proinflammatory molecules, including adhesion molecules 
and growth factors and these in tum trigger the entry o f T-lymphocytes and monocytes 
into the arterial wall [4]. Adhesion molecules, such as vascular cell adhesion molecule- 
1 (VCAM-1) and P-selectin, on the surface o f  the endothelial cells interact with their 
counterligands on leukocytes [5]. Chemotactic molecules, such as monocyte 
chemotactic protein-1 (MCP-1), are also induced by endothelial cells and
Apolipoprotein (Apo) E deficient mice (ApoE") mice with a disruption in the MCP-1 
gene, or its receptor CCR2 show a marked reduction in atherosclerotic lesions [6]. This 
suggests that the interaction of the MCP-1 protein with the CCR2 receptor contributes to 
monocyte recruitment in atherosclerosis. Once firmly adhered, the leukocytes migrate 
across the endothelial monolayer into the intima where they proliferate and the 
monocytes differentiate into macrophages. This is a critical step in atherosclerosis and a 
study involving osteopetrotic mice which have a natural mutation in their macrophage 
colony-stimulating (M-CSF) gene confirms the role of macrophage in lesion 
development; these mice were significantly resistant to atherosclerosis [7].
Extensive oxidation of LDL leads to fragmentation o f the Apolipoprotein B (ApoB) 
component, which renders the particle unable to bind to the LDL receptor (LDL-R). 
Oxidised LDL (Ox-LDL), instead, binds to the scavenger receptors, SR-A and CD36, 
expressed on macrophages and smooth muscle cells [8]. It has been reported that 
transgenic mice deficient in CD36 and SR-A, do not accumulate cholesteryl esters from 
modified lipoproteins in macrophages [9], The cholesteryl ester-engorged macrophages 
eventually become foam cells [10] and it is this accumulation of lipids and foam cells in 
the intima that form the earliest lesions o f  atherosclerosis, termed fatty streaks. 
Macrophages also undergo apoptosis throughout all stages o f  atherosclerosis and an in 
vivo study has demonstrated that in early lesions macrophage death is beneficial as both 
lesion size and macrophage load are reduced [11]. Conversely, it has recently been 
reported that an early form o f Ox-LDL, minimally oxidised LDL (mmLDL), may offset
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the apoptotic effect of extensively Ox-LDL on macrophages, thus, prolonging their 
survival in lesions [12].
As the atherosclerotic process continues additional monocytes and T-lymphocytes are 
attracted to the lesion by pro-inflammatory cytokines, such as tumour necrosis factor-a 
(TNF-a) and interleukin-ip (IL-ip) [13]. TNF-a is upregulated in atherosclerotic 
plaques and when the activity o f  this gene is blocked in ApoE-deficient mice, lesion 
size and expression o f intracellular adhesion molecule-1 (ICAM-1), VCAM-1 and 
MCP-1 are reduced [14]. Other cytokines, interleukin-10 (IL-10) and transforming 
growth factor p (TGF-p), are thought to have a protective, anti-inflammatory role in 
atherosclerosis. Overexpression o f  IL-10 in LDL-R deficient mice significantly reduces 
lesion size [15] and in a mouse model where TGF-P signalling is blocked in T-cells, the 
disease process is accelerated [16].
The inflammatory response also stimulates the migration and recruitment o f  smooth 
muscle cells (SMCs) from the media into the intima resulting in a fibro-fatty lesion [17]. 
Following further enlargement and restructuring, combined with continued lipid 
accumulation, an advanced, complex plaque develops which is characterised by a 
central lipid-rich necrotic core bounded on its lumen side by a fibrous cap containing 
SMCs and connective tissue. Eventual rupture and destabilisation of the plaque is 
initiated by the activation of macrophage, T-cells and mast cells, which release 
inflammatory cytokines, proteases, coagulation factors, free radicals and vasoactive 
molecules. Matrix metalloproteinases (MMPs) released from macrophage are 
implicated in the rupture of plaques due to their ability to degrade extracellular matrix 
proteins and their increased expression in vulnerable plaques [18]. A recent study has 
demonstrated that overexpression o f tissue inhibitor o f  metalloproteinase (TIMP)-2 
attenuates plaque development and destabilisation [19]. Other studies, however, have 
added controversy to the role of MMPs and have shown that some enhance plaque cap 
growth and stability [20]. Plaque rupture and thrombosis subsequently leads to major 
clinical complications such as myocardial infarction and stroke [10]
1.3 Lipoproteins and their metabolism
Initially a- and p-migrating lipids were discovered by electrophoresis of human plasma 
[21] and this was followed, in 1945, by the isolation of P-migrating lipoproteins using
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an ultracentrifugal flotation technique [22]. Lipoproteins were further classified into 5 
sub-fractions based on their flotation densities and were named, chylomicrons, very low 
density (VLDL), intermediate density (IDL), low density (LDL) and high density 
(HDL) lipoproteins [23]. The general lipoprotein structure comprises a core of 
triglycerides and cholesteryl esters, which are surrounded by a single layer of 
phospholipids, free cholesterol and apolipoproteins. The latter family o f  proteins 
includes Apo(a), AI, All, AIV, AV, B48, B100, Cl, CII, CIII and E and has a major 
function in lipid transport and metabolism.
1.3.1 Metabolism of triglyceride rich lipoproteins
Apolipoprotein B100 and E (ApoBlOO, ApoE) are synthesised in the liver and are 
important mediators in the binding o f lipoproteins to their receptors; ApoBlOO binds 
only to the LDL-R, while ApoE binds to both the LDL-R and LDL-receptor related 
proteins (LRP) [24;25]. ApoB48, in contrast, is synthesised in the intestine and has a 
major role in chylomicron metabolism. Chylomicrons are large triglyceride rich-dietary 
lipids that are secreted by intestinal mucosal cells into the lymph and then rapidly 
lipolysed by lipoprotein lipase (LPL). The resulting free fatty acids are delivered to 
peripheral tissues, while the remnant particles are taken up by the liver, first via 
attachment to the cell surface molecules, heparan sulphate proteoglycans (HSPGs), 
ApoE and hepatic lipase (HL), followed by transfer to the LDL-R and LRP [26] (Figure 
1-2). Triglycerides and cholesterol are synthesised by the liver and secreted as VLDL, 
which are large due to their high triglyceride content. Once in the circulation they 
undergo lipolysis and are reduced to IDL, half o f  which are subsequently taken up by 
the liver and the remainder are degradated further into LDL. LDL have a rich 
cholesteryl ester core surrounded only by ApoBlOO and remain in the circulation for 
much longer than VLDL or IDL. As discussed in section 1.2 LDL deposits cholesterol 
within cells of the arterial wall and, therefore, elevated plasma levels are correlated with 
atherosclerosis. Lipoprotein(a) (Lp(a)) is a variant of LDL and has the same structure, 
but contains an additional apo(a) polypeptide. The concentration of Lp(a) in the 
circulation is also highly variable among individuals and studies have shown that 
elevated levels are an independent risk factor for cardiovascular disease [27;28].
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1.3.2 HDL metabolism and Reverse Cholesterol Transport (RCT)
HDL is secreted as nascent HDL into the circulation by the liver or intestine, or formed
from VLDL and chylomicron surface remnants. The mature HDL particle is 
predominantly comprised o f  cholesteryl esters and surrounded by Apolipoproteins AI 
and All (ApoAI and All), which provide structure and confer receptor binding activity 
[29], Epidemiological studies have shown that both HDL-cholesterol (HDL-C) and 
ApoA-1 plasma levels are inversely correlated with the risk o f  CHD [30] and transgenic 
animal studies have further demonstrated their anti-atherosclerotic properties [31]. 
Although the mechanisms by which they inhibit the progression of atherosclerosis is not 
fully understood, they are thought to have several atheroprotective functions. These 
include anti-inflammatory and anti-oxidant effects [32;33] and, more importantly, they 
are essential for reverse cholesterol transport (RCT). RCT involves the efflux o f  excess, 
unesterified cholesterol from peripheral tissues and macrophages and its delivery to the 
liver for removal. The process is initiated by the interaction o f  lipid-free ApoA-I with 
the adenosine triphosphate (ATP) binding cassette transporter (ABC) AI, which results 
in the formation o f pre-p HDL. This nascent HDL is subsequently converted to HDL2 
and HDL2 by the enzyme lecithin-cholesterol acyltransferase (LCAT) which esterifies 
the cholesterol. These modified HDL particles can then bind to ABCG1 transporters 
which mediate a second cholesterol efflux pathway predominantly in macrophage [34]. 
HDL-C is either transferred to ApoB containing lipoproteins by the cholesteryl ester 
transfer protein (CETP), or taken up by the liver via the scavenger receptor B1 (SR-BI) 
and deposited into the bile. Interestingly, in a recent report using an ApoA-I deficient 
mouse model, the specific contribution o f  ApoA-I in the prevention and regression o f 
atherosclerosis was elucidated. ApoA-I exerts an anti-atherosclerotic effect 
predominantly through macrophage RCT and the HDL anti-inflammatory function, both 
o f which were discovered to be independent o f  the plasma levels of HDL-C [35]. 
Macrophage RCT is a term more appropriately used when this process is discussed in 
relation to atherosclerosis, as it is these cells in the arterial wall that become overloaded 
with cholesterol and from which efflux occurs.
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Figure 1-2. An overview of lipoprotein metabolism [10]
Lipoprotein metabolism can be divided into three sections: chylomicron (blue section), 
HDL (pink section) and VLDL/IDL/LDL metabolism (white section). All lipoproteins 
are composed o f triglycerides (TG), cholesteryl ester (CE), phospholipid (PL) and 
protein (ApoE, ApoC, ApoBlOO, ApoB48, ApoAI, ApoAII, ApoAIV) at different relative 
proportions. Chylomicrons are secreted by the intestine into the lymph and lipolysed by 
LPL. The resulting free fatty acids are delivered to peripheral tissues, while the 
remnant particles are taken up by the liver. Triglycerides and cholesterol are 
synthesised by the liver and secreted as VLDL, which undergo lipolysis and are reduced 
to IDL Half the IDL is taken up by the liver and the remainder are degradated further 
into LDL which have a rich cholesteryl ester core surrounded only by ApoBlOO. HDL 
is secreted as nascent HDL into the circulation by the liver or intestine, or formed from 
VLDL and chylomicron surface remnants. The mature HDL particle is predominantly 
comprised o f cholesteryl esters and surrounded by ApoAI and AIL
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1.3.3 Lipoprotein related disorders
Elevated plasma cholesterol levels, particularly cholesterol transported by LDL, plays a 
key role in the development of atherosclerosis. Although environmental aspects are to 
blame for most forms o f hypercholesterolaemia, genetic factors also strongly influence 
the levels o f  plasma lipoproteins. Mutations in the LDL-R gene results in a dominant 
Mendelian disorder known as familial hypercholesterolaemia (FH) and patients 
consequently have elevated plasma levels o f  cholesterol and LDL [36]. Familial 
defective ApoBlOO (FDB) is another common lipid disorder which is caused, most 
frequently, by a point mutation in the ApoBlOO gene; mutant forms are, thus, unable to 
bind to the LDL-R and individuals demonstrate high cholesterol levels due to defective 
LDL clearance [37]. Familial combined hyperlipidaemia (FCH) is characterised by 
elevated VLDL, IDL and LDL and although the primary causative gene has yet to be 
identified, a recent study has reported a strong association with the upstream 
transcription factor 1 gene on human chromosome 1 q 2 1 [38]. Finally, common variants 
o f  the ApoE gene markedly influence plasma cholesterol levels and are the cause of 
type III hyperlipoproteinaemia [39] (discussed in more detail in section 1.4.4).
1.4 Apolipoprotein E
As discussed in section 1.3 ApoE was first discovered in the early 1970s as a protein 
constituent of VLDL [40]. Further research identified ApoE as an important component 
o f  several classes o f  plasma lipoproteins and it is now viewed as a key molecule in the 
maintenance o f  plasma cholesterol homeostasis.
1.4.1 ApoE synthesis and expression
ApoE is most abundant in the liver, however, it is also expressed in the brain, spleen, 
lung, ovary, adrenal gland, kidney and muscles. Plasma ApoE is largely secreted by the 
liver (-90%) and a small amount is derived from extra-hepatic sources, such as 
macrophages [41]. The normal human plasma ApoE level ranges from 50 to 80pg/ml 
and increases in hypercholesterolaemic patients.
The human ApoE gene has been mapped to chromosome 19 [42] and contains four 
exons separated by three introns. ApoE is a secretory protein and is synthesised and 
released via the classical secretory pathway. The translated product is 317 amino acids 
in length and contains a signal peptide o f  18 amino acids at the amino-terminal end,
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which directs the polypeptide chain to the endoplasmic reticulum. From there the ApoE 
protein precursor is transferred to the Golgi where it undergoes intracellular proteolysis 
and O-glycosylation at Thr194, prior to being secreted into the plasma as a 34-kDa 
glycoprotein. Newly secreted ApoE from the liver is highly sialylated and in plasma it 
exists, predominantly, in a non-sialylated form [43]. ApoE sialylation, however, is not 
essential for the synthesis or the secretion o f  the protein [44]; thus, the functional 
relevance o f  this process remains unclear.
1.4.2 ApoE gene regulation
ApoE gene expression is regulated in a tissue-dependent manner and in response to 
changes in cell morphology and various extracellular/intracellular factors. Studies have 
demonstrated enhanced transcriptional activation o f  the ApoE gene during the 
differentiation of monocytes into macrophages [45], and the proximal promoter region 
o f the gene is thought to be implicated [46]. In macrophages, ApoE gene expression is 
upregulated by cholesterol loading [47] and by inflammatory mediators, such as TNF-a 
[48] and TGF-p [49], Interferon-gamma (IFN-y), interleukin-1 and granulocyte colony- 
stimulating factor, in contrast, inhibit the production o f ApoE by macrophages [49-51]. 
ApoE expression is also modulated by cyclic AMP (cAMP); in HepG2 cells it has been 
shown to downregulate transcription via elements within a specific region of the 
promoter [52].
Several polymorphisms in the proximal promoter region o f ApoE have been identified 
which are associated with variations in transcriptional activity due to differential 
binding o f nuclear proteins [53]. Interestingly, an association between the -219G/T 
polymorphism w ith decreased plasma ApoE levels and an increased risk of myocardial 
infarction has been discovered [54]. Despite evidence demonstrating the role o f  the 
proximal promoter in the regulation of ApoE expression, this region of the gene 
requires distal enhancers to direct transcription in all cells of the transgenic mouse. 
ApoE expression is mediated by hepatic control regions 1 and 2 in the liver [55] and by 
multi-enhancers (ME) 1 and 2 in adipocytes and macrophages [56], Furthermore, ME1 
and ME2 contain a conserved liver-X receptor responsive element which mediates lipid- 
inducible expression of ApoE in macrophage [57].
At the post-translational level, newly synthesised ApoE in macrophages is either 
secreted or directed along the lysosomal pathway for degradation [58] and this has been
22
shown to be regulated by artificial phospholipid vesicles and lipoproteins [59]. ApoE 
secretion from cells is reported to be stimulated by cholesterol enrichment [60], 
acceptors involved in cholesterol efflux (ApoAI, HDL) [61 ;62] and the cholesterol 
transporters ABCA1 and ABCG1 [60]. More recently, oleic acid was found to 
modulate the glycosylation o f ApoE in macrophage and thereby stimulate its secretion 
[63].
Interestingly, it has been discovered that ApoE can avoid degradation and instead 
undergo recycling and subsequently re-secretion [64]. Reports have demonstrated the 
presence o f triglyceride-rich lipoprotein (TRL) derived ApoE in the peripheral recycling 
endosomes o f the cell rather than the lysosomal compartments [65]. Not all TRL 
constituents, however, follow the same intracellular fate; TRL lipids and ApoB, for 
example, are targeted along the classical degradative pathway, in common with LDL. A 
study has also reported an association between recycled ApoE and HDL in 
macrophages; HDL-derived ApoAI is thought to be internalised and targeted to 
endosomes containing ApoE in order to promote ApoE recycling and cholesterol efflux 
[66].
1.4.3 ApoE structure
In a lipid-free state ApoE consists o f two independently folded a-helical domains, 
which are separated by a protease-sensitive, loop (Figure 1-3). The amino-terminal (N) 
domain (residues 1-191), made up o f four amphipathic a-helices, is the functional 
domain, which contains the recognition site for the LDL-R and LRP [67]. This receptor 
binding site is localised to an arginine and lysine rich section on helix 4 which, in 
addition, binds with high-affmity to HSPG [68]. This domain also contains the binding 
site for scavenger receptor class B type I (SR-B1) [69]. In a lipid-free state, however, 
ApoE cannot firmly bind to either phospholipids or lipoproteins. The carboxyl-terminal 
(C) domain (residues 216-299), which is highly a-helical [70], contains the major lipid 
binding site (residues 244-272) and facilitates helix-helix interactions to encourage 
ApoE self-association and helix-lipid interactions [71].
1.4.4 ApoE polymorphisms and functional consequences
ApoE is a polymorphic glycoprotein coded by three alleles (e2, c3, e4) that result from a 
single gene locus. ApoE3 is the most common and is considered the “wild-type”
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isoform as it contributes little to the normal variation o f plasma lipids. The rarest form, 
ApoE2, differs from ApoE3 by an A rgl58C ys substitution and ApoE4 varies by a 
Cysl 12Arg substitution [72]. The functional consequence o f the substitution in ApoE2 
is a reduced ability o f  this isoform to bind to the LDL-R [73]. The salt bridge between 
A rgl58 and A spl54 is eliminated which subsequently alters the conformation o f the 
domain and its ability to interact with the receptor. Furthermore, the isoforms differ in 
their lipoprotein binding preferences: ApoE4 has a high affinity for VLDL and LDL, 
whereas, ApoE3 and ApoE2 preferentially associate with HDL [74]. The interaction 
between the N- and C-terminal domains in ApoE4 is thought to govern this difference. 
The arginine at position 112 changes the orientation o f the side chain o f  Arg61, 
allowing interaction with an acidic residue in the C-terminal domain and consequently 
altering the lipoprotein preference [75]. The ApoE isoforms also have a varying effect 
on their own plasma level and on ApoB, triglycerides, total cholesterol and LDL- 
cholesterol. ApoE2 is, most often, associated with raised levels o f ApoE and 
triglyceride and decreased levels o f  ApoB and cholesterol; ApoE4, in contrast, is linked 
to a decrease in ApoE and an increase in ApoB and cholesterol levels [76].
The ApoE variants associate with CVD as a result o f these functional consequences. 
ApoE2 is well documented as a risk factor for recessive, type III hyperlipoproteinaemia 
(HLP) which is characterised by increased plasma cholesterol and triglyceride. The 
majority o f patients with type III HLP are homozygous for apoE2, although not all e 2/e 2 
carriers develop this disease, as more than 90% are normolipidaemic. Due to the 
receptor-binding defect o f  ApoE2, the main metabolic abnormality in type III HLP is 
delayed clearance o f  remnant lipoproteins; this alone, however, is not sufficient to cause 
the disease. ApoE2 binds more efficiently with HSPG/LRP, suggesting that hormonal, 
environmental and/or genetic factors are required to develop overt type III HLP. 
Interestingly, dominant inheritance o f this condition occurs with several rare ApoE 
variants, for example ApoE3Lc,den; like ApoE2, this variant has a receptor-binding 
defect, but only a single mutant allele is required for development o f the disease. 
ApoE4 is also associated with dominant hyperlipoproteinaemia [76] and several studies 
link ApoE4 with greater risk for CVD. It was reported that male carriers o f the e 4 allele 
from nine populations had a 40% greater risk o f mortality from CHD compared with e 2 
or e 3/e 3 carriers [77]. Furthermore, a recent meta-analysis has verified the e 4 allele as a 
significant risk factor for CHD [78]. ApoE4, in addition, has a pronounced association 
with neurodegenerative disorders, such as Alzheim er‘s disease [79].
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Figure 1-3. Structure of human ApoE
The model illustrates the structural regions and the polymorphic sites (residues 112 and 
158) that distinguish ApoE3 from ApoE4 and ApoE2 [80].
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1.4.5 The role of ApoE in lipoprotein metabolism and transport
The primary function o f ApoE is to mediate the uptake and degradation o f  lipoproteins.
ApoE bind poorly to receptors on the liver when attached to large lipoproteins, such as 
VLDL and Chylomicrons; thus, ApoE mainly directs the metabolism o f small remnant 
lipoprotein-derived triglycerides and cholesterol by delivering them to the liver, where 
the cholesterol is excreted and dietary fatty acids are metabolised or re-secreted as 
triglycerides with VLDL. ApoE utilises two receptor pathways in order to transport and 
deliver the lipoproteins on which it resides. ApoE binds to the LDL-R on parenchymal 
liver cells and with much higher affinity than ApoBlOO, therefore, indirectly regulating 
the level o f LDL [76]. The second pathway involves another hepatic receptor, LRP, 
which is mainly utilised for the clearance o f chylomicron remnants. Before mediating 
hepatocyte endocytosis, these receptors require additional cell surface molecules, 
including HSPGs and hepatic lipase (HL), which function to capture and rapidly 
sequester the ApoE bound lipoproteins from the plasma [81].
ApoE utilises several other means, unrelated to receptor-mediated endocytosis, to 
regulate the metabolism o f lipoproteins. Firstly, increased synthesis and secretion o f 
ApoE by the liver and its accumulation in the plasma has been shown to stimulate 
hepatic VLDL and triglyceride production [82]. Secondly, ApoE activates enzymes 
such as HL, CETP and LCAT which all promote the maturation o f HDL [83-85]. Most 
importantly, however, ApoE has a contributory role in RCT [86] and there is now a 
considerable amount o f  evidence suggesting that ApoE can directly influence 
macrophage lipid efflux. It was reported that ApoE-depleted HDL from human or 
ApoE-deficient mice had a decreased ability to promote cholesterol efflux from mouse 
peritoneal macrophage, but its function was restored by the addition o f exogenous ApoE 
[87]. Interestingly, more efficient cholesterol efflux was observed in fibroblasts 
stimulated with “lipid-poor” ApoE (y-LpE) from e3/e3 carriers in comparison to that 
from both e2/e2 and e4/e4 individuals [88]. Cholesterol efflux from macrophages is 
also enhanced by endogenously expressed ApoE [89], although the mechanism by 
which it achieves this remains unclear. One possibility is that the interaction o f secreted 
ApoE with proteoglycans on the cell surface facilitates passive desorption o f lipid from 
the plasma membrane via ABCA1 [90;91]. Alternatively, stimulation o f cholesterol 
efflux by endogenous ApoE could depend on its intracellular synthesis and transport 
through internal cellular membranes before secretion. Indeed, studies have shown that 
ApoE potentially mediates lipid efflux independent o f ABCA1 expression [92];
26
furthermore, a recent report provides evidence for the existence o f an ABCA1- 
independent pathway that requires the intracellular synthesis and/or transport o f ApoE 
[93]. At atherosclerotic lesion sites, macrophages only secrete ApoE and not ApoAI, 
the latter, instead stimulates ApoE secretion from these cells and this has been 
demonstrated to be independent o f ABCAI-mediated cholesterol efflux [62]. It could 
therefore be assumed that ApoE is the dominant acceptor in clearing cholesterol from 
arteries, however, a mechanism for ApoAI-mediated removal o f cholesterol from 
macrophage foam cells has recently been proposed. It is speculated that proteins 
secreted from macrophages, for example lipid and cholesteryl ester transfer proteins, 
remodel spherical HDL, which results in the dissociation o f stable, lipid-poor ApoAI. 
This renders ApoAI available as a substrate for the macrophage ABCAI transporter 
which can efflux excess cholesterol [94]. Nevertheless, the maintenance o f cholesterol 
homeostasis in macrophages is crucial in preventing foam cell formation, which 
ultimately re-enforces the anti-atherosclerotic properties o f  ApoE (discussed in more 
detail in section 1.6).
1.4.6 ApoE and non-lipid lowering functions
Initial evidence that ApoE has anti-atherogenic properties that are independent o f its 
action on cholesterol transport and metabolism came from a study that used transgenic 
mice expressing high levels o f human ApoE in the arterial wall. Significant reduction 
in atherosclerotic lesions was reported without observing any difference in the plasma 
cholesterol level and lipoprotein profile [95]. Later, Thomgate et al. [96] found that 
ApoE expression in the adrenal glands o f ApoE-null mice, at levels too low to correct 
hypercholesterolaemia, was sufficient to provide atheroprotection in these mice. Most 
importantly, a recent study has directly demonstrated, for the first time, that 
physiological levels o f ApoE can induce the regression o f atherosclerosis independently 
o f lowering plasma cholesterol levels [97]. Here the authors used hypomorphic 
ApoEK1lM xl-C re mice, which express very low levels o f an ApoE4-like form o f mouse 
ApoE at 2-5% o f normal levels in plasma. These mice are normolipidaemic and 
develop hypercholesterolaemia on a high-fat diet, which can be reversed when a chow 
diet is resumed. Induction o f physiological levels o f plasma ApoE in these mice was 
discovered to enhance removal o f neutral lipids from the fibrotic core; their plasma 
cholesterol level, however, remained comparable to a control group. This new finding 
facilitates further research into the mechanisms responsible for the non-lipid, anti- 
atherosclerotic effect o f ApoE.
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Indeed, several biological functions o f ApoE have been identified that are unrelated to 
lipid transport and metabolism and which contribute to its anti-atherogenic activity. 
Although absent in normal vessels, ApoE is highly expressed in atherosclerotic plaques 
and research has shown that it is largely macrophage derived [98]. Furthermore, this 
macrophage-synthesised ApoE has been discovered to exert local affects on the 
surrounding cells o f the vessel wall. Firstly, ApoE inhibits platelet aggregation 
[99; 100] by stimulating the release o f NO, apparently via a signal transduction pathway 
involving an initial interaction with ApoE receptor 2 (ApoER2) [101; 102]. Many o f the 
anti-atherosclerotic mechanisms used by ApoE involve suppression o f different stages 
o f  the inflammatory response. ApoE has been shown to inhibit the expression o f 
VCAM-1 on TN F-a stimulated human umbilical vein endothelial cells (HUVECs) 
again via interaction with ApoER2 and induction o f endothelial NO production [103]. 
Other anti-inflammatory properties o f  ApoE include modulation o f the T-helper-type-I 
immune response by regulation o f  interleukin-12 (IL-12) [104], and ApoE has recently 
been implicated in CD 1-mediated presentation o f exogenous lipid antigens [105]. 
Additional, non-lipid lowering actions o f ApoE involve the inhibition o f smooth muscle 
cell migration and proliferation. LRP was identified as the receptor that mediates ApoE 
inhibition o f smooth muscle cell migration [106] and the process was demonstrated to 
occur via activation o f cAMP/protein kinase A [107]. In contrast, ApoE inhibition o f 
smooth muscle cell proliferation was found to be mediated via its binding to HSPG 
[108] and the resulting activation o f  inducible nitric oxide synthase (iNOS) [109]. 
Reports have also exhibited evidence that ApoE has anti-oxidant properties [110] with 
the responsible region o f ApoE being identified as the receptor-binding domain [111]. 
Inhibition o f  lipid oxidation could, thus, prevent the accumulation o f oxidised LDL and 
ultimately help protect against atherosclerosis.
ApoE also plays a modulatory role in macrophage phagocytosis o f apoptotic cells; in 
vitro, ingestion o f apoptotic cells by ApoE-deficient macrophages was attenuated and in 
ApoE-knockout mice they accumulate in a range o f tissues. Interestingly, the increased 
number o f apoptotic bodies in these tissues resulted in a higher population o f 
macrophage and this was in turn associated with a systemic increase in pro- 
inflammatory markers, such as TN F-a [112]. The involvement o f ApoE in apoptosis, 
although in a different facet, has been farther observed in a study, which identified 
ApoE as a potential tumour-associated marker in ovarian cancer. Inhibition o f  ApoE
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expression led to G2 cell cycle arrest and apoptosis in an ApoE-expressing ovarian 
cancer cell line and it was hypothesised that the downstream proliferative and anti- 
apoptotic signals activated by ApoE, through its binding to the LDL-R, are used by 
tumour cells to maintain cell growth [113]. Finally, ApoE has been reported to impede 
subendothelial retention o f LDL, which is thought to be an initial step in atherogenesis. 
An early study discovered that ApoE impairs the lipase-mediated retention o f LDL 
[114] and more recently ApoE was found to restore the decreased atherosclerotic 
potential o f proteoglycan-binding-defective LDL which depends on its lower affinity 
for artery-wall proteoglycans [115].
1.5 Transgenic mouse models for hyperlipidaemia and atherosclerosis
Mice have become the most valuable experimental animals due to their small size, easy
maintenance, short breeding time and their potential for use in transgenesis and gene 
targeting studies. However, mice exhibit important differences in their lipoprotein 
profile compared with humans; they bear relatively low steady-state concentrations o f 
VLDL and LDL and their plasma cholesterol is mainly found in the HDL fraction. 
Notwithstanding these differences, mice and humans largely carry the same set o f genes 
to control lipoprotein metabolism [116]. In the absence o f atherogenic plasma 
lipoproteins, mice naturally resist the development o f atherosclerosis. A change in the 
balance o f the VLDL and LDL fractions and a general increase in ApoB containing 
lipoproteins is needed to promote this disease in mice, via either genetic or dietary 
means. The C57BL/6J mouse is the most atherosclerosis susceptible strain, but even on 
a pro-atherogenic/high-fat diet, they only develop small immature fatty streak lesions 
with largely lipid-laden foam cells. It is therefore, not surprising that prior to the advent 
o f genetically modified animals, the use o f mice in atherosclerosis research remained 
limited.
1.5.1 The ApoE-deficient mouse model
In 1992, two separate research groups created the ApoE-deficient (A poE 7 ) mouse 
through targeted gene inactivation [ 117; 118]. On a normal chow diet, these mice 
develop atherosclerotic lesions and have a plasma total cholesterol ranging from 
500mg/dL to 800mg/dL; this is due to a severe defect in the clearance o f remnant 
lipoproteins from plasma. When fed a Western-type diet, cholesterol-rich VLDL 
further accumulate and a subsequent doubling in plasma cholesterol is observed. In
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fact, their lipid distribution resembles that found in patients with type III 
hyperlipidaemia, although the VLDL composition differs [119]. Atherosclerotic lesions 
in ApoE' ' mice increase in size and complexity with age. In young mice, the lesions are 
mainly centred in the aortic sinus but become widely distributed throughout the arterial 
tree when the mice reach 8 to 9 months o f age. As early as 10 weeks, foam cell deposits 
are apparent and by 5 months, moderate lesions additionally containing free cholesterol 
and smooth muscle cells are observed. Beyond 8 and 9 months o f age the lesions are 
much more complex and start to resemble a fibrous plaque [120].
When the animals are fed a Western-type diet, the progression o f atherosclerosis is 
advanced by at least 6 weeks with lesions developing more rapidly throughout the 
vascular tree. This type o f diet also renders the lesions more lipid-rich [121]. 
Interestingly, heterozygous ApoE-deficient mice (ApoE+/ ) develop atherosclerosis on a 
high-fat diet, even though their plasma lipid levels remain comparable to those o f  wild- 
type mice; suggesting that mice lacking one allele o f ApoE are susceptible to diet- 
induced atherosclerosis [121]. Advanced fibrous plaques are observed in ApoE'7' mice 
after only 6 months on a high-fat diet; these plaques are characterised by a fibrous cap 
containing smooth muscle cells surrounded by connective tissue matrix which covers a 
central lipid-rich necrotic core [122]. Several studies have reported that these advanced 
lesions can spontaneously become unstable and rupture [123; 124]. The brachiocephalic 
artery, which is the first branch from the aortic arch, is a well-defined area in which to 
study plaque stability and rupture. A poE '* mice, when fed a high-fat diet, exhibit a high 
frequency o f  plaque rupture in these arteries; these ruptured plaques also show many o f 
the characteristics o f  vulnerable plaques in humans [125]. Furthermore, it has recently 
been reported that ApoE' ' mice on a high-fat diet for a period as short as 8 weeks, 
develop unstable atherosclerotic plaques in the brachiocephalic artery which are prone 
to rupture [126]. Mouse models o f plaque rupture are continually being developed, with 
the purpose to help our understanding o f plaque development, destabilisation and 
rupture. There has been a considerable amount o f discussion, however, over the 
phenotype o f the unstable lesion and it is disputed how closely ruptured plaques in the 
mouse model resemble vulnerable plaques in humans.
In humans, ApoBlOO is the principal structural protein o f liver-derived lipoproteins, 
whereas, in mice, two-thirds o f the lipoproteins metabolised by the liver contain 
ApoB48. ApoBlOO and ApoB48 are the translated protein products o f the same gene,
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however, the latter isoform is a truncated version due to ApoB mRNA editing and as a 
consequence lacks the receptor-binding domain [127]. Editing o f ApoB mRNA only 
occurs in the intestine o f humans which, in contrast to mice, renders ApoB48 
exclusively involved in chylomicron formation [128]. In ApoE'7' mice, ApoBlOO 
naturally becomes the principle ligand mediating hepatic remnant clearance through the 
LDL-R; as a result the plasma from these mice is normally absent in ApoB 100-VLDL, 
but contains very high levels o f  the binding defective ApoB48-VLDL [129]. LDL 
receptor deficient mice (LDLR'7'), in contrast, have a disproportionate increase in 
ApoBlOO in their plasma and on a chow diet have low cholesterol levels with only 
slight atherosclerotic lesions. It would therefore, be logical to infer that ApoB48 is 
more atherogenic than ApoBlOO. However, on a high-fat diet, LDLR'7* mice develop 
severe atherosclerosis [121], while modification o f the ApoB gene in ApoE'7' mice to 
promote the exclusive expression o f  either ApoB48 or ApoBlOO failed to have an effect 
on susceptibility to atherosclerosis [130].
Histological methods are routinely used to assess atherosclerotic plaques in ApoE'7' 
mice, which obviously requires euthanizing the animals. Non-invasive imaging 
techniques that are normally used for patients are now being investigated as an 
alternative means to evaluate lesion progression. One study applied a non-invasive 
magnetic resonance microscopy technique to live ApoE'7' mice fed a Western diet; here 
they were able to accurately quantify aortic root lesions and even characterise lesion 
components [131].
The ApoE " mouse has ultimately revolutionised the study o f mechanisms o f 
atherosclerosis and understandably, it has become the most popular and convenient 
mouse model used by researchers around the world. It has recently proved its versatility 
in a study undertaking gene expression profiling during plaque progression [132] and 
for proteomic/metabolomic analyses o f atherosclerotic vessels [133].
1.5.2 The ApoE3Leiden transgenic mouse model
Transgenic mouse models expressing mutant forms o f ApoE have also been generated 
in order to further our understanding o f hyperlipidaemia and atherosclerosis. The 
ApoE3uiden transgenic mouse carries a gene construct consisting o f the ApoE3Leiden 
gene from a human carrier, A poCl and hepatic regulatory elements. Although 
endogenous ApoE is still present in these mice, they develop a hyperlipidaemic
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phenotype, which resembles that o f the dominant trait observed in humans. When fed a 
normal chow diet, the mice exhibit an increase in plasma total cholesterol and 
triglyceride, which dramatically increases when the animals are transferred to a high-fat 
diet; the increase was mainly observed in the VLDL and LDL fractions. Interestingly, 
on the high-fat diet the ApoE3Leiden protein was equally distributed between VLDL, 
LDL and HDL, whereas on normal chow the protein was predominantly in the HDL 
fraction [134]. A further study reported atherosclerotic lesion development in 
ApoE3uidcn mice fed a high cholesterol/cholate diet; moreover, atherogenesis was 
positively correlated with serum cholesterol levels [135]. Although this mouse model is 
less susceptible to atherosclerosis than the ApoE'7' mouse, the fact that the mice carry 
the human ApoE3Leiden gene allows a clearer insight into the nature o f the disease in 
humans.
1.5.3 Mouse models containing common human ApoE alleles
Knock-in mouse models containing the most common human ApoE alleles, i.e., E2, E3
and E4, have been generated [136-138]. In these models, the endogenous mouse ApoE 
gene is replaced by the corresponding human gene using homologous recombination in 
embryonic stem cells. Mice expressing human ApoE2 exhibit many characteristics o f 
Type III HLP on a normal chow diet; their plasma total cholesterol and triglyceride 
levels are raised, predominantly in the VLDL fraction and they develop atherosclerotic 
lesions [138]. It is believed, however, that there must be an additional underlying cause 
for the pronounced phenotype observed in these mice as humans homozygous for 
ApoE2 rarely develop HLP. Furthermore, the genetic factors that trigger Type III HLP 
in humans must already be present in mice. It was proposed that the reduced 
availability o f ApoBlOO in mice, due to ApoB mRNA editing, could be responsible, 
since they, consequently, become more dependent on ApoE2-mediated lipoprotein 
clearance which has a reduced ability to bind to the LDL-R. A study, however, 
demonstrated that sole expression o f binding-competent ApoBlOO in ApoE2 knock-in 
mice was not sufficient to reverse the hyperlipidaemic phenotype [139]. These results 
indicate that the complete penetrance o f the type III HLP phenotype in this mouse 
model is not entirely dependent on the difference in ApoB editing between humans and 
mice. Another possible explanation is the reduced expression o f the LDL-R in mice as 
over-expression o f  the human LDL-R in ApoE2 knock-in mice was discovered to 
ameliorate the plasma lipoprotein profile [140].
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The ApoE3 and ApoE4 knock-in mice exhibit very similar phenotypes, although they 
differ slightly in lipoprotein distribution as mice homozygous for ApoE4 have increased 
steady-state levels o f non-HDL lipoproteins due mainly to reduced plasma VLDL 
clearance. On normal chow diets, plasma lipid levels in both these mouse models are 
significantly lower than the levels in ApoE2 knock-in mice. On high cholesterol diets, 
the ApoE4 knock-in mouse develops larger atherosclerotic plaques than the ApoE3 
knock-in mouse, however, these comparative observations demonstrate that a difference 
in ApoE structure alone is sufficient to alter VLDL metabolism and atherosclerosis risk 
in mice [136]. Interestingly, in ApoE4 transgenic mice, which also over express the 
LDL-R, the rate at which triglyceride-rich lipoproteins are cleared was not increased 
and instead lipoprotein remnants were found to accumulate. It was, subsequently, 
hypothesised that ApoE4 becomes trapped in the liver due to its greater affinity for the 
LDL-R, rendering lipoproteins unable to bind to LRP and, ultimately, slowing their rate 
o f clearance [141].
1.6 Evidence for the therapeutic potential of ApoE to treat 
atherosclerosis and hyperlipidemia
As discussed in the previous sections, ApoE is generally considered anti-atherogenic
due to its main function in lipoprotein metabolism and transport and the fact that 
ApoE*' mice are grossly hypercholesterolaemic and develop spontaneous 
atherosclerotic lesions. There is now a significant amount o f evidence endorsing the 
human ApoE gene as a strong candidate for therapeutic manipulation to treat 
atherosclerosis and hyperlipidaemia. One study demonstrated that intravenous injection 
o f plasma-purified ApoE into Watanabe heritable hyperlipidaemic (WHHL) rabbits 
could markedly reduce plasma cholesterol and significantly regress atherosclerotic 
lesions in these animals over a period o f eight months [142]. Similarly, overexpression 
o f ApoE in the liver o f transgenic mice was found to reduce plasma cholesterol and 
triglyceride and prevent diet-induced hypercholesterolaemia [143]. Moreover, the same 
protection was conferred in transgenic mice with diabetic hyperlipidaemia [144]. 
Interestingly, when a synthetic peptide representing the ApoE binding site was 
intravenously injected into ApoE A mice, a 30% reduction in total plasma cholesterol 
was observed; the peptide selectively associated with cholesterol-rich lipoproteins and 
mediated their clearance [145]. Similarly, when an ApoE mimetic peptide consisting o f 
the ApoE receptor binding domain, covalently linked to a well-characterised class A
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amphipathic helical peptide 18A, was intravenously injected into WHHL rabbits, 
plasma cholesterol levels were reduced and endothelial functions were improved [146].
Several studies have also assessed whether ApoE produced in the arterial wall by 
macrophage and other cell types could have an effect on the development o f 
atherosclerosis. In one study, human ApoE expression was directed only to the 
macrophage o f ApoE*7' mice and was discovered to prevent arterial wall lipid 
accumulation and to markedly reduce atherosclerosis [147]. Linton et al. [148] 
transplanted bone marrow from wild-type mice into ApoE*7' mice, thereby reconstituting 
the expression o f murine ApoE by macrophages. ApoE was, subsequently, detected in 
the plasma, which normalised plasma lipid levels and, importantly, protected the 
animals against the development o f  atherosclerosis. Later, in a similar study, ApoE'7* 
mice were transplanted with ApoE+/+ bone marrow and assessed for regression o f 
established atherosclerotic lesions. Although macrophage-derived ApoE, which 
provides approximately 10% o f plasma ApoE in normal mice, was sufficient to 
eliminate hypercholesterolaemia and protect against the progression o f aortic lesions, it 
failed to induce significant regression o f established atherosclerosis [149].
Despite the above evidence, which lends support to the therapeutic potential o f ApoE to 
treat hyperlipidaemia and atherosclerosis, reports have shown that overexpression and 
accumulation o f ApoE can, in fact, cause hypertriglyceridaemia. Huang and colleagues 
[150] found that expressing supraphysiological levels o f  human ApoE3 in transgenic 
mice lacking endogenous ApoE caused a three-fold increase in plasma triglyceride with 
a concomitant increase in VLDL and a decrease in HDL. This hypertriglyceridaemic 
effect o f ApoE overexpression in ApoE*7* mice is thought to be caused by both 
stimulation o f VLDL-triglyceride production and impaired VLDL lipolysis and can be 
eliminated by deletion o f the carboxyl-terminal lipid-binding domain. Injection o f a 
high dose o f an adenovirus vector expressing a truncated form o f ApoE2, lacking its 
lipid binding domain, did not increase plasma triglyceride levels in these mice and, 
moreover, normalised the hypercholesterolaemia [151]. The results from a recent study 
further indicate that residues 261, 264, 265, 268 and 269 in the C-terminal domain o f 
ApoE are responsible for the hypertriglyceridaemic effect and, in addition, were found 
to displace ApoA-I from HDL, resulting in a reduction in plasma ApoA-I and HDL 
levels. Most importantly, these findings have allowed a recombinant ApoE variant with 
improved function to be generated [152]. Interestingly, the sensitivity and severity o f
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ApoE-induced hypertriglyceridaemia is intensified by, either bolus injection o f purified 
ApoE in ApoE'7'* LDL-R'7’ mice or injection o f  an adenovirus expressing a LDL-R 
binding-defective form o f ApoE4 in ApoE'7* mice. Their data suggests that the LDL-R 
may represent the only physiological route for clearance o f ApoE bound lipoproteins in 
mice [153].
1.7 Gene Therapy
Somatic gene therapy typically involves the delivery o f a functional gene into the 
nucleus o f a target cell with the aim to treat disease-causing, loss-of-function mutations. 
Although gene therapy was initially intended to be a treatment and cure for inherited 
genetic disorders, the majority o f  clinical trials now target acquired disorders such as 
cancer, vascular disease and degenerative neurological conditions. Difficulties, 
however, in achieving sustained gene expression in host cells and in developing safe 
and efficient gene-delivery methods have greatly impeded the progress o f these clinical 
trials. The main problem is the vehicles that are being used to deliver the therapeutic 
genes to the target tissue. Research efforts are now focusing on understanding the 
molecular basis o f how viruses and viral vectors interact with the host. Vectors with 
improved efficiency, specificity and safety are currently being developed; this, however, 
is a substantial challenge, which needs to be overcome before gene therapy can fully 
achieve all o f its promises.
1.7.1 Viral vectors
Viruses are employed as a gene therapy tool essentially because they can efficiently 
gain access to host cells, which they then use for their survival and replication. The 
viral life cycle is divided into two distinct phases: infection and replication. The viral 
genome is introduced into the cell following infection and this subsequently leads to the 
expression o f early phase genes involved in viral regulation. A late phase then follows, 
in which structural genes are expressed and new viral particles are assembled [154]. In 
most gene therapy applications today, viral vectors are constructed in such a way that 
makes them as safe as possible. While genes controlling the viral infection pathway and 
those that are required for in cis functions, such as packaging the vector genome into the 
virus capsid, are left intact, viral genes that lead to replication and toxicity are deleted. 
An expression cassette, consisting o f a promoter and transgene o f interest, is then 
cloned into a modified viral backbone, in which unwanted genes are deleted. A separate
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helper construct, however, is provided in trans which contains genes that are involved 
in replication and encapsidation; this is co-transfected along with the vector genome 
into packaging cells to produce the recombinant vector particle [155] (Figure 1-4, A). 
The vector particles are then ready to be transduced into the target cell; they enter the 
cell through a receptor-mediated process and then undergo uncoating. Once in the 
nucleus the vector genome forms transcriptionally active dsDNA molecules, and either 
persists as an episome or becomes integrated into the host genome itself (Figure 1-4, B).
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Figure 1-4. The production of a viral vector and its transduction into the target cell [154]
(A) The helper plasmid contains genes essential for viral replication and encapsidation, and this is co-transfected along with the vector DNA, carrying 
the expression cassette, into packaging cells. Viral proteins are produced which initiate replication o f the vector DNA, leading to the production o f  
multiple copies. The vector genomes are then packaged into viral particles by structural proteins, which recognise vector but not helper DNA. (B) 
The viral particles enter the cell through a receptor-mediated process and then undergo uncoating. Once in the nucleus the vector genome forms 
transcriptionally active dsDNA molecules and, depending on the vector, can persist as an episome or become integrated into the host genome. This is 
followed by the production o f the therapeutic mRNA and protein.
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1.7.1.1 Classes of viral vectors
There are currently five main classes o f viruses from which viral vectors are derived, 
which include oncoretrovirus, lentivirus, adenovirus (Ad), adeno-associated virus 
(AAV) and herpes simplex-1 virus (HSV-1). They all have varying properties and are, 
therefore, suitable for different applications. One major distinction is their ability to 
either integrate into the host genome or persist in the cell nucleus as extrachromosomal 
episomes. Oncoretrovirus vectors are the most widely used in clinical trials, mainly 
because they were the first viral vectors to be developed and they are integrating 
vectors, therefore, they have the potential to permit stable transgene expression in 
dividing cells. In 2002, a report announced the success o f  a clinical trial in which bone 
marrow cells from X-linked severe combined immunodeficiency (SCIDX1) patients 
were transduced, ex vivo, with a retroviral vector, murine leukaemia virus (MLV) [156]. 
The treatment provided a complete cure for 8 o f the 11 patients whom suffered no 
complications. Unfortunately, although sustained transgene expression was 
demonstrated, the remaining three patients developed a leukaemia-like disease [157]. 
Further investigation revealed that the MLV vector had integrated near and activated an 
oncogene [158], clearly highlighting the risk o f insertional mutagenesis.
A major limitation o f oncoretroviruses is their inability to transduce non-dividing cells; 
research is, therefore, focusing on the development o f lentiviruses which can transduce 
both proliferating and non-proliferating cells [159; 160]. Lentiviruses are derived from 
human immunodeficiency virus (HIV) and are modified to the extent that very little o f 
the virus genome is present in the vector, thus minimising its ability to replicate in the 
host. The development o f the self-inactivating lentivirus vector, which contains 
deletions o f the regulatory elements in the downstream long-terminal repeat sequence, 
further enhances its biosafety. The therapeutic potential o f lentivirus vectors has been 
demonstrated in primate models o f Parkinson’s disease [161] and other in vivo studies 
have shown efficient lentivirus transduction o f muscle [162], liver [163] and also brain; 
including the effective delivery o f  ApoE2 [164].
Herpes simplex virus-1 (HSV-1) is a human pathogen and around 80% o f the 
population are already infected by it. The virus establishes latency as an episome in the 
CNS, sometimes for the individual’s entire lifetime, and when re-activated travels to the 
epithelium to undergo replication. HSV are non-integrative and contain a double­
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stranded DNA molecule. The vectors are made replication defective by deleting the 
immediate-early genes required for lytic infection and expression o f all other viral 
proteins. Replication-defective HSV vectors have been widely applied in animal 
models for the treatment o f cancer [165] and neurological diseases [166]. Long-term 
transgene expression has been achieved in the CNS with the use o f a HSV vector 
containing a neuron-specific latency-activated promoter [167]. The main drawback, 
however, with these vectors is the immune response and cytotoxicity that develops upon 
their administration [168; 169].
Adenoviruses consist o f a non-enveloped, icosahedral capsid containing a linear double­
stranded DNA genome that exists and propagates as extrachromosomal episomes. 
Although recombinant adenoviral vectors (rAd) are the most efficient gene transfer 
system in a broad range o f tissues and infect both dividing and non-dividing cells, they 
preferentially transduce the mammalian liver following systemic delivery. 
Unfortunately, the rAd vector has had to be extensively modified to reduce its 
immunogenicity; only two viral early genes were deleted from the 1st generation 
vectors, which induced strong cytotoxic and host immune responses, culminating in 
only transient transgene expression. Reduced toxicity and prolonged transgene 
expression, however, has been demonstrated in animal studies with the use o f a 2nd 
generation vector, lacking additional early genes [170; 171]. Furthermore, the 
introduction o f  a helper-dependent rAd (HD-Ads) vector [172], in which all viral genes 
are deleted, has shown the most significant reduction in rAd vector-related toxicity and 
immunogenicity in vivo [173-175].
1.7.2 Adeno-associated viruses (AAV)
AAVs are human parvoviruses that were first discovered as contaminants in adenovirus 
cultures. This single-stranded DNA-containing nonenveloped virus has the best safety 
profile among all viral vectors as wild-type AAV (wtAAV) infection has never been 
associated with human disease, making it an ideal candidate for gene therapy. AAV has 
also been classified as a dependovirus because it requires a helper virus, such as 
adenovirus, for productive infection in vitro, which further endorses its safety. wtAAV 
has the ability to establish latent infection in vitro and integrates into the AAVS1 site of 
human chromosome 19 [176]. Recombinant AAV (rAAV), in contrast, rarely integrates 
and forms extrachromosomal, intermolecular concatemers in the target cell. 
Interestingly, this circular structure is thought to be responsible for rAAVs long-term
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episomal persistence and ability to direct stable transgene expression in muscle tissue 
[177]. Although reports have shown that, within the liver, rAAV can integrate into the 
host’s chromosomal DNA, it is only a small fraction and extrachromosomal forms are 
the primary source o f rAAV mediated gene expression [178]. The worrying issue, 
however, is that the small percentage that does integrate, preferentially integrates into 
active gene and accompanies chromosomal deletions, which may lead to loss-of- 
function insertional mutagenesis [179]. A recent study has further highlighted hot spots 
for integration in the liver, which, disconcertingly, include gene regulatory sequences 
[180]. This issue, ultimately, has important implications for future clinical trials and 
further research is needed, especially since only AAV serotype 2 has been examined for 
its potential to integrate, other serotypes may not behave in the same manner. 
Interestingly, rAAV integrants could not be detected following transduction o f skeletal 
muscle [181], which perhaps reinforces the safety o f muscle compared with liver.
1.7.2.1 AAV structure/biology
The wild-type AAV genome is only 4.7 kb and is composed o f two genes, rep and cap , 
which encode four replication proteins and three capsid proteins respectively. 
Preferential integration into the AAVS1 site requires the nicking activity o f two large 
replication proteins, Rep 78 and 68 [182], which also have additional roles in AAV 
transcription and replication. DNA packaging into the preformed capsid within the 
nucleus o f the cell involves the smaller proteins, Rep 40 and 52. The icosahedral virion 
shell is made up o f  three capsid proteins V pl, Vp2 and Vp3 in proportions o f 1:1:10 
respectively. Vp3 is used in receptor recognition at the surface o f cells and the N- 
terminus o f Vpl contains a phospholipase domain essential for viral infectivity [183]. 
The AAV genome is flanked by two inverted terminal repeats (ITRs) which have a T- 
shaped hairpin structure containing a terminal resolution site (trs) and a rep binding 
element (RBE) that play essential roles in replication and encapsidation (Figure 1-5). 
The ITR is the only required cis-acting viral component necessary for genome 
replication, integration and packaging into the capsid. The rep and cap genes in the 
rAAV vector therefore, can be replaced with an expression cassette, consisting o f the 
promoter, transgene and polyadenylation signal (Figure 1-5). The rep and cap genes 
are, instead, provided in trans from a different plasmid along with a helper construct 
containing the Ad early region genes, El A, E1B, E4 and E2A and Ad virus-associated 
RNAs. El A is responsible for transactivation o f AAV gene expression and E4 and E1B 
help the transport o f mRNA to the cytoplasm, thereby regulating AAV gene expression.
40
Transcription from the vector promoter is initiated by the help o f the E2A DNA binding 
protein, which is additionally involved in AAV DNA replication. The Ad virus- 
associated RNAs helps in initiating AAV protein synthesis by inhibiting the host cell 
shutoff mechanism o f translation induced by interferons [184].
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Figure 1-5. WtAAV genome and rAAV transgene cassette
This figure illustrates the structure o f  the wtAA V genome, which contains rep and cap 
genes that are flanked by two ITRs. The ITR has a T-shaped structure resulting from 
the palindromic sequence folded on itself to optimise potential base pairing. The 
positions o f  the Terminal Resolution Site (TRS), the Rep Binding Element (RBE) and a 
portion o f the small internal palindromes within the terminal hairpin (RBE) are 
indicated. The rAAV transgene cassette consists o f  a promoter (Pro), the gene o f  
interest and a polyadenylation site (pA). Below this is the helper plasmid which 
contains essential genes for viral replication and encapsidation.
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1.7.2.2 AAV serotypes
Currently eleven different serotypes (designated AAV1 to AAV11) and over one 
hundred genomic variants o f AAV from human and non-human primate samples have 
been identified [185]. AAV serotypes 1, 2, 3, 4 and 6 were discovered as contaminants 
o f adenovirus cultures, whereas 5 was isolated from a human genital site [186]. The 
high frequency o f neutralising antibodies to serotypes 2, 3 and 5 in the human 
population suggests that they are o f human origin [187], while serological evidence 
indicates AAV4 to be o f non-human primate origin [188]. Interestingly, AAV6 appears 
to have arisen from homologous recombination between AAV1 and AAV2 [189] and 
has a >99% amino acid homology with AAV1. Novel serotypes o f AAV, including 
AAV7, 8 and 9, and over 100 new and unique variants have been identified through 
work conducted by Gao and colleagues. They used a PCR screening technique on a 
number o f human and non-human primate tissue samples and with sequence alignments 
were able to generate a phylogenetic tree separating the new AAV serotypes and 
isolates into nine clades [190; 191] (Figure 1-6). Two additional serotypes, designated 
AAV 10 and AAV11, have recently been identified in cynomolgus monkey tissue. 
Phylogenetic analysis o f their capsid proteins showed that they resembled most AAV8 
and AAV4 respectively [192].
All serotypes, apart from AAV6, exhibit a significantly different amino-acid sequence 
o f the capsid proteins, with the most divergent region located in VP3 [193]. Table 1-1 
shows the capsid amino acid homology between AAV serotypes 1-9 and it is clear that 
AAV4 and AAV5 share the least homology with other serotypes.
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Figure 1-6. A phylogenetic tree separating the AAV serotypes and isolates into 
clades
Gao and colleagues used a PCR screening technique on a number o f  human and non­
human primate tissue samples and with sequence alignments were able to generate a 
phylogenetic tree separating the new AAV serotypes and isolates into nine clades 
[190; 194J. The origin o f  each AA V serotype is indicated.
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Serotype AAV1 AAV2 AAV3 AAV4 AAV5 AAV6 AAV7 AAV8 AAV9
AAV1 100 83.3 86.8 63 57.9 99.2 84.8 83.9 82.2
AAV2 83.3 100 87.9 59.9 57.3 83.4 82.4 82.8 81.7
AAV3 86.8 87.9 100 62.8 58.4 87 84.8 85.7 83.6
AAV4 63 59.9 62.8 100 52.5 62.7 63.4 63.1 62.2
AAV5 57.9 57.3 58.4 52.5 100 58 57.7 57.6 56.7
AAV6 99.2 83.4 87 62.7 58 100 85 84 82.1
AAV7 84.8 82.4 84.8 63.4 57.7 85 100 87.8 81.8
AAV8 83.9 82.8 85.7 63.1 57.6 84 87.8 100 85.3
AAV9 82.2 81.7 83.6 62.2 56.7 82.1 81.8 85.3 100
Table 1-1. Capsid amino acid homology among AAV serotypes 1 to 9
1.7.2.3 AAV production and purification
Initially, production o f rAAV involved the co-transfection o f cells with vector DNA and 
a packaging plasmid followed by infection with Ad [195]. Concerns, however, were 
raised over the safety o f this method as AAV stocks were often contaminated with 
adenoviral capsids. Significant improvements have since been made and currently the 
method o f choice requires a triple transfection o f vector DNA, containing the transgene 
cassette, a packaging plasmid to supply Rep and Cap proteins, and a helper plasmid 
carrying Ad genes [196]. It is also now possible to scale-up AAV production by the use 
o f  cell lines that stably express the desired vector DNA and the essential Rep and Cap 
genes; infection with Ad is all that is needed to generate rAAV [197]. Furthermore, 
Urabe and colleagues have developed a baculovirus expression vector system for large- 
scale rAAV production in SF9 insect cells [198]. Their method involves the co- 
infection o f SF9 cells with a Rep-baculovirus, a VP-baculovirus and an AAV vector 
genome baculovirus; the rAAV particles produced are identical to those generated in 
mammalian cells in both physiological properties and biological activities. The 
baculovirus helpers, however, were discovered to be prone to passage-dependent, loss- 
of-function deletions, which resulted in a decrease in rAAV titer. The system has since 
been modified to alleviate the instability and a much more efficient and convenient 
method has now been generated for the large-scale production o f AAV [199].
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Another significant development in the production o f AAV has been the generation o f 
pseudotyped AAV vectors. It is now possible to cross-package the AAV2 vector 
genome with capsid proteins o f a different serotype [200]. To achieve this, a triple 
transfection is carried out with a helper plasmid containing AAV2 ITRs and rep 
proteins, but with cap proteins from an alternative serotype. Unbiased comparisons can 
therefore, be made between different serotypes, since they all contain identical AAV 
genomes.
Caesium chloride density gradient ultracentrifugation was the conventional method for 
the purification o f AAV, however, this technique resulted in a significant loss in viral 
titer and vector preparations often varied in quality. Non-ionic iodixanol gradients 
followed by ion-exchange or heparin-affmity column chromatography are now more 
routinely used [201]. Heparin-affmity columns can only be applied to the purification 
o f AAV-serotypes 2 and 6 due to their ability to bind to heparin sulphate; however, 
alternative protocols based on ion-exchange chromatography have been developed for 
serotypes 1, 2, 5 and 8 [202;203].
1.7.2.4 AAV and tissue tropism
Early studies were based on AAV2 as it was the first serotype to be fully characterised 
and demonstrated high transduction efficiency in a broad range o f tissues and cells in 
vitro. Unfortunately, rAAV2 is less efficient in vivo and clinical trials have shown little 
progress. For example, in a study with haemophilia B patients, intramuscular transfer 
and transient expression o f factor IX was evident, although persistence o f the gene was 
not sufficient for long-term efficacy [204]. Fortunately, the alternative serotypes have 
been evaluated and show strikingly improved transduction efficiencies in a variety o f 
tissue types. AAV1, AAV6 and AAV7 show high levels o f transduction in skeletal 
muscle [191 ;205-208], whereas, AAV8 has a higher tropism for the liver and in a 
murine model was found to have 10-100 fold higher transduction than AAV2 
[191 ;209;210]. Unlike other serotypes, AAV8 can transduce multiple organs and
disseminate throughout the body; Nakai et al. found that intravascular administration o f 
a rAAV8 vector at a high dose could transduce all the skeletal muscles throughout the 
body [211]. Furthermore, a recent study demonstrated systemic gene transfer in skeletal 
and cardiac muscle following intravenous injection o f AAV8 [212]. It can therefore be 
considered as a robust vector for gene transfer, albeit caution is required as spillover and 
undesirable transduction could have adverse consequences. Inagaki and colleagues
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have recently discovered that AAV9 is as robust as AAV8 and can also cross vascular 
endothelial cell barriers very efficiently and transduce many nonhepatic tissues 
following systemic administration [213], This study and two others have also shown 
that serotype 9 preferentially transduces the myocardium and, in terms o f gene delivery 
efficiency to this tissue, outperforms AAV8 [214;215].
Interestingly, one study has shown that the primary barrier to transduction o f the liver 
with AAV2 is slow uncoating o f its vector genome in the nucleus. Conversely, vector 
genomes packaged inside AAV6 and AAV8 do not persist as encapsidated molecules, 
but uncoat rapidly and are, therefore, able to convert to stable, biologically active 
double-stranded molecular forms more efficiently [216]. Furthermore, a recent study 
has helped to elucidate the transduction mechanisms o f AAV8. Here, they screened a 
mouse liver complementary DNA library for cellular proteins capable o f interacting 
with the viral capsid proteins. The researchers identified two endosomal proteases, 
cathepsins B and L, which act as uncoating factors for a number o f other viruses and, in 
the report, they demonstrate the ability o f these cathepsins to bind to and cleave the 
capsids o f both AAV8 and AAV2. Interestingly, AAV2 and AAV8 were found to be 
processed differently by the proteases and AAV8 exhibited a quicker rate o f cleavage; 
these differences were thought to account for the more rapid uncoating and higher 
transduction efficiency o f AAV8 [217].
1.7.2.5 AAV and cell surface receptors
The diverse tissue tropisms o f different AAV serotypes is partly due to their binding to 
alternate cellular receptors. AAV2 has been shown to bind to various receptors 
including HSPG [218], human fibroblast growth factor receptor 1 (FGFR1) [219], 
hepatocyte growth factor receptor [220] and integrins a vp5/ a vpi [221]. Furthermore, 
the amino acids within the capsid o f AAV2 that contribute to HSPG binding have been 
identified [222]. These amino acids are not present in the capsids o f AAV1, AAV3 and 
AAV6, yet serotypes 3 and 6 still have the ability to bind HSPG [200;206]; other 
residues must, therefore, be responsible for heparin binding. In a similar manner to that 
o f AAV2, AAV3 also binds to FGFR1 [223]. In contrast to the aforementioned 
serotypes, AAV4 uses sialic acid, and AAV5 both sialic acid and platelet-derived 
growth factor (PDGF) receptors, for binding [224;225]. Recent reports have also shown 
that in certain cell types, sialic acid is used by both AAV1 and AAV6 [226;227], and a 
further study has established that they use N-linked and not O-linked sialic acids [228].
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The laminin receptor (Lam-R) has recently been identified as the receptor for AAV8 
and, in addition, was found to play an important role in the transduction o f serotypes 2, 
3 and 9. The Lam-R is constitutively expressed in several tissues, which may explain 
the broad tissue tropism o f AAV8 [229].
1.7.2.6 AAV and immunity
Unlike adenoviruses, little or no innate immunity is induced following AAV vector 
transfer in vivo. An adaptive immune response, however, does occur which can 
eliminate the vector and the transfected cells, thus limiting sustained transgene 
expression. Adaptive immunity includes a humoral response, characterised by the 
production o f neutralising antibodies specific for the vector or transgene antigen, and a 
cell-mediated response involving T-cells and N-K cells. The adaptive cell-mediated 
response, however, is far weaker with AAV vectors than with other viral vectors due to 
the inability o f AAV to efficiently transduce or activate antigen presenting cells (APCs).
The prevalence o f anti-AAV2 antibodies in the human population ranges from 35 to 
80% according to the age group and geographic location [187]. Pre-existing immunity 
to AAV2 ultimately creates an additional barrier to effective gene delivery by an AAV2 
vector and reduces the efficiency o f repeated administration. Neutralising antibodies to 
other AAV serotypes have also been identified in the human population. Xiao et al. 
screened a cohort o f 77 normal human volunteers for the presence o f neutralising 
antibodies to AAV serotypes 1 and 2 and found that 20% had anti-AAVl antibodies and 
27% had anti-AAV2 antibodies [230]. The prevalence o f neutralising anti-AAV5 and 6 
antibodies has also been assessed in 37 normal individuals; only 10-20% were 
seropositive for AAV5 and 20-30% seropositive for AAV6 [231]. Neutralising anti- 
AAV5 antibodies are clearly uncommon and, in fact, one study reported that they were 
consistently negative in 85 healthy human subjects [232]. Several studies carried out in 
animals have shown that neutralising antibodies eliminate or greatly reduce the levels o f 
transgene expression o f the re-administered vector. Repeated administration o f AAV2, 
in particular, was found to inhibit transgene expression in both the lung [233] and liver 
[234]. Fortunately, the alternative AAV serotypes offer more benefit in terms o f 
evading the host immune response [235;236]. The cross-reactivity between neutralising 
antibodies o f different serotypes has been assessed. For example, Halbert and 
colleagues re-administered various AAV vectors in mouse lung and discovered that 
serum from mice pre-immunised with AAV2 did not neutralise AAV6 infection, and
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vice-versa, indicating that neutralising anti-AAV2 and 6 antibodies do not cross-react in 
mice [237]. Another study found that AAV1, 2 and 5 could be cross-administered in 
immunocompetent mice without causing any significant change in gene expression 
[208].
One o f the main advantages o f  using the non-human primate isolates AAV7, 8, 10 and 
11 is their ability to evade the human immune system; neutralising antibodies to these 
serotypes are rare in human serum and when present are low in activity [192;194;207]. 
For example, haemophilia B dogs receiving intraportal injections o f an AAV2/8 vector, 
expressing factor IX, did not develop vector-related toxicity and antibodies against the 
transgene [238]. There is also a lack o f cross-reactivity between mouse antisera against 
AAV2, AAV10 and AAV11 capsids [239]. Furthermore, intrapleural administration o f 
an AAV 10 vector, expressing alpha 1-antitrypsin, provided long-term transgene 
expression in mice pre-immunised with AAV5 [240]. AAV serotype 9, although 
isolated from human tissue, also has the ability to circumvent the neutralising effect o f 
pre-existing AAV antibodies. Recently, an AAV9 vector was found to efficiently 
transduce murine alveolar and nasal epithelia and, most importantly, could be re­
administered without diminution [241].
1.7.2.6.1 Factors influencing immune responses against the AA V vector
Both cell-mediated and humoral responses to components o f the AAV vector and the
delivered transgene depend on a number o f factors; these include the nature o f the
transgene, the promoter used, the route o f administration, vector dose and host factors.
The route o f administration and promoters are the two factors more relevant to the work
carried out in this thesis, which are therefore discussed in more detail below.
Route of administration
Several studies have shown that the extent o f the immune response varies greatly with 
the route o f administration. Mice that were given AAV-ovalbumin (OVA) injections 
intraperitoneally, intravenously or subcutaneously all developed antibodies against 
OVA and cytotoxic T-cells specific to OVA. A much weaker cytotoxic cell-mediated 
response, however, was generated in mice injected via the muscle [242]. Conversely, in 
a later study using muscle directed AAV2 gene transfer, OVA expression was 
completely eliminated by a local immune response, involving cytotoxic T-cells [243]. 
Interestingly, a cell-mediated response to human factor IX was observed in mice after
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intramuscular administration, but a much weaker immune response was elicited 
following hepatic gene transfer [244]. One explanation for this is that immune tolerance 
has, previously, been found to favour the high expression o f factor IX and the 
associated antibody suppressive CD4+ T-cells produced following liver directed gene 
transfer [245]. Another report, however, has further complicated the issue o f anti-AAV 
immunity; in this study an autoimmune response in nonhuman primates resulted from 
AAV vector transfer o f erythropoietin injected into the muscle and aerosolised in the 
lung. This immune response could not be restricted to specific serotypes as it was 
observed in 3 o f the 4 serotypes tested and was not due to intramuscular administration 
as it was also seen in macaques where the AAV vector was administered via the lung 
[246],
Promoters
Interactions between transgene promoters and the host immune system have been well 
documented. Cytokines present at the site o f injection can either inhibit or activate 
promoters. For example, IFN-y and IL-10 were discovered to down-regulate the 
activity o f the cytomegalovirus (CMV) promoter in endothelial cells, whereas, TN F-a, 
IL -lp  and IL-4 increased promoter activity [247]. Mouse strain-specific differences in 
the induction o f these cytokines has also been hypothesised to influence CMV shut­
down [248]. In addition, the CMV promoter is subject to transcriptional silencing in 
some tissues, by methylation o f the CpG dinucleotides [249]. The hybrid version o f this 
promoter, CMV enhancer/chicken p-actin (CAG), however, is not susceptible to 
silencing and has been reported to show 137-fold higher transgene expression compared 
with the CMV promoter in the liver [250]. The CAG promoter was also found to be 
more active than the CMV promoter in the lung [251] and has exhibited efficient 
transgene expression in muscle [252]. Although both CMV and CAG drive high levels 
o f  transgene expression in many different types o f cells and tissues, expression from 
these promoters is often only temporary and inactivation by the host immune system is 
likely instigated.
One approach that is now being used in an attempt to evade the host immune system is 
the incorporation o f  a promoter in the vector that constrains expression to the tissue 
being transduced. Several reports have shown that tissue-specific promoters 
significantly eliminate host immune reactions to the vector and transgene. A recent
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study directly compared the efficiency o f two AAV vectors driven by a liver-specific 
promoter (LSP) and a CAG promoter. No antibodies against the transgene were 
detected in response to the AAV-LSP vector, whereas the CAG-driven vector provoked 
an escalating cellular immune response resulting in a much lower level o f transgene 
expression [253]. The importance o f using tissue-specific promoters in skeletal muscle 
has also been documented. The muscle creatine kinase (MCK) promoter, which was 
first used by Cordier et al. [254] has been reported in several studies to evade the host 
immune response. In one study, a MCK promoter/enhancer directed a high level o f 
muscle-restricted transgene expression and provoked only a humoral (not cellular) 
immune response [255]. Similarly, a recent study found that a hybrid promoter 
containing the MCK enhancer and simian virus 40 (SV40) promoter yielded long-term 
expression o f a reporter gene following electrotransfer o f  the plasmid into mice; 
expression using the CMV and CAG promoters, however, diminished within a few 
weeks [256]. Tissue specificity has also been achieved with the use o f a small, MCK 
regulatory element, CK6 [257] and a synthetic C512 promoter, consisting o f a 
combination o f several myogenic regulatory elements (TEF-1, MEF-1, MEF-2 and 
TEF-1) [258]. One study demonstrated therapeutic levels o f F.IX transgene expression 
from the C512 promoter in vivo, however, it failed to eliminate antibody formation in 
response to F.IX [259]. In another report the CK6 promoter, although only 10% as 
active as the ubiquitous CMV promoter in vivo, regulated microdystrophin gene 
expression and was readily tolerated by mice for at least 8 weeks [260].
1.7.2.7 Skeletal muscle as a target tissue for AAV transduction
Skeletal muscle is an important target for gene delivery and it is now viewed as an
attractive alternative to the liver. Muscle is easily accessible for delivery o f vectors, 
highly vascularised and actively secretory and a stable tissue with little nuclear 
turnover, which allows it to function as a reservoir for heterologous expression o f 
recombinant proteins [261 ;262]. Indeed, the transduction o f skeletal muscle with rAAV 
has been extensively applied to animal models for the treatment o f various genetic 
diseases. AAV has a natural tropism for muscle fibres and several studies have shown 
that when rAAV vectors are injected into muscle transgene expression reaches a plateau 
and is sustained for weeks [263;264]. In fact, Xiao et al. [264] observed maintained 
expression o f LacZ  following muscle transduction for 1.5 years without elicitation o f an 
immune response.
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In 1999, Chao et al. administered a rAAV2 vector expressing FIX into the skeletal 
muscle o f haemophilic B dogs and demonstrated circulating FIX at levels o f 1-2% of 
normal for a year post-injection, albeit plasma infusions were still required [265]. 
Improvements, however, were reported a year later using a CMV-driven rAAV2 vector; 
sustained therapeutic levels o f FIX and partial correction o f whole blood clotting and 
activated thromboplastin time were achieved in treated dogs [266]. AAV-mediated 
gene transfer to skeletal muscle has also been assessed for its potential to treat muscle 
wasting diseases such as limb-girdle muscular dystrophy [267-269]. In a recent report, 
Pacak et al. intramuscularly injected sarcoglycan-deficient mice with a creatine kinase 
promoter-driven AAV serotype 1 vector expressing the human sarcoglycan gene. 
Expression was localised to the sarcolemma and reduced muscle fibre damage was 
apparent; moreover, animals showed continued tissue correction for 6 months post­
administration o f vector [268]. In a canine model o f Duchenne muscular dystrophy, 
prolonged AAV6-mediated microdystrophin expression in the skeletal muscle was 
achieved using a short course o f immunosupression. Canine microdystrophin was still 
present in the muscle 30 weeks post-injection and its expression restored localisation of 
components o f the dystrophin-associated protein complex at the muscle membrane 
[270].
1.7.2.8 AAV vector improvements
1.7.2.8.1 Hybrid AA V vector engineering from  different AA V serotypes
Despite the fact that AAV has enjoyed some success in human clinical trials, several
challenges remain. For example, the prevalence o f pre-existing neutralising antibodies
in humans previously exposed to AAV significantly attenuates the efficacy o f AAV
vectors [233;234]. Additional problems with AAV vectors include their limited
packaging capacity [271], poor infection o f refractory cells [272] and achieving targeted
delivery o f therapeutic transgenes to specific tissue types. These challenges have
therefore, prompted the generation o f new AAV vectors with selective features from
different serotypes that synergistically enhance transgene expression.
Hauck et al. developed a strategy to generate mosaic vectors, which have a capsid 
structure composed o f a mixture o f capsid proteins from different serotypes. By mixing 
helper plasmids encoding the capsid proteins o f AAV1 and AAV2 in the transfection 
process, he was able to combine the strong affinity o f AAV1 for muscle and the high
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heparin binding activity o f AAV2 into one hybrid vector [273]. Using a similar 
approach, Rabinowitz et al. generated mosaic vectors by the transfection o f pairwise 
combinations o f helper constructs for AAV serotypes 1 to 5 at different ratios. Some o f 
the properties o f the two serotypes were shared, some were masked and some were 
dominant depending on the ratio o f the helper plasmid used. Furthermore, additive 
properties, found in neither o f the parental serotypes were observed in the new mosaic 
vectors. Another interesting observation was the differing mosaic AAV titers; high 
titers were obtained from mosaic vectors involving a combination o f either serotypes 1, 
2 or 3, whereas intermediate AAV titers were obtained from serotype 5 mixtures [274].
Chimeric vectors differ from mosaic vectors in that they contain capsid proteins that 
have been modified by amino acid or domain swapping between different serotypes. 
Samulski and colleagues have recently shown that it is possible to transfer the muscle 
binding characteristics o f AAV1 to AAV2 by swapping only five amino acid residues. 
The same group have produced a chimeric AAV3 vector, exhibiting higher transduction 
efficiency in mouse heart compared with the parental AAV3; this was achieved by 
substituting similar amino acid residues [239]. Another study has reported the 
characterisation o f a chimeric vector, named AAV-221-IV, for its effectiveness in the 
treatment o f haemophilia B in mice. Here they replaced amino acids 350 to 430 o f 
AAV2 VP1 with the corresponding amino acids from VP1 o f AAV1 and discovered 
that intramuscular injection o f this hybrid vector produced 4-10 fold higher human 
factor IX expression in the plasma compared with the AAV2 vector [275].
Directed evolution has been used in a number o f facets, for example to generate 
enzymes with novel catalytic qualities [276] and retroviruses with new properties [277]. 
Directed evolution can be brought about by strategies such as DNA shuffling and error- 
prone PCR, which generate diversity by recombination and combining useful mutations 
from individual genes. Maheshri et al. have developed an efficient and high-throughput 
method to generate AAV vectors with improved capabilities. They produced a large 
AAV2 library with randomly distributed capsid mutations and selected for AAV 
variants that had altered receptor-binding properties and with the ability to evade 
neutralising antibodies [278].
1.7.2.8.2 Other new technologies fo r  AA V vector improvements
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Short peptide sequences that encode specific receptor ligands have been engineered into 
the AAV capsid open reading frame as a way to alter vector tropism. These changes 
can result in vectors with expanded or more selective tropism. The success o f the 
introduction o f receptor-targeting peptides into AAV capsid proteins depends on proper 
surface display and presentation o f the ligand to its receptor. Extended work has 
therefore, been carried out to identify the best position for insertion in the AAV2 capsid. 
Girod et al. inserted a peptide containing an RGD m otif into the surface loop position 
(residue 587) o f AAV2. The modified vector was capable o f transducing a cell line 
normally refractory to AAV2 infection [279]. Phage display methods o f randomised 
peptide sequences have also been used to select peptides with cell-specific binding 
properties. For example, AAV2, normally has a relatively poor tropism for endothelial 
cells, however, insertion o f a phage display-derived peptide increased the efficiency and 
selectivity o f AAV2 endothelial cell transduction following intravenous injection [280]. 
Caution, however, is required with these techniques since the genetic insertion o f 
foreign sequences can often result in loss o f function or loss o f virion integrity. A novel 
approach to AAV vector targeting has, thus been described which involves engineering 
AAV vectors to be metabolically biotinylated during production in mammalian cells. 
These biotinylated vectors can be easily purified by affinity chromatography on an 
avidin resin and also efficiently targeted to cells engineered to express the avidin-biotin 
receptor [281].
Several techniques have been used to overcome the packaging constraint o f AAV 
(Figure 1-5); for example “mini-genes” have been generated which fit into a single 
AAV virion [282] and large genes have been split into small fragments which are then 
packaged into separate AAV viruses. The key issue, however, with the latter approach 
is the ability o f the fragments to reassemble into a functional expression unit within the 
cell. One approach has been to split the gene into two overlapping fragments, which 
then re-assemble in the cell through homologous recombination between the two 
fragments. AAV6 has demonstrated the highest efficiency for overlapping vector- 
mediated muscle gene therapy [283].
1.7.3 Self-complementary AAV vectors
A major limiting factor in the efficiency o f ssAAV vectors is their requirement for 
either host-cell mediated synthesis o f the complementary-strand or annealing o f the plus 
and minus strands from two separate viral particles co-infected into the same cell.
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Samulski et al. (2001), however, have found a way to circumvent this problem by 
packaging both strands as a single DNA molecule. By utilising the knowledge that 
rAAV DNA o f half or less than the wtAAV genome length can be packaged as a dimer 
[284] they have developed a self-complementary vector [285]. In this construct the 
terminal resolution site (trs), from which replication initiates, is deleted from one o f the 
ITR regions and the effect is that replication initiates from the wild-type ITR, proceeds 
through the mutant end without terminal resolution and continues back across the 
genome, using the opposite strand as a template to create the dimer. The result is a 
linear self-complementary genome with two wild-type ITRs at either end and a mutated 
ITR in the middle (Figure 1-7). After uncoating in the cell nucleus, the vector rapidly 
undergoes base pairing to form a double-stranded molecule without the help o f the host, 
thus, bypassing the rate-limiting step. In one study, transduction o f mouse liver, muscle 
and brain with the scAAV vector demonstrated faster onset o f gene expression and 
higher transduction efficiency when compared with the conventional ssAAV [286]. A 
later study also reported stable and rapid transgene expression following intramuscular 
injection o f a scAAV vector, but, in addition, discovered that transgene expression from 
scAAV was balanced over time by the ssAAV vector [287]. Molecular rearrangement 
o f the ssAAV vector genome into either circular or linear concatemers is an essential 
event for stable persistence o f the transgene in vivo [177; 178]. A double stranded 
structural intermediate is required for such molecular rearrangements to occur, and since 
this event does not occur immediately after transduction, a rapid disintegration o f linear 
single-stranded vector genome follows. In contrast, delivery o f the double-stranded 
scAAV genome may account for stable persistence early after transduction. Recently, 
Nathwani et al. reported a 20-fold improvement in human FIX expression in mice, 
following transduction o f the liver with an AAV8 pseudotyped scAAV vector. 
Furthermore, they found that an AAV5 pseudotyped scAAV vector mediated efficient 
transduction in non-human primates with pre-existing immunity to AAV8 [288].
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Figure 1-7. Conventional ssAAV vs scAAV vectors
This diagram illustrates how ssAAV and scAAV vectors differ in the size o f  their 
transgene cassette, their replication and generation into viral particles and their 
infection and formation o f transcriptionally active rAA V genomes. Both vectors are 
flanked by ITRs. however, the right-hand ITR o f scAA V vectors is mutated by deleting 
the terminal resolution site (TRS) within the D sequence (AD/TRS). The effect is that 
replication initiates from the wild-type ITR, proceeds through the mutant end without 
terminal resolution and continues back across the genome, using the opposite strand as 
a template to create the dimer. The result is a linear self-complementary genome with 
two wild-type ITRs at either end and a mutated ITR in the middle. The scAA V transgene 
cassette, however, must be half the size o f  the conventional ssAAV vector, which is 
achieved by using truncated promoters [288] and/or removing non-coding sequences. 
After uncoating in the cell nucleus, the vector genomes are converted into double­
stranded transcriptionally active DNA. For ssAA V-mediated transduction, annealing o f  
plus and minus genomes, and perhaps second-strand synthesis is required, both o f  
which are considered rate limiting steps. For scAAV vectors, the complementary 
sequences rapidly hybridise to form stable DNA duplexes.
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1.8 Non-viral, plasmid-based gene therapy
The main advantage o f using non-viral vectors is their safety; they have reduced 
immunogenicity and, since they are only expressed episomally, their capacity for 
insertional mutagenesis is minimal. Another key benefit is their ability to be 
manufactured in quantity and to high purity at a low cost. Unfortunately, in humans, 
non-viral gene transfer has been greatly hindered by poor transfection efficiency and 
failure to achieve sustained gene expression, nevertheless, recent advances have helped 
to improve their efficiency and cell-specificity. Conventional non-viral methods o f 
delivering transgenes include the interaction o f DNA with cationic polymers; for 
example, liposomal formulations, which encapsulate the DNA and allow the plasmid to 
be phagocytosed by the cell [289]. Cationic peptide sequences with nuclear-import 
signals and which assist DNA compaction [290], and polyethylenimine, which can be 
conjugated to a cell-specific ligand for receptor-mediated endocytosis [291], have also 
been used to enhance plasmid DNA delivery. These methods can effectively assist 
DNA entry into the cell in vitro\ however, in vivo the transfection efficiency is poor and 
only transient gene expression is achieved. Barriers to efficient in vivo transfection 
include blood plasma proteins, binding to a broad variety o f non-target cell types and 
the extracellular matrix. Transfection complexes must, therefore, be soluble, small 
enough to allow passage through physiological barriers and have target cell specificity. 
Once inside the cell, the passage o f the transgene to the nucleus is also hampered by 
obstacles such as cytoplasmic degradative enzymes and the double-membrane structure 
o f  the nuclear envelope.
The most important improvements in plasmid delivery, however, have been achieved 
with the use o f physical methods such as hydrodynamic pressure [292], microinjection 
o f DNA into individual cells [293] and electroporation [294]. Electroporation or 
electrotransfer involves the application o f an electrical field to the cells or tissue, which 
increases cell membrane permeability and facilitates the transport o f plasmid DNA into 
and through the cell. Electroporation was originally developed for in vitro transfection 
[295] and has now become a standard laboratory method. Skeletal muscle has been the 
most investigated target tissue for gene therapy by in vivo electroporation due to its 
ready access and ability to sustain long-term expression o f the episomal plasmid. 
Intramuscular electroporation has, therefore, been tested therapeutically with many gene 
types in numerous disease models. This technique resulted in highly efficient transfer
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o f the p-galactosidase reporter gene in dystrophic muscle with limited muscle damage. 
Approximately 40% o f muscle fibre was efficiently transfected over a period o f 1 week, 
with both the superficial and deep portions o f the dystrophic muscle displaying P- 
galactosidase expression [296]. In cancer gene therapy, intramuscular electrotransfer o f 
IL-12 resulted in significant levels o f plasma IL-12, which persisted for at least 60 days 
and completely regressed murine tumours [297]. Another success in cancer therapeutics 
was reported with electroporation-mediated intramuscular injection o f a plasmid 
expressing TIMP-4. Here, sustained plasma TIMP-4 levels were demonstrated for a 
period o f 14 days and accompanied by significant tumour suppression [298]. The direct 
electrotransfer o f a plasmid expressing human IL-1 receptor antagonist (IL-IRa) to 
skeletal muscle was reported to reduce the incidence o f collagen-induced arthritis with 
the effect lasting for 20 days. The investigators demonstrated a peak on day 10 in the 
level o f IL-IRa in the injected area and in serum, followed by a gradual decrease [299]. 
In most studies, electroporation significantly enhanced and resulted in long-term gene 
expression compared with injection o f plasmid DNA alone. The means, however, by 
which electroporation enhances gene expression in skeletal muscle is debatable. It is 
widely believed that the electric pulses create pores in the membrane through which the 
plasmids move by an electrophoretic effect [300]. Another study proposed a 
mechanism o f DNA uptake by receptor-mediated endocytosis [301]. Neither o f these 
mechanisms, however, explain how prolonged transgene expression is achieved in 
muscles after electroporation, although one recent report suggests that activation and 
transfection o f myogenic satellite cells, which develop into regenerated muscle fibres, 
could be involved [302].
Extra-chromosomal replication and stability is another hurdle for plasmid-mediated 
gene delivery. Plasmid DNA that is delivered to the nucleus is generally not replicated 
and is lost during the breakdown o f the nuclear envelope at mitosis. A plasmid, 
however, has been generated that contains an SV40-ori sequence and the 
scaffold/matrix attachment region (S/MAR) from the human P-interferon gene cluster 
[303]. This plasmid, designated “pEPI”, does not require viral genes for episomal 
maintenance and is stably propagated over several cell generations in culture without 
selection [304]. The S/MAR element in pEPI has been found to interact with 
components o f the nuclear matrix [305]. Interestingly, one study reported that the CMV 
promoter, in a vector construct containing S/MAR, was not subject to silencing by 
cytosine methylation and, thus, long-term gene expression was observed. Whether this
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was due to the S/MAR present in this construct, the episomal status o f the vector or a 
combination o f both, is still uncertain [306]. The bacterial backbone o f plasmid DNA 
also seems to be a factor in transgene silencing. Recently the use o f DNA vectors 
devoid o f bacterial sequences gave robust and persistent transgene expression [307].
The methods discussed above all rely on the host cell machinery to achieve long-term 
nuclear gene expression, but at the same time avoid disrupting host gene expression or 
signalling pathways. This factor makes non-viral gene transfer preferable over the 
currently used viral-based methods. Furthermore, these advances in non-viral gene 
transfer now make the potential to mimic viral mechanisms, such as nuclear 
maintenance and replication, more realistic.
1.9 Gene therapy and ApoE
1.9.1 Viral
Recombinant adenoviruses (rAd) were used for the first gene transfer studies with ApoE 
in 1995; they reported a lowering in plasma cholesterol in ApoE'7* mice and a 
deceleration in aortic atherogenesis following intravenous injection [308]. 
Unfortunately, further research using this first generation rAd vector was hindered due 
to a strong cytotoxic T-cell immunological response directed against both the transgene 
and the rAd proteins. Transduced hepatocytes were cleared and repeat vector 
administration was precluded as a result o f this immune response. Significant progress, 
however, was seen 5 years later in a study where ApoE'7' and immunodeficient mice 
were cross-bred and injected with rAd.ApoE3; a complete regression in advanced 
plaques at 6 months was demonstrated [309].
Prolonged ApoE transgene expression and reduced toxicity was observed with a 2nd 
generation rAd vector, which had additional viral genome sequences deleted or 
inactivated in other early genes (E2 and/ or E4). One study used this new rAd vector to 
compare hepatic expression o f different human ApoE isoforms in ApoE'7' mice with 
established atherosclerotic lesions. ApoE4 was found to be less effective in reducing 
regression and, most importantly, liver-secreted ApoE gained access to the arterial 
intima, where it is believed to sequester excess cellular cholesterol [310], A subsequent 
study using this 2nd generation rAd vector expressing ApoE3 further demonstrated the 
non-lipid lowering effect o f ApoE. Here they found that liver-derived ApoE could
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induce regression o f pre-existing atherosclerotic plaques in LDLR*7* mice without 
lowering plasma cholesterol levels and altering the lipoprotein profile. Furthermore, the 
expressed ApoE markedly reduced isoprostane levels, a marker o f oxidative stress, 
highlighting that the anti-oxidant property o f ApoE contributes to its atheroprotective 
actions [311].
An improved rAd.ApoE3 vector, with E l, E3 and DNA polymerase deleted, exhibited 
high levels o f plasma ApoE and normalised the hyperlipidaemia in ApoE'7' mice. 
Inhibition o f early aortic lesions in these mice as well as regression o f advanced 
atheroma in older animals was also observed, however, the effect was transient due to 
cellular shutdown o f the CMV promoter [312]. Nevertheless, sustained ApoE transgene 
expression was achieved with the use o f a (E1-, E3-, polymerase-, pTP-) rAd vector 
containing either a liver-specific promoter [313] or a promoter for cellular elongation 
factor l a  (E F -la ) [314]. Although plasma ApoE levels were low, significant 
retardation o f atherosclerosis was demonstrated. An alternative rAd vector, known as 
the helper-dependent rAd (HD-rAd), has also been used for ApoE mediated gene 
transfer. A single intravenous injection o f this vector carrying the mouse ApoE 
genomic locus into ApoE*7* mice provided lifelong correction o f hypercholesterolaemia. 
Interestingly, the same vector expressing ApoE cDNA did not perform as well; ApoE 
levels slowly declined over time resulting in a partial return o f the 
hypercholesterolaemic phenotype [315].
Replication-defective rAAV are attractive candidate vectors for gene transfer as, unlike 
rAd vectors, they are non-pathogenic and devoid o f all viral structural genes, which 
diminishes the potential for a host immune response. For these reasons, rAAV vectors 
have also been used to mediate ApoE gene transfer. An AAV vector expressing human 
ApoE3 was used to transduce the tibialis anterior (TA) muscle o f young ApoE*7* mice 
and although hyperlipidaemia was not reversed, as the levels o f ApoE secreted were 
low, there was a 29% reduction o f plaque formation up to 3 months later [316]. This 
study utilised a rAAV vector derived from AAV serotype 2, which is now well 
documented to be inefficient in vivo compared with other serotypes and could explain 
the disappointing outcome. Indeed, liver-directed administration o f a pseudotyped 
AAV2/8 vector, expressing ApoE, into ApoE*7* mice produced normal human levels (50 
to 80/ig/ml) in the plasma [317]. More recently, intravenous injection o f AAV2/7 and 
AAV2/8 vectors expressing human ApoE3 produced sustained therapeutic levels o f
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ApoE3 in plasma and cholesterol levels were lowered for up to 1 year. Furthermore, at 
termination atherosclerosis in these mice was completely prevented [318].
1.9.2 Non-viral
Transplantation o f normal (ApoE+/+) bone marrow cells into ApoE'7' mice successfully 
restores ApoE expression and, consequently, results in the reversal o f 
hypercholesterolaemia and prevention o f atherosclerosis progression in these animals 
[148; 149]. One study has determined the minimal concentration o f plasma ApoE 
required to reduce plasma cholesterol completely. By mixing ApoE+/+ bone marrow 
with A poE '' bone marrow in increasing amounts and transplanting it into ApoE'7' 
recipient mice, it was deduced that only approximately 1/ig ApoE/ml plasma (2.5% o f 
normal levels) was required [319]. A novel gene therapy approach for the treatment o f 
atherosclerosis in ApoE*7* mice has been the transplantation o f homologous bone 
marrow cells, transduced with ApoE-expressing retroviral (RV) vectors. Initial studies 
using this technique observed ApoE expression from arterial macrophages and 
protection from early atherosclerosis in treated animals [320;321]. Later, a self- 
inactivating retroviral vector with macrophage-restricted expression was developed and 
which was reported to reverse both hypercholesterolaemia and atherosclerotic lesion 
development [322].
1.9.2.1 Plasmid-mediated
Although muscle does not normally secrete ApoE, non-hepatic, non-macrophage- 
derived ApoE is known to be atheroprotective [96;323]. For example, Rinaldi et al. 
injected naked plasmid DNA expressing human ApoE3 into the skeletal muscle o f 
A poE" mice and observed a sustained lowering in plasma cholesterol [324]. Another 
study, in contrast, reported that plasmid injections o f ApoE into the muscle o f ApoE'7' 
mice was not effective in reducing hyperlipidaemia, although, atherosclerotic lesion and 
xanthoma formation were significantly reduced after 9 months [325].
1.9.2.2 Cell-based therapies
A cell-based gene therapy approach utilising endothelial cells secreting ApoE has also 
been developed. The investigators delivered the endothelial cells intradermaly into 
ApoE'7' mice and found a significant lowering in plasma cholesterol, which was 
concomitant with a reduction in atherosclerotic lesion size [326]. Further refinement o f
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the cell-based gene-therapy approach for ApoE gene transfer has been investigated by 
Tagalakis et al. Here, Chinese hamster ovary (CHO) cells expressing human ApoE3 
were encapsulated into alginate-based microspheres and implanted into the peritoneal 
cavity o f ApoE'7' mice. ApoE3 was successfully secreted into the plasma, which 
lowered total cholesterol levels and increased atheroprotective HDL. Unfortunately, by 
day 14 both ApoE and total cholesterol levels had rebounded, which was believed to be 
due to the emergence o f anti-ApoE antibodies, perhaps exacerbated by a non-specific 
host inflammatory reaction to capsule constituents [327].
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Vector/expression
plasmid
Animal
model
Target tissue Plasma total 
cholesterol
Lipoprotein profile Plaque development and 
regression
Duration of expression Ref.
rAd.CMV.ApoE3 (1st 
generation)
ApoE mice Liver 84% 4 4 VLDL/IDL/LDL and 
T in HDL
4 in aortic lesion 
development
1 month [308]
rAd.CMV.ApoE3 (I s* 
generation)
ApoE'7' nude 
mice
Liver 84% 4 4 VLDL/IDL/LDL and 
t  in HDL
87% 4 in advanced aortic 
lesions
6 months [309]
rAd.CMV.ApoE2/E3/ 
E4 (2nd generation)
ApoE’7' mice Liver E2 = 50% 4 
E3 and E4 = 
70% 4
4 VLDL/IDL/LDL and 
t i n  HDL
E2/E3/E4 ^  4 in 
progression, and E3 
regression
6 weeks [310]
rAd.CMV.ApoE3 (2nd 
generation)
LDLR'7'
mice
Liver No 4 No change 53% regression o f advanced 
lesions
6 weeks [311]
rAd.CMV.ApoE3 (2nd 
generation Pol' vector)
ApoE'7' mice Liver and 
muscle
Liver-directed 
= 1
Liver-directed = 4 
VLDL/IDL/LDL and T 
in HDL
Liver-directed = 38% 4 in 
progression and 40% 
regression
Gradual decline after 7 days [312]
rAd.LSP.ApoE3 (2nd 
generation)
ApoE'7' mice Liver No 4 No change 30% 4 aortic lesion 
development
Very low plasma levels over 
28 weeks
[313]
rAd.EF-la.ApoE3 (2nd 
generation)
ApoE'7' mice Liver No 4 No change 15% 4 aortic lesion 
development
Very low plasma levels over 
37 weeks
[314]
HD-rAd.ApoE3 ApoE ' mice Liver 50% 4 4 VLDL/IDL/LDL and 
t  in HDL
Lesion-free aortas after 2.5 
years
Detectable levels for >4 
months
[315]
rAAV2.CMV.ApoE2/
E3
ApoE'7' mice Muscle No 4 No change E3 => 29% 4 aortic lesion 
development
Undetectable levels [316]
rAAV 2/7. LSP. ApoE3 
and
rAAV 2/8. LSP. ApoE3
ApoE'7' mice Liver 92% 4 4 VLDL/IDL/LDL and 
t  in HDL
Lesion-free aortas after 1 
year
Stable expression for 128 
days and gradual decline 
thereafter
[318]
RV.CMV.ApoE3 ApoE'7' mice Ex-vivo bone 
marrow cells
No 4 No change Significant 4 aortic lesion 
development
Expression for 5.5 months [320]
Self-inactivating
RV.CMV.ApoE3
ApoE*7* mice Ex-vivo bone 
marrow cells
66% 4 No data 74% 4 aortic lesion 
development
59% the level o f  wt mice 12 
weeks post-transplantation
[322]
p.CMV.ApoE3 ApoE*;" mice Muscle 42% 4 4 VLDL/IDL/LDL and 
t  in HDL
No data Very low plasma levels 4 
weeks post-injection
[324]
p.CMV.ApoE2/E3 ApoE*7" mice Muscle No 4 No change E2 20-30% 4 aortic 
lesion development
E2 => detectable levels, E3 
=> undetectable levels
[325]
Table 1-2 Viral and non-viral gene therapy approaches for the delivery of ApoE
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1.10 Aims of thesis
The main aim o f this thesis is to identify and evaluate a potentially safe and effective 
rAAV vector(s) for reversing hypercholesterolaemia and regressing atherosclerotic 
plaques, namely muscle-based expression o f human ApoE3 using rAAV to provide 
sustained systemic delivery. The work/steps carried out to achieve this aim are as 
follows:
• To construct ssAAV2 and scAAV2 plasmids all expressing human ApoE3, but 
driven by three different promoters, including two muscle specific (C512 and 
CK6) and one constitutive promoter (CAG). Cultured C 2C 12 myoblasts were then 
transiently transfected with all plasmids to check their ability to express ApoE3 in 
vitro.
• To directly inject these plasmids into skeletal muscle o f ApoE'7' mice via electro­
transfer and assess their efficiency in vivo.
• To generate pseudotyped ssAAV and scAAV vectors by packaging the AAV2 
vector genome with the capsid from AAV serotype 7.
• The ssAAV and scAAV vectors, expressing ApoE3 were directly injected into 
skeletal muscle o f ApoE'7' mice to form stable transgenic myofibres secreting 
ApoE.
• To evaluate the ability o f these gene therapeutics to reverse hyperlipidaemia in this 
murine preclinical model o f human heart disease. These studies will allow direct 
comparison o f ssAAV and scAAV as gene therapy vectors and determine the most 
efficient promoter to drive ApoE3 expression.
•  The ssAAV2/7.CAG.ApoE3 vector performed significantly better than the muscle- 
specific promoter-driven AAV vectors. We, therefore, decided to pseudotype the 
ssAAV2.CAG.ApoE3 vector with additional serotypes 8 and 9, which were 
directly injected into the skeletal muscle o f young ApoE'7' mice. These serotypes 
were selected as both are reported to transduce various tissues efficiently and 
globally through systemic vector administration. Furthermore, there are no studies 
to date that have assessed transgene expression following direct injection o f AAV9 
into skeletal muscle.
•  This study will allow the direct comparison o f serotypes 7, 8 and 9 and determine 
which is most efficient for AAV transduction into skeletal muscle, with the 
ultimate goal to reverse hyperlipidaemia and inhibit the progression o f 
atherosclerosis.
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Chapter 2:
Materials and Methods
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2 MATERIALS AND METHODS
2.1 Materials
2.1.1 Plasmid vectors and DNA resources
The ssAAV2.CAG plasmid was kindly given to us by Dongsheng Duan (University o f 
Missouri, Columbia, MO USA), while Jeffrey S. Chamberlain (University o f 
Washington, Seattle, Washington USA) and George Dickson (Royal Holloway 
University o f London, Egham, Surrey) provided the CK6 and C512 promoters 
respectively. The scAAV2 plasmid was from Amit C. Nathwani (Department o f 
Haematology, University College London, London, U.K). The p.CMV.DsRed2-Cl 
plasmid (p.CMV.RFP) was purchased from BD Clontech.
2.1.2 Animals
C57BL/6 ApoE 7' mice were bred and housed at The Royal Holloway University o f 
London, and had originally been generated by inactivation o f the mouse ApoE  locus 
through homologous recombination [328].
2.1.3 Cell culture reagents
Dulbecco’s modified Eagle’s medium (DMEM, Sigma, Gillingham, Dorset, UK) 
Heat-inactivated fetal bovine serum (FBS, Sigma)
Heat-inactivated horse serum (Sigma)
L-glutamine (Sigma)
Streptomycin (lOmg/ml) and penicillin (10,000 units/ml) solution (Sigma)
Phosphate-buffered saline (PBS; 138mM NaCl, lOmM Na2HP04, 1.75mM KH2P 04, 7.2mM 
KCL)
Trypsin-EDTA (0.25% trypsin and 0.2g EDTA) (Sigma)
Dimethylsulphoxide (DMSO; Sigma)
Trypan blue (Sigma)
Lipofectamine™ 2000 (Invitrogen, Paisley, UK)
2.1.4 Molecular Biology reagents
Bovine serum albumin (BSA; Sigma)
NuPAGE® LDS sample buffer (4x) (Invitrogen)
P-mercaptoethanol (Sigma)
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MagicMark™ XP (Invitrogen)
NuPAGE® Novex 4-12% Bis-Tris polyacrylamide gels (Invitrogen)
NuPAGE® MES SDS running buffer (20*) (Invitrogen; 50mM MES, 50mM Tris base, 0.1% 
SDS, ImMEDTA)
NuPAGE® Antioxidant (Invitrogen)
Hybond ECL nitrocellulose membrane (Amersham Biosciences, Piscataway, USA)
Hybond-hT nitrocellulose membrane (Amersham Biosciences)
NuPAGE® Transfer buffer (20*) (Invitrogen; 25mM Bicine, 25mM Bis-Tris, ImM EDTA) 
Ponceau S solution (Sigma)
Tween 20 (Sigma)
ECL detection system (Amersham Biosciences)
Hyperfilm ECL (Amersham Biosciences)
Restriction endonucleases (New England BioLabs, Ipswich, MA, USA)
Calf intestinal alkaline phosphatase (CIP) (New England BioLabs)
10* DNA ligase buffer (Promega; 300mM Tris-HCl (pH 7.8 at 25°C), lOOmM MgCl2, lOOmM 
DTT and lOmM ATP)
T4 DNA ligase (Promega, Southampton, UK)
S.O.C medium (Invitrogen; 2% tryptone, 0.5% yeast extract, lOmM NaCl, 2.5mM KC1, lOmM 
MgCL, lOmM MgS04, 20mM glucose)
LB agar (Sigma; 1% tryptone, 0.5% yeast extract, 1% NaCl, agar 15 g/L)
LB broth (Sigma; 1% tryptone, 0.5% yeast extract, 1% NaCl)
Ethidium bromide (Sigma)
Agarose (Biogene, Kimbolton, Cambs., UK)
10* BLUEJUICE Gel Loading Buffer (Invitrogen; 65% sucrose, lOmM Tris-HCl, lOmM 
EDTA, 0.3% bromophenol blue)
Novex TBE Hi-Density Sample Buffer (Invitrogen; 18mM Tris base, 18mM boric acid, 0.4mM 
EDTA, 3% Ficoll, 0.02% bromophenol blue, 0.02% Xylene Cyanol)
TBE running buffer (Invitrogen; 89mM Tris base, 89mM boric acid, 2mM EDTA)
CelLytic MT Mammalian Tissue Lysis/Extraction Reagent (Sigma)
Complete mini, EDTA-free Protease Inhibitor cocktail tablets (Roche, Welwyn Garden City, 
Hertfordshire, UK)
Ampicillin sodium salt (Sigma)
Kanamycin (Sigma)
Benzonase (Sigma)
Optiprep density gradient medium/ Iodixanol (Sigma)
DNase I amplification grade (Invitrogen)
Proteinase K (Sigma)
Glycogen (Invitrogen)
Infinity cholesterol liquid stable reagent (Thermo Electron Corporation, Manchester, UK)
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2.1.5 Antibodies
Polyclonal goat anti-human ApoE antibody (#0650-1904, Biogenesis, Poole, UK)
Anti-goat IgG (whole molecule, peroxidase conjugate) (Sigma)
Goat polyclonal anti-human ApoE antibody (#178479, Calbiochem/Merck Biosciences) 
Recombinant Apolipoprotein E (#178475, ApoE3 isoform; Calbiochem/Merck Biosciences)
2.1.6 Kits
Bio-Rad Protein Assay Kit (Bio-Rad, Hemel Hempstead, UK)
ECL Protein Biotinylation Module (Amersham Biosciences)
TMB substrate kit (Pierce, Perbio Science, Northumberland, UK)
DH5a chemically competent E.coli (Invitrogen)
One shot TOP 10 chemically competent E.coli (Invitrogen)
Wizard Plus SV miniprep DNA Purification System (Promega)
QIAquick Gel Extraction Kit (Qiagen, Crawley, West Sussex, UK)
EndoFree Plasmid Maxi kit (Qiagen)
QuantiTect SYBR Green PCR Kit (Qiagen)
PureLink™ HiPure Plasmid Megaprep kit (Invitrogen)
ECL direct nucleic acid labelling and detection system (Amersham)
Hydragel Lipo + Lp(a) K20 kit (Analytical Technologies, Hampshire, UK)
The PlusOne silver staining kit (GE Healthcare, Buckinghamshire, UK)
2.1.7 Equipment
Nalgene Cryo 1°C Freezing Container (Fisher Scientific, Leicestershire, UK)
37°C incubator (Jencons Millenium C 02 incubator, Jencons-PLC, Leighton Buzzard, UK) 
Inverted phase-contrast microscope (Nikon TMS, Jencons-PLC)
Dynex plate-reader (Jencons-PLS, East Sussex, UK)
Novex Western Transfer apparatus (Invitrogen)
Compact X4 (X-ograph Imaging Systems, Wiltshire, UK)
Dynex plate washer (Dynex Technology, West Sussex, UK)
Horizon minigel apparatus (Life Technologies)
UVP Epi Chem II Darkroom (Jencons-PLC)
Image analysis software (Labworks UVP, Media Cybernetics, USA)
XCell SureLock Mini-Cell (Invitrogen)
UVIKON 930 spectrophotometer (Kontron Instruments, Bletchley, UK)
BTX ECM 830 electroporator and Tweezertrodes (Kramel Biotech, Cramlington, UK) 
Rotor-stator homogeniser (Scientific Laboratory Supplies Ltd, Nottingham, UK)
RotorGene RG3000 (Corbett Research, Cambridge, UK)
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Quick-Seal Ultra-Clear Ultracentrifuge tubes (Beckman Coulter, Buckinghamshire, UK 
Biomax 100 ultrafiltration device (Millipore, Watford, UK)
96-well dot-blot manifold apparatus (Schleicher and Schuell, London, UK)
Hydragel K20 applicator carrier (Analytical Technologies)
Electrophoresis chamber (Analytical Technologies)
Hyrys 2 Hit densitometer with the Phoresis software (Analytical Technologies)
2.2 Methods
2.2.1 Molecular biology methods
2.2.1.1 Polymerase Chain Reaction (PCR)
PCR is a process by which a section o f DNA can be amplified in a sequence-specific 
manner. The selected region o f a genome can be amplified a billion-fold with the use o f 
short oligonucleotide primers o f 15-30 bases in length, which possess sequence 
complementarity with the target. The primers lie on opposite strands o f DNA and flank 
the region to be amplified. Each cycle o f the reaction requires a heat denaturation step 
to separate the double-stranded DNA and this is achieved by heating the target DNA to 
94°C or more. The DNA is then cooled to allow the oligonucleotide primers to anneal 
specifically to complementary sequences and the primers are extended using 
thermostable DNA polymerase. The extension reaction creates two double-stranded 
target regions, which can be denatured, again ready for a second cycle o f hybridisation 
and extension. A third cycle produces two double-stranded molecules that comprise the 
target region in double-stranded form. By repeated cycles o f heat denaturation, primer 
annealing and extension, there follows a rapid exponential accumulation o f the target 
fragment o f DNA.
2.2.1.1.1 General PCR protocol
For each PCR a master mix was prepared as shown in Table 2-1.
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Reaction component Volume (/il) Final concentration
10* PCR buffer 2.5 1*
50mM MgCl2 0.75 1.5mM
lOmM dNTP mix 0.5 200/xM
10/xM Forward primer 1.5 0.6/xM
10/xM Reverse primer 1.5 0.6/xM
Taq polymerase (5U//xl) 0.25 1.25U
DNA template 5 50ng
Nuclease-free water 13 -
Total Volume 25
Table 2-1. PCR master mix components
In order to minimise contamination, gloves were worn at all times, filter-protected 
pipette tips were used and the reactions were prepared in a designated PCR room. In 
addition a negative PCR control was set up which contained all the above components 
apart from the DNA template. The initial denaturation step at 94°C was carried out for 
5 min, followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at 58°C-68°C 
for 30 sec and polymerisation at 72°C for 30 sec. A final ‘polishing o f f  polymerisation 
step at 72°C for 5min completed the PCR. A primer design tool called ‘DNA 
calculator’ on the Sigma Genosys website (http://www.sigma- 
genosys.com/calc/DNACalc.asp) was used to design all the primers (Table 2-2); this 
tool provided essential information such as melting temperature (Tm), and potential 
secondary structure and primer dimer formation. All PCRs were carried out in a Bio- 
Rad iCycler, which has a heated lid to prevent loss o f sample through evaporation upon 
heating.
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Primer Sequence (5’ to 3’) Tm (°C)
TF T CCAAGGAGCTGCAGGCGGCGCA 83
TR ACAGAATTCGCCCCGGCCTGGTACACTGCCA 84
BSRGIC512F AGT C AGT GT AC AT A AT GATT AACCCGCC AT GC 73
XHOC512R AT AAT ACTCG AG ACC AT GGT GGCG AT GG AT CC 77
C512NheF AT CTT AGCT AGCCGT AGCC AT GCT CT AG AC AT 72
C512Acc65R CGCGGTACCGTCGACTGCAGAATTCCT 78
CK6NheF AT ATT AGCT AGC AACCCGCC ATGCT ACTT AT C 71
CK6BsiWIR AT ATT ACGT ACGT G ATTCGGCCGT CT AG AGG A 74
CK6F1 T CT AGGCT GCCC AT GT AAGG 64
CKR1 AGG AGCCT AC AGGGT GT G A 62
ApoEQ-PCRF AAG AACT G AGGGCGCT GAT G 66.6
ApoEQ-PCRR GTT GTTCCTCC AGTT CCG AT 62.9
Table 2-2. Primer sequences used for PCR 
2.2.1.2 Agarose gel electrophoresis
Both PCR products and plasmid DNA digests were analysed using agarose gel 
electrophoresis. Double-stranded DNA molecules migrate through the gel matrix from 
the cathode to the anode area and separate according to their size. Ethidium bromide, 
when added to the gel, intercalates between adjacent base pairs o f the DNA molecules 
and allows visualisation o f distinct DNA bands when viewed under ultraviolet (UV) 
light. A DNA fragment o f a given size migrates at increasing rates through gels 
containing lower concentrations o f agarose. For efficient separation, the smaller the 
fragment the higher the percentage o f agarose in the gel.
A minigel electrophoresis apparatus was set up as recommended by the manufacturer. 
For a 1% agarose gel, 0.5g o f agarose was dissolved in 50ml o f 1* Tris-borate EDTA 
(TBE) buffer (lOOmM Tris, pH 8.4, 90mM boric acid and ImM EDTA) by heating in a 
microwave. Once the solution had cooled, ethidum bromide was added at a 
concentration o f 0.5^g/ml and the gel solution was then poured into the minigel 
cassette, within the electrophoresis chamber. When the gel had set, the comb was 
removed and a sufficient volume o f TBE buffer was added to cover the surface o f the
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gel. The DNA samples were mixed 4:1 with 10x BLUEJUICE Gel Loading Buffer and 
10-20/xl o f each sample along with a DNA ladder were loaded into each well. The gel 
was subjected to electrophoresis at 150V for 20min or until the dye-front was ~ 1cm 
from the bottom of the gel. The gel was visualised on a UV transilluminator connected 
to a computer operated camera and image analysis software (UVP Epi Chem II 
Darkroom).
2.2.1.3 TBE gel electrophoresis
Pre-cast polyacrylamide TBE gels were also used in this study, as they require less 
sample concentration and volume have high resolution and sensitivity and give lower 
background staining than agarose gels. Both 20% and 6-20% TBE gels were used with 
the XCell SureLock Mini-Cell electrophoresis apparatus. DNA samples were mixed 
with 5* Novex TBE Hi-Density Sample Buffer (final concentration I*) and, following 
the addition o f 200ml o f 1x TBE running buffer to the upper buffer chamber and 600ml 
to the lower buffer chamber, the samples along with a DNA ladder were loaded into the 
appropriate wells. The gel was subjected to electrophoresis at 200V for lh  and then 
carefully removed and stained with 0.5/ig/ml o f ethidium bromide for lOmin on a 
shaker. The gel was visualised as described above.
2.2.1.4 Real-time quantitative PCR (Q-PCR)
Real-time Q-PCR allows the reaction to be monitored as it progresses and is an 
extension o f the PCR technique which Kary Mullis and colleagues developed in the 
mid-1980s [329;330]. A basic PCR “run” can be separated into 3 phases, termed the 
exponential, linear and plateau phases. During the exponential phase, an exact doubling 
o f product is accumulating at every cycle, while in the following linear phase, the 
substrates are being consumed, the reaction is slowing and products are beginning to 
degrade. The plateau phase is when the reaction has stopped and therefore no more 
products are being made. Traditional PCR results are obtained from this final end­
point. The end-point, however, is variable from sample to sample and agarose gels are 
not able to resolve these differences in yields. In contrast, it is the highly precise 
exponential phase, which is monitored in Q-PCR, allowing determination o f the initial 
copy number, or relative quantity o f a particular gene as expressed within that system. 
Fluorescence is measured during each cycle and an increase in reported fluorescent 
signal is directly proportional to the amount o f PCR product. At the end o f a reaction, a
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threshold fluorescence is defined which is measured as a function o f the background 
fluorescence. For each reaction, it is possible to establish a cycle number at which this 
threshold is crossed, termed the Cycle Threshold (Ct). The CT is directly proportional 
to the amount o f starting template in the reaction (Figure 2-1 A).
PCR product can be detected using either fluorescent dyes or fluorescently labelled 
sequence-specific probes. In this study the SYBR® Green I fluorescent dye was used, 
which binds to the minor groove o f all double-stranded DNA molecules, emitting a 
fluorescent signal o f a defined wavelength on binding (Figure 2-2). The only 
disadvantage o f using SYBR Green I is that non-specific PCR products and primer- 
dimers will also contribute to the fluorescent signal. The PCR conditions must 
therefore be altered to increase the specificity o f  the reaction. In addition, a melt curve 
can be performed immediately following the PCR, which is used to analyse the 
specificity o f the reaction (Figure 2 -IB). A melt curve is achieved by gradually 
increasing the thermocycler temperature from the annealing (~55-60°C) to the 
denaturing temperature (~99°C). The SYBR Green dye is released into the reaction mix 
as the amplicon denatures and this should occur at a specific temperature for each 
reaction product formed. More than one peak is observed on the melt curve if  non­
specific binding has occurred and ideally, only one peak should be present.
2.2.1.4.1 Real-time Q-PCR protocol
Real-time Q-PCR was used in this study solely for the quantification o f viral titer, 
therefore, purified virus was the template for all reactions. The virus preparations were 
diluted 1:1000 with nuclease-free water and 5/xl o f this was used in the reaction. Primer 
sequences within the ApoE gene (ApoEQ-PCRF and ApoEQ-PCRR) were designed to 
amplify a 72bp amplicon. A reaction mix was prepared, as shown in Table 2-3, using 
the Quantitect kit (Qiagen), which contains a ready-prepared 2* mix o f PCR buffer, 
dNTPs, MgCh, Tag polymerase and SYBR Green I dye.
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Reaction component Volume (ji 1) Final concentration
2x Quantitect mix 12.5 lx
10/xM Forward primer 1 0.4/iM
10/iM Reverse primer 1 0.4/xM
DNA template 5
Nuclease-free water 5.5 -
Total Volume 25
Table 2-3. Real-time Q-PCR reaction mix components
The amounts listed in the table were added to 0.2ml thin-walled, flat-cap, PCR tubes 
and then placed in the RotorGene RG3000. The following programme was used for all 
reactions:
Reaction step Temperature Time
Enzyme activation 95°C 10 min
Annealing 95°C 15 sec
Extension 60°C 15 sec r* x 4 0  cycles
Final extension 72°C 20 sec J
The reaction was followed immediately with a melt curve analysis to give a measure o f 
the reaction specificity. The copy number o f DNA in each sample was calculated from 
a standard curve o f known amounts o f linearised vector DNA, which was serially 
diluted from 102 to 108.
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Figure 2-1. Typical amplification plot and melt curve
(A) Different individual Ct values are obtained from the defined threshold. The graph 
represents the background fluorescence A, the exponential phase B, the linear phase C, 
and the plateau phase D. (B) A melt curve revealing only one peak in each template 
sample and verifying the specificity o f the primers. As expected the negative control 
samples (without template) do not show any amplification.
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Figure 2-2. The principle of SYBR Green 1 based detection of PCR products in 
real-time PCR
When the DNA is denatured, the SYBR Green dye diffuses free, but following 
polymerisation the dye intercalates with the double-stranded product giving rise to a 
rapid increase in fluorescence emission.
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2.2.1.§ Extraction and Purification of DNA
The QIAquick Gel Extraction Kit was used for the purification o f DNA from agarose 
gel or directly from a PCR and restriction enzyme digest reaction. The relevant DNA 
bands were excised from the agarose gel using a UV light and scalpel and weighed to 
determine the volume o f solubilisation and binding buffer (QG solution) to be added. 
The QG solution was added to the gel slice at a ratio o f 3:1 (e.g lOOmg gel = 300/il QG 
solution) and the mixture placed at 50°C to solubilise the gel. One gel vol o f room 
temperature isopropanol was then added to the solution and, if  extracting DNA directly 
from a PCR or restriction enzyme digest, an additional 3 vol o f QG solution and 1 vol 
o f isopropanol were added to the reaction mix. The solution was then transferred to a 
QIAquick spin column and centrifuged at 13,000 rpm for lm in to allow binding o f 
DNA. The flow-through was discarded and the column was washed with 0.75ml o f PE 
buffer and re-centrifuged as before and then for an additional 2min to remove any traces 
o f ethanol. The DNA was eluted with 30/xl o f nuclease-free water and the concentration 
determined by measuring the optical density at 260nm (OD260) with a UVEKON 930 
spectrophotometer. The following equation was used:
DNA concentration (iig/ml) = OD26o x 50 (spectrophotometric conversion rate)* dilution factor
2.2.1.6 Restriction enzyme digestion of plasmid DNA
Restriction endonucleases are enzymes purified from bacteria that recognise and cleave 
specific and short nucleotide sequences within DNA. Restriction sites comprise 
palindromes o f 4, 5, 6 or more bp, each with an axis o f rotational symmetry. Cleavage 
by a restriction enzyme produces either cohesive (having either a 5 ' or 3 ' single­
stranded protrusion) or blunt-ended (no single-stranded protrusion) fragments. 
Cohesive fragments can be subsequently ligated to plasmids if their single-stranded 
protrusions or ‘overhangs’ are compatible. All blunt-ended fragments can be ligated to 
each other.
Manufacturer recommended buffers and instructions were used to digest up to 2/ig of 
plasmid DNA. The reaction buffers (NEBuffers 2 to 4) contained varying 
concentrations o f Tris-HCl (pH 7.5), NaCl, and MgC^. A restriction enzyme reaction 
was set up as detailed below (Table 2-4) and incubated at the optimum temperature for 
at least 2h.
77
Component Volume Oil) Final
concentration/amount
Reaction buffer (10x) 2 lx
BSA (lO x) 2 lx
Restriction enzyme 
(10U//xl)
1 10U
DNA - 2/ig
Nuclease-free water - To a total volume o f 20/il
Table 2-4. The restriction enzyme reaction components
All the enzymes used in this study and their required conditions are detailed in Table 
2-5. In most cases a double digest was performed where the DNA was cleaved 
simultaneously with two restriction enzymes and a buffer was selected that resulted in 
the most activity for both enzymes. However, when different incubation temperatures 
were needed for each enzyme, or when no single buffer was found to satisfy their buffer 
requirements, the reactions were carried out sequentially. Between each reaction, a 
purification step was necessary to remove any previously used buffer and restriction 
enzyme.
78
Restriction
enzyme
Cleavage site Reaction conditions for 
optimal activity
X hol C/TCGA G 
G AGCT/C
NEBuffer 2 at 37°C
Spel A/CTAG T 
T GATC/A
NEBuffer 2 at 37°C
X bal T/CTAG A 
A GATC/T
NEBuffer 2 at 37°C
SapI GCTCTTC(N)i
CGAGAAG(N)4
NEBuffer 4 at 37°C
BsrGI T/GTAC A 
A CATG/T
NEBuffer 2 at 37°C
Acc65I G/GTAC C 
C CATG/G
NEBuffer 3 at 37°C
SnaBI TAC/GTA
ATG/CAT
NEBuffer 4 at 37°C
EcoRV GAT/ATC 
CT A/TAG
NEBuffer 3 at 37°C
N hel G/CTAG C 
C GATC/G
NEBuffer 2 at 37°C
BsiWI C/GTAC G 
G CATG/C
NEBuffer 3 at 55°C
BssHII G/CGCG C 
C GCGC/G
NEBuffer 3 at 50°C
MscI TGG/CCA
ACC/GGT
NEBuffer 4 at 37°C
Smal CCC/GGG
GGG/CCC
NEBuffer 4 at 25°C
Table 2-5. Restriction enzyme cleavage sites and reaction conditions
2.2.1.7 Ligation reaction
During ligation in vitro, DNA ligase catalyses the formation o f a phosphodiester bond 
between adjacent nucleotides only if one nucleotide carries a 5’-phosphate residue and 
the other carries a 3 ’-hydroxyl terminus. Prior to performing a ligation reaction 
between plasmid and insert, it is necessary to remove the 5’-phosphate residues from 
both termini o f the plasmid DNA with alkaline phosphatase to minimise re- 
circularisation o f plasmid DNA. The following reaction mix was prepared (Table 2-6):
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Component Volume (fil) Final
concentration/amount
Purified linear vector 
(eluted in 30/il)
30 1-2/ig
10x NEBuffer 3 4 lx
C alf intestinal alkaline 
phosphatase (CIP) (1 U//xl)
1 1U
Nuclease-free water 5 Total volume = 40/il
Table 2-6. Alkaline phosphatase reaction components
The reaction mix was incubated for lh  at 37°C and then purified through a Qiagen 
column. For all ligations a 1:3 molar ratio o f vectoriinsert DNA was used and the 
following equation was used to convert molar ratios to mass ratios for a given plasmid 
and insert DNA fragment size:
(ng o f vector* kb size o f insert/ kb size o f vector) * molar ratio (insert .vector) = ng o f insert 
The reaction mix was composed o f the following (Table 2-7):
Component Volume (/iI) Final concentration/amount
Vector - lOOng
Insert - Calculated from equation
10x DNA ligase buffer 1 lx
T4 DNA ligase (2 Weiss 
Units//il)
0.5 1U
Nuclease-free water - To a total volume o f lO/il
Table 2-7. Ligation reaction components
The reaction components were then mixed and incubated at room temperature for 4h. A 
control reaction mix was also prepared containing every component apart from the 
insert DNA; this allows background level o f re-circularised plasmid to be assessed.
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2.2.1.8 Transformation of plasmid DNA in competent E. coli.
The ability o f bacterial cells to take up recombinant DNA vectors is enhanced when the
cells are in a ‘competent’ state [331]. This can be achieved by treating bacterial cultures 
with an ice-cold solution o f 50mM calcium chloride prior to heating. D H 5a and TOP 10 
chemically competent E.coli were used for the transformation reactions in this study. 
Firstly, 5/xl o f the ligation reaction was gently mixed with either 50/xl o f TOPIO or 
100/xl o f D H 5a cells and incubated on ice for 30min. The D H 5a cells were then heat- 
shocked for exactly 45sec in a 37°C water bath, while the TOPIO cells were incubated 
for 30sec in a 42°C water bath. Both D H 5a and TOPIO transformation mixes were then 
placed on ice for 2min, followed by the addition o f 900/xl and 250/xl o f S.O.C medium 
respectively and incubation at 37°C in a shaking incubator for lh. A volume o f 50/xl o f 
the transformation mix was then spread onto a pre-dried Luria Bertani (LB) agar plate 
containing either 100/xg/ml o f ampicillin or 50/xg/ml o f kanamycin (depending on the 
plasmid antibiotic resistance) and left overnight in a 37°C incubator. The ampicillin and 
kanamycin plates allow only transformed bacteria to grow as the vectors contain either 
an ampicillin or kanamycin resistance gene. The next day single colonies were picked 
and grown in 5ml o f LB broth containing the appropriate antibiotic by overnight 
incubation in a 37°C shaking incubator. Recombinants were identified by PCR directly 
from the overnight cultures; primers were designed to amplify the insert (see results 
section 3.2.1.1) and the initial denaturation step was extended to lOmin. The cultures 
were purified using the Wizard Plus SV miniprep DNA Purification System (see section 
2.2.1.9) and recombinants were confirmed by restriction enzyme digestion.
2.2.1.9 Plasmid DNA mini-prep purification
The overnight culture was first centrifuged at 13,000 rpm for 2min prior to the use o f 
the Wizard Plus SV miniprep DNA Purification System. The supernatant was removed 
and the cell pellet was re-suspended in 250/xl o f Cell Resuspension Solution (50mM 
Tris-HCl (pH7.5), lOmM EDTA, 100/xg/ml RNAse A). This was followed by the 
addition o f 250/xl o f Cell Lysis Solution (0.2M NaOH, 1% SDS), a short incubation at 
room temperature for 5min and then the addition o f 10/xl o f Alkaline Protease solution 
to inactivate endonucleases and proteins. After 5min incubation at room temperature, 
350/xl o f Neutralization Solution (4.09M guanidine hydrochloride, 0.759M potassium 
acetate, 2.12M glacial acetic acid) was added and the solution was immediately mixed 
by inversion and centrifuged at 13,000 rpm for lOmin. The cleared lysate was 
transferred to a spin-column and centrifuged at 13,000 rpm for lmin, after which the
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flow-through was discarded and the column washed with 750/d o f Column Wash 
Solution (60mM potassium acetate, lOmM Tris-HCl (pH 7.5), 60% ethanol). The 
column was washed a second time and then the plasmid DNA eluted by adding 50/d o f 
nuclease-free water and centrifuging at 13,000 rpm for lmin.
2.2.1.10 Plasmid DNA maxi-prep purification
Larger amounts o f endotoxin-free plasmid DNA were needed for animal injections and 
for in vitro transfections to produce recombinant AAV; it was necessary, therefore, to 
use an EndoFree Plasmid Maxi kit to purify the plasmid DNA for these applications. 
Endotoxins are cell membrane components o f Gram-negative bacteria (e.g, E.coli), 
which strongly decrease the transfection efficiency o f DNA into cultured cells and cause 
fever, endotoxic shock syndrome and activation o f the complement cascade in animals. 
It was essential, therefore, to remove any traces from the plasmid preparations and to 
ensure that all plastic-ware and media were free from endotoxin contamination. A 
starter culture was diluted 1:500 into 100ml o f LB broth containing the appropriate 
antibiotic and grown overnight in a 37°C shaking incubator. The bacterial cells were 
harvested by centrifugation at 6,000* g for 15min at 4°C and then re-suspended in 10ml 
buffer P I . The cells were then lysed by the addition o f 10ml o f buffer P2 and incubated 
at room temperature for 5min. A volume o f 10ml o f chilled buffer P3 was then added 
to the lysate, mixed thoroughly and poured into a QLAfilter cartridge. After a lOmin 
incubation at room temperature to allow the precipitate to float to the top o f the 
solution, a plunger was inserted into the QLAfilter cartridge and the lysate was filtered 
into a 50ml tube. A volume o f 2.5ml o f buffer ER was added to the solution, mixed 
thoroughly and then incubated on ice for 30min. During this time, a QIAGEN-tip 500 
was equilibrated by the addition o f 10ml o f buffer QBT and allowed to empty by 
gravity flow. The filtered lysate was applied to the column and was again allowed to 
enter the resin by gravity flow, after which the column was washed with 2* 30ml o f 
buffer QC. The DNA was eluted with 15ml o f buffer QN and precipitated by the 
addition o f 10.5ml (0.7 vol) o f room-temperature isopropanol and centrifuged 
immediately at 15,000* g for 30min at 4°C. The supernatant was carefully decanted 
and the DNA pellet was washed with 5ml o f endotoxin-free room-temperature 70% 
ethanol and centrifuged as before for lOmin. The pellet was air-dried for 5-10min and 
re-suspended in endotoxin-free TE buffer or sterile 0.9% NaCl for animal injections.
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2.2.1.11 Plasmid DNA mega-prep purification
The PureLink™ HiPure Plasmid Megaprep kit was used to isolate even larger quantities 
o f plasmid. This kit uses an anion exchange resin to purify plasmid DNA to a level 
equivalent to two passes through CsCl gradients and provides efficient endotoxin 
removal (levels are <0.1 EU/pg DNA). A starter culture was diluted 1:500 into 1.5L o f 
LB broth containing the appropriate antibiotic and grown overnight in a 37°C shaking 
incubator. The bacterial cells were harvested by centrifugation at 6,000x g for 15min at 
4°C and then re-suspended in 50ml o f buffer R3. A 50ml volume o f lysis buffer (L7) 
was then added to the cell suspension to lyse the bacterial cells and the tube was 
inverted gently until a homogeneous lysate was observed. Following 5min incubation 
at room temperature, 50ml of precipitation buffer (N3) was added to neutralise the 
lysate, which was mixed gently but thoroughly until a completely non-viscous and 
homogeneous mixture was obtained. A white, flocculent precipitate o f proteins, cellular 
debris, genomic DNA and detergent is formed during this process. The bacterial lysate 
was then poured into a megaprep lysate filtration cartridge attached to a 500ml Duran 
bottle and a vacuum source. Before applying the vacuum, the lysate was left to stand 
for 2min without agitation, which allows the precipitate to float to the top and ensures 
efficient filtration without clogging. Around 125ml o f clarified lysate containing 
plasmid DNA was drained though after the vacuum was applied and to further ensure 
that all lysate had passed through the cartridge, 50ml o f wash buffer (W8) was added. 
Next, the lysate was passed over a vacuum-assisted megaprep DNA binding filter, 
which was pre-equilibrated with 100ml o f buffer EQ. The negatively charged 
phosphates on the DNA backbone interact with the positive charges on the resin surface 
and under moderate salt conditions the plasmid DNA binds to the resin. RNA, protein, 
carbohydrates and other impurities are washed away by the addition o f 350ml o f wash 
buffer. The binding cartridge was then attached to a sterile (autoclaved) Duran bottle 
and the plasmid DNA was eluted under high salt conditions with 50ml o f elution buffer 
(E4). The eluted DNA was finally desalted and concentrated by an alcohol precipitation 
step as described before in section 2.2.1.10.
2.2.2 Cell culture
Human Embryonic Kidney (HEK) 293-T cells and murine C2C12 myoblast cells were 
the two cell lines used in this study. C2C12 myoblasts, which are derived from normal 
adult C3H mouse leg muscle, divide rapidly and can differentiate into post-mitotic, 
multinucleate myotubes when exposed to horse serum or low-serum medium. HEK
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293-T cells are a packaging cell line which constitutively express the adenovirus E l a 
protein and the SV40-T antigen [332] and are generally used for the production o f viral 
vectors. This cell line is used in preference to conventional 293 cells as they show a 
high level o f transfection efficiency and subsequently improved rAAV yields.
2.2.2.1 General culture maintenance and cryopreservation
Both cell lines mentioned above are adherent and were cultured in 75 or 175cm2 tissue 
culture flasks, in DMEM, supplemented with 10% (v/v) FBS, 2mM L-glutamine, 
100/xg/ml streptomycin and lOOIU/ml penicillin. They were maintained in an incubator 
at 37°C with a humidified atmosphere o f 5% CO2 and 95% air. The cells were split by 
trypsinisation when semi-confluent; they were first washed with warm PBS (37°C) and 
incubated with 0.25% (v/v) trypsin-EDTA at 37°C for 2min, which was then neutralized 
by the addition o f pre-warmed fresh growth medium. The cells were then re-suspended 
and split 1:3-1:6.
For cryopreservation, the cells were first pelleted at 300g for 5min and then re­
suspended in 90% FBS and 10% (v/v) DMSO; this solution lowers the freezing point 
and allows the cells to be slowly cooled without any damage. The cell suspension was 
divided into 1.8ml cryovials and initially placed in a Nalgene Cryo 1°C Freezing 
Container and stored at -80°C for 5-6h which reduces the temperature by 1°C per min. 
The cells were subsequently transferred to liquid nitrogen for long-term storage.
Trypan blue was used to count the cells and assess cell viability; it is a dye that is only 
retained by dead cells, therefore, differentiating them and allowing only the viable cells 
to be counted. Trypan blue was diluted 1:10 with cell suspension and pipetted into the 
chambers o f  a haemocytometer, which was then observed under an inverted phase- 
contrast microscope. The number o f viable cells were counted in 8 * 1mm squares with 
a total volume of 10"4 cm3. The average was then multiplied by the dilution factor and 
104 to give the number o f cells per ml.
2.2.2.2 Transient transfection of murine C2C12 myoblasts
Murine C2C12 myoblasts were seeded at a concentration o f 2* 105 per well o f a 6-well 
plate and left overnight to adhere. The cells were cultured in DMEM containing 10% 
(v/v) heat-inactivated FBS (incubated at 55°C for 30min), 2mM L-glutamine, 100/ig/ml
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streptomycin and lOOIU/ml penicillin. For transfection the next day the cells needed to 
be 90-95% confluent to obtain high efficiency and expression levels, and to minimize
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decreased cell growth associated with high transfection activity. Lipofectamine 2000, 
which is a cationic lipid, was used for transfection o f the C2C12 cells, adding plasmid 
DNA at a ratio o f 1:2. In two separate microfuge tubes, 2/xg o f plasmid and 4/xl o f 
Lipofectamine™ 2000 were diluted in 50/rl o f DMEM without FBS and antibiotics and 
incubated at room temperature for 5min. The diluted plasmid and lipofectamine 
solutions were then gently mixed together (total volume o f lOOjrl) and incubated at
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room temperature for 20min to allow the plasmid-Lipofectamine 2000 complexes to 
form. During this incubation period, the normal growth medium from the cultured 
myoblasts was removed and replaced with 2ml o f DMEM without FBS and antibiotics. 
The lOO/il complex solution was then added drop-wise to the cells in one well o f the 6- 
well plate and the cultures incubated at 37°C for 5h. Following transfection, the 
medium was removed and replaced with fresh DMEM containing 10% FBS, glutamine 
and antibiotics and the cultures were left to grow under normal conditions for 24h. 
They were then either processed for ApoE analysis or transferred for a further 24h to 
DMEM containing 5% heat-inactivated horse serum to induce cell differentiation and 
fusion into large multinucleate myotubes.
2.2.2.3 Protein quantification
Samples o f medium were transferred to pre-chilled microcentrifuge tubes, and 
centrifuged at 13,000 rpm for 5min at 4°C to pellet any dead cells. The supernatant was 
concentrated 10* using 30,000 MWCO vivaspin concentrators and total protein was 
quantified using the ‘Bio-Rad Protein Assay K it’. This assay is based on the Bradford 
dye-binding procedure [333] in which the Coomassie Brilliant Blue G-250 dye changes 
colour in response to various concentrations o f protein.
Seven dilutions o f the protein standard BSA were prepared in PBS, ranging from 
160/ig/ml -  2.5j^g/ml. A volume o f 160/xl o f each standard and sample was added in 
triplicate to appropriate wells o f a 96-well plate, followed by 40/xl o f dye reagent 
concentrate. The samples were mixed thoroughly and incubated at room temperature 
for at least 5min. The optical density (OD) at 595nm was read using a Dynex plate- 
reader, allowing a standard curve o f O D 5 9 5  versus concentration to be plotted and from 
this the concentration o f test samples was determined.
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2.2.3 Recombinant AAV vector production
As described in section 1.7.2.3, AAV production has changed significantly over the 
years. One important improvement has been the development o f plasmids containing 
parts o f the Ad genome necessary for rAAV production, resulting in the elimination o f 
infectious helper virus contamination. Such plasmids have been developed by Grimm 
et al. [334], Matsushita et al. [335] and Xiao et al. [196] and all reported good yields, if  
not better than those observed using infectious helper Ad virus. Grimm et al. used a 
two-plasmid system in which the helper Ad genes, the Rep68/78 genes and the Cap 
genes are assembled into one plasmid and the AAV vector sequences are in another. 
Xiao et al. in contrast, developed a three-plasmid system in which the helper Ad genes 
were separated from the Rep and Cap genes and placed into two different constructs.
2.2.3.1 Triple transfection of rAAV plasmid, helper Ad plasmid and packaging 
plasmid into 293-T cells
In this study, the three-plamid system was used which involved the triple transfection o f 
293-T cells with a helper Ad plasmid (HGTI) a pAAV-based plasmid (a vector flanked 
by the AAV-serotype 2 ITRs and harbouring the cDNA o f interest), and a packaging 
plasmid containing the AAV Rep and Cap genes, at a molar ratio o f 3:1:1 respectively 
(Figure 2-3). Since the generation o f pseudotyped AAV vectors was required, the 
packaging construct contained AAV2 Rep proteins, but Cap proteins from an alternative 
serotype (7, 8 or 9).
The day before transfection, 293-T cells were seeded into 40 (15cm diameter) dishes at 
a cell density o f between 8-9.5 * 106 cells/dish, so that the cultures were about 70% 
confluent the following day. On the day o f transfection, the following transfection 
mixture was prepared for 10 dishes in a 50 ml Falcon tube:
Plasmid/reagent Amount/volume Final concentration
HGTI 300/xg
pAAV lOOjig
pAAV7-2 100/xg
2.5M CaCl2 1.25ml 0.25M
ddH20 made up to 12.5ml
Table 2-8. Components of the transfection mix
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While aspirating the above mix with a 1ml pipette to create bubbles, 12.5ml 2x HEPES- 
buffered saline (HBS; 280mM NaCl, lOmM KC1, 1.5mM Na2HP0 4 , 12mM dextrose 
and 50mM HEPES; pH 7.05) was added at a steady slow rate. The transfection mix 
was incubated at room temperature for 2min and then the entire 25ml was transferred to 
200ml o f pre-warmed growth medium and mixed gently by inversion. The culture 
medium was removed from the 10 (15cm diameter) dishes containing the 293-T cells 
and 22ml o f the transfection mix was carefully added without disruption o f the cell 
monolayer. After an incubation period o f 2 to 3 days, the culture medium was removed 
from the transfected cells leaving 2-3ml in each dish into which the cells were scraped. 
The scraped cells from each dish were then pooled and pelleted by centrifugation at 
lOOOg for lOmin and the cell pellet was re-suspended in 15ml cell lysis buffer (150mM 
NaCl, 50mM Tris-HCL; pH 8.5). The cells were then lysed by four cycles of 
freeze/thaw by alternately placing in ethanol/dry ice and then a 37°C water bath. Lysis 
o f the cells results in the release o f the AAV particles into the supernatant. The lysate 
was then treated with 3/fi (100 Units) o f benzonase, which is an enzyme used to 
dissociate aggregated rAAV particles by digesting any extraneous nucleic acid, before 
purification. An aggregate o f virus particles would behave as a single transducing unit, 
therefore, it is important that these are separated to maximise the infectious virus titer. 
The benzonase-treated lysate was vortexed, followed by incubation at 37°C for lh  and 
then centrifugation at 6,500 rpm for 20min to clarify the cell lysate.
2.2.3.2 Purification of the clarified lysate by iodixanol step gradient 
ultracentrifugation
To isolate the rAAV particles from the clarified lysate, the latter was loaded onto a step- 
gradient o f iodixanol. Upon ultracentrifugation the virus particles sediment into the 
40% iodixanol gradient fraction. The most concentrated iodixanol fraction (60%) is the 
lower layer and functions as a cushion to prevent the particles pelleting at the bottom of 
the tube. The iodixanol fractions were prepared as shown in Table 2-9.
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%  Iodixanol Iodixanol
(ml)
5M NaCl 
(ml)
*5x PBS-MK  
(ml)
ddH20
(ml)
Phenol Red 
0*1)
15% 12.5 10 10 17.5
25% 20.8 - 10 19.2 100
40% 33.3 - 10 6.7 -
60% 50 - - - 100
Table 2-9. Preparation of iodixanol fractions
* 5x PBS-MK (5x PBS, 5mM M gCl2, 12.5mMKCL)
The clarified lysate was transferred to a Quick-Seal Ultra-Clear Ultracentrifuge tube 
using a Pasteur pipette and then carefully underlayed with the iodixanol fractions in the 
following order (Figure 2-3):
9ml 15% iodixanol 
6ml 25% iodixanol 
5ml 40% iodixanol 
5ml 60% iodixanol
The remaining space in the tube was filled with cell lysis buffer before heat-sealing the 
ultracentrifuge tube. Ultracentrifugation o f the iodixanol step-gradient was performed 
in a Beckman Ultracentrifuge using a Type 60Ti rotor at 60,000 xg for 90min. The 
40% fraction is easily distinguished owing to the presence o f phenol red in the 25% and 
60% iodixanol fractions. Using a 19-gauge needle and 10ml syringe, the 40% fraction 
was removed by carefully puncturing the tube at the 60%/40% interface and 
withdrawing no more than 4.5ml o f the fraction. The purified virus was then loaded 
onto a single Biomax 100 ultrafiltration device and the volume brought up to 15ml with 
lx  PBS-MK. The filter device was centrifuged at 2000g at room temperature until 
approximately 1ml remained. The virus stock was re-diluted and re-concentrated a 
second time, ending with a final volume o f 500jil, which could then be stored at -80°C.
2.2.3.3 Determination of virus particle titer by DNA dot-blot hybridisation 
analysis
To estimate the virus particle titer, rAAV vector genomes were isolated from 1/ri and 
5/il portions o f the virus stock and transferred to a nitrocellulose membrane, together
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with a serial dilution o f known quantities o f the corresponding pAAV vector. To 
extract vector genomes, the virus was treated with DNase I (lU//xl) to digest any 
extraneous DNA. To the 1/xl and 5/xl virus portions, 5/xl o f DNase I and 20/xl o f 10x 
DNase I reaction buffer was added and brought to 200/xl with serum-free DMEM. 
Following incubation at 37°C for lh , the virus was treated with 200/xl o f 2* proteinase 
K buffer (20mM Tris-HCl, 20mM EDTA and 1% (w/v) SDS) containing 100/xg o f 
proteinase K and incubated a second time at 37°C for 1.5h. The proteinase K digests the 
virus capsid proteins releasing the vector genome. The vector DNA was then isolated 
by the addition o f 400/xl o f phenol:chloroform:isoamyl alcohol (25:24:1) and vortexed 
to form an emulsion, which was centrifuged at 10,000 g for lOmin. The upper aqueous 
phase was transferred to a 1.5ml microfuge tube and 40/xl 3M sodium acetate (pH 5.2) 
and 2/xl o f glycogen (20/xg//xl) was added. This was vortexed and then 1ml ethanol (2.5 
vol) was added, mixed and incubated at -80°C for 30min to precipitate vector genome 
DNA. The preparations were centrifuged at 10,000 g for 20min at room temperature to 
pellet the DNA, which was clearly visible due to the presence o f glycogen. The 
supernatant was removed and the pellets washed with 800/xl 70% ethanol and 
centrifuged at 10,000 g for 5min at 4°C. Once the supernatant had been removed, the 
DNA pellets were air-dried and dissolved in 400/xl o f 0.4M NaOH/lOmM EDTA (pH 
8).
For dot blot analysis, a two-fold serial dilution o f the corresponding pAAV vector was 
prepared, ranging from 80ng to 0.3125ng. To each 5/xl pAAV dilution, 400/xl o f 0.4M 
NaOH/lOmM EDTA was added. While heating the viral and plasmid samples at 100°C 
for 5min a piece o f Hybond-IsT nitrocellulose membrane and three pieces o f 3MM 
Whatman blotting paper were cut to the size o f the dot-blot manifold and pre-wetted in 
ddH20. The manifold was set up with the membrane overlaying the three sheets o f 
blotting paper and attached to a vacuum pump. Each well to be used in the analysis was 
washed with 400/xl o f d d ^ O  and the vacuum was applied to dry. The two denatured 
vector genome samples and the pAAV DNAs were then added to the appropriate wells 
o f the apparatus and the vacuum applied. Once the samples had passed through, each 
well was rinsed with 400/xl 0.4M NaOH/lOmM EDTA and the membrane was removed 
and air-dried for 15min.
The ECL direct nucleic acid labelling and detection system was used for labelling the 
DNA probe and the subsequent hybridisation and detection o f the DNA dot-blot. The
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membrane was first rinsed in 2x SSC (NaCl and Na3Citrate*2H20) and transferred to a 
hybridisation cylinder with 34ml ECL gold hybridisation buffer containing lg  NaCl and 
1.7g ECL blocking agent pre-dissolved at 42°C for 2h. The membrane was pre­
hybridised by incubation with rotation at 42°C for a minimum of lh. Meanwhile, the 
DNA probe, which was lOOng o f an agarose gel-purified DNA fragment derived from 
the pAAV vector, was diluted to 10ng//il in ddELO and denatured by incubating at 
100°C for 5min. The denatured DNA was cooled on ice and 10/d DNA labelling 
reagent was added, mixed gently, followed by the addition o f 10/d o f glutaraldehyde 
solution. The labelling mix was vortexed and incubated at 37°C for lOmin. The 
labelled DNA probe could then be added to the cylinder containing the pre-hybridised 
membrane and incubated at 42°C with rotation overnight. The next day the 
hybridisation mix was replaced with 100ml pre-warmed primary wash buffer (1L = 2x 
SSC, 360g urea, 4g SDS) and incubated at 42°C with rotation for 30min. The wash 
procedure was repeated once more and then the membrane was removed and washed 
twice with 400ml o f 2x SSC at room temperature for 6min with gentle agitation. 
Detection was carried out by chemiluminescence, with the use of an ECL system 
(described in section 2.2.4.1).
To calculate the number o f rAAV particles present in the virus stock, the number o f 
vector genomes present in lng o f the pAAV plasmid vector used in the DNA dot-blot 
hybridisation was determined. This value could then be used to determine the number 
o f  virus particles present in the virus stock. See Figure 2-4 for details o f the 
calculations carried out. The intensity o f the signals produced by the l/il and 5/xl 
portions o f virus stock was compared with those o f the quantified pAAV serial dilution 
and densitometric analyses was used to estimate the number o f vector genomes in ng in 
each dot (Figure 2-4).
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Figure 2-3. Production and purification of rAAV vector particles
The three-plamid system was used for the production o f  rAAV vector particles, which 
involved the triple transfection of293-T cells with a helper Ad plasmid (HGTI) a pAA V- 
based plasmid (a vector flanked by the AAV-serotype 2 ITRs and harbouring the cDNA 
o f interest), and a packaging plasmid containing the AA V Rep and Cap genes, at a 
molar ratio o f  3:1: l  respectively. Cell lysates were prepared two days after 
transfection and rAA Vparticles purified by iodixanol gradient ultracentrifugation.
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1. The molecular weight of the pAAV plasmid in Daltons = 
size of plasmid * 650 (average molecular weight of lbp)
2. The number of plasmid molecules present in lg = MW of 
plasmid in Daltons + 6.02* 1023 (Avogadro’s number)
3. To convert into molecules/ng = number of plasmid 
molecules in lg* 10'9
Figure 2-4. DNA dot-blot hybridisation analysis
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2.2.3.4 AAV capsid-protein detection by silver staining
Purified virus stock was mixed with NuPAGE LDS sample buffer (4x), denatured by 
boiling for lOmin at 100°C and then analysed by electrophoresis on a NuPAGE® Novex 
4-12% Bis-Tris polyacrylamide gel (see section 2.2.4.1 for details). The PlusOne silver 
staining kit was used to visualise the separated viral capsid proteins (VP1, VP2 and 
VP3). The gel was fixed by immersing in fixing solution (100ml ethanol, 25ml glacial 
acetic acid, 125ml ddP^O) for 30min, which was then removed and replaced with 
sensitising solution (75ml ethanol, 10ml sodium thiosulphate (5% w/v), 17g sodium 
acetate, 1.25ml glutardialdehyde (25% w/v), 164ml ddH20). The gel was sensitised for 
30min with constant shaking and washed 3 times for 5min with ddtLO. The silver 
solution (25ml silver nitrate solution (2.5% w/v), 0.1ml formaldehyde (37% w/v), 
225ml ddthO ) was then added and left shaking for 20min. This was followed by 2 
washes for lm in with ddH20 and immersion o f the gel into developing solution (6.25g 
sodium carbonate, 0.2ml formaldehyde (37% w/v), 250ml ddLLO) until the bands on 
the gel had reached the desired intensity. The reaction was stopped by the addition o f 
stopping solution (3.65g EDTA-Na2*2H20 and 250ml ddtLO) and after 5min the gel 
was washed a final time with ddthO .
2.2.4 Human ApoE expression and detection
2.2.4.1 ApoE Western blot
In Western blotting, electrophoretically separated proteins are transferred from a SDS- 
polyacrylamide gel to a nitrocellulose membrane and probed with antibodies that react 
specifically with the antigens in the target protein attached to the membrane. Western 
blotting is therefore, primarily used to identify and quantify a specific protein o f interest 
in a complex mixture o f proteins.
The total protein per well loaded onto the SDS-polyacrylamide gel depended on the 
sample; for example, 40 pg was typically used for cell culture supernatant and tissue 
lysate samples, whereas 2/xl o f plasma (80-100/xg) was loaded. The protein samples
(ft)were mixed with PBS, NuPAGE LDS sample buffer (4*) and p-mercaptoethanol as 
follows (Table 2-10):
93
Component Volume
m
Final
concentration/amount
Protein sample - 40/xg
NuPAGE® LDS sample buffer (4x) 5 lx
P-mercaptoethanol (50x) 1 lx
PBS - To a total volume o f 
20/nl
Table 2-10. Preparation of protein samples for SDS-polyacrylamide gels
The samples were boiled for 5min at 100°C and, along with a protein molecular weight 
standard marker (MagicMark™ XP), loaded onto a NuPAGE® Novex 4-12% Bis-Tris 
polyacrylamide gel with lx  NuPAGE® MES SDS running buffer. NuPAGE® 
Antioxidant (500/*l), which keeps the protein samples in a reduced state and prevents 
re-oxidation, was added to the upper (cathode) buffer chamber o f the elecrophoresis 
tank and the gel was subjected to electrophoresis at 200V for 35min.
The proteins were then transferred from the gel to Hybond ECL nitrocellulose
(5f)membrane using wet blotting. Blotting pads were first soaked in 1 * NuPAGE Transfer 
buffer, containing 10% methanol and antioxidant (1ml per litre o f transfer buffer) and 
placed into the cathode (-) core o f the blot module. One pre-soaked sheet o f 3MM 
absorbent paper was placed on top o f the gel and used to lift the gel o ff the 
electrophoresis plate and onto the blotting pads with the gel facing upwards. Pre­
soaked nitrocellulose membrane was then placed on top o f the gel, followed by another 
piece o f pre-soaked absorbent paper and 2 blotting pads. The transfer sandwich module 
was placed in a Novex Western Transfer apparatus and the middle blot module was 
filled with transfer buffer and the outer buffer chamber with deionised water. Blotting 
was carried out for 90min at 25V.
Following transfer, the membrane was stained with Ponceau S solution to check that 
protein had successfully transferred and then the membrane was blocked by incubating 
with PBS containing 5% Marvel milk powder and 0.1% Tween-20 for 2h at room 
temperature using continuous shaking. The membrane was then probed with a 
polyclonal goat anti-human ApoE primary antibody, which was diluted 1:1,500 with 
PBS/Tween (0.1%), 1% Marvel and 1% BSA. Following overnight incubation at 4°C 
on a rotating shaker, the membrane was washed 3 times for lOmin in PBS/tween and
94
then stained with anti-goat IgG (whole molecule, peroxidase conjugate) secondary 
antibody, diluted 1:10,000 with PBS/Tween (0.1%), 1% Marvel and 1% BSA, for lh  at 
room temperature with continuous shaking. The membrane was then washed as before 
and detection was carried out by chemiluminescence, using an ECL system. This 
involves the oxidation o f luminol by horse radish peroxidase (HRP) in the presence o f a 
chemical enhancer such as phenol with the emitted light (438nm) detected by short 
exposure to blue-light sensitive autoradiograph film. The ECL substrate was added to 
the membrane, which was secured in a film cassette and then exposed briefly to 
autoradiograph film (Hyperfilm ECL). The film was subsequently developed in an 
automatic bench top processor.
2.2.4.2 Enzyme-Linked Immunosorbent Assay (ELISA) for measurement of 
ApoE concentration
ELISA is a sensitive immunodetection method that uses biotinylated capture antibodies 
to detect specific antigens in a complex o f proteins. Antibodies against ApoE are now 
available from several companies and this has made it possible to develop an ELISA 
that can subsequently be used to measure accurately the concentration o f ApoE in serum 
or conditioned medium. An optimised sandwich ELISA for ApoE had previously been 
developed in our laboratory and was used for this project. It is termed sandwich assay 
because an antibody-antigen-antibody complex is formed and the quantity o f antigen is 
measured by using a biotin-labelled detecting antibody, which allows it to be conjugated 
to HRP. The HRP conjugated antibody-antigen complex is then exposed to the 
substrate tetra-methylbenzidine (TMB) to produce a visible colour change (to yellow). 
The colour intensity is proportional to the concentration o f target antigen and can be 
measured in a microplate reader.
An ECL Protein Biotinylation Module was used to biotinylate the goat polyclonal anti­
human ApoE detection antibody. The antibody was diluted in 2.5ml o f 40mM 
bicarbonate buffer to give a working concentration o f 1 mg/ml and then 100/d o f the 
biotinylation reagent was added. The solution was incubated for lh  at room 
temperature and passed through a Sephadex G25 column, eluting with 5ml PBS. The 
eluted fractions (200/d) were analysed by a spectrophotometer to locate the antibody 
and the concentration o f appropriate pooled fractions measured by a Bradford assay 
(section 2.2.23) using IgG as the standard.
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The following buffers were prepared prior to starting the ELISA:
• 10x Blocking buffer (50mM Tris, 150mM NaCl, ImM M gCb.pH 7.4)
• lx  Assay buffer (0.05% gamma-globulin, 50mM Tris, 150mM NaCl, 0.01% 
Tween-40, pH 7.4)
•  10x Washing buffer (lOmM Tris, 150mM NaCl, 0.05% Tween-20 pH 7.4)
Immediately before use, the blocking and assay buffers were supplemented with 1 % and 
0.5% BSA (w/v), respectively, and were filtered through a 0.22/xm vacuum filter.
The ELISA plate was prepared by coating each well o f a Nunc Maxisorp 96-well 
immunoassay plate with 100/d o f goat polyclonal anti-human ApoE capture (1°) 
antibody at a concentration o f 1.5/ig/ml (diluted in PBS). The plate was covered and 
either incubated overnight at 4°C or for 4h at 37°C in a humidified incubator. Following 
incubation, the unbound capture antibody was shaken from the wells and 350/d o f lx  
blocking buffer was added to each well to prevent non-specific binding. After blocking 
for lh  at 37°C, the plate was washed using a programmed Dynex plate washer, which 
washed each well 5 times with 300/d o f lx  washing buffer. Seven dilutions o f a 
recombinant ApoE3 standard were prepared in assay buffer ranging from 160ng/ml -  
2.5ng/ml. A vol o f 50/d o f each sample and standard was added in triplicates to the 
appropriate wells and the plate was covered and incubated overnight at 37°C in a 
humidified incubator. The following day the plate was washed as before and 50/d o f 
biotinylated detection antibody, diluted to a concentration o f 3/ig/ml in assay buffer 
containing 1% (v/v) goat serum, was added to each well. The plate was covered and 
incubated for lh  on a shaker at room temperature and this was followed by further 
washing and the addition o f 100/d o f  streptavidin-HRP (supplied with the ECL Protein 
Biotinylation Module) diluted 1:1000 with assay buffer. After 30min incubation at 
room temperature the plate was washed and 100/d o f TMB substrate (equal volumes o f 
0.004% (v/v) H2O2 and TMB dye) was added to each well. The plate was wrapped in 
aluminium foil and incubated for 30min on a shaker at room temperature, after which 
the enzymatic reaction was stopped by the addition o f 2M H 2 S O 4  (100/x 1/well). The 
absorbance at 450nm was immediately measured using a Dynex microplate reader.
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2.2.5 In vivo studies
2.2.5.1 Intramuscular injection of plasmid DNA
In vivo experiments were carried out on C57BL/6 ApoE'A mice, which were housed in a 
minimal disease facility with food and water ad libitum. Prior to intramuscular (i.m) 
injection tail bleeds were taken and the mice were anaesthetised with 
fentanyl/fluanisone and midazolam. This was followed by the injection o f the tibialis 
anterior (TA) muscles with 10U (25/xl at 0.4U//il) o f bovine hyaluronidase which is an 
enzyme that breaks down components o f the extracellular matrix and causes the muscle 
to become porous. Hyaluronidase has been shown to significantly improve transduction 
efficiency o f plasmid DNA in skeletal muscle [336;337]. Injections were carried out 
using a 27-gauge needle in a proximal-to-distal direction in the TA muscle. Two hours 
post-hyaluronidase treatment, 25/xg (1 /xg//xl) o f plasmid DNA in sterile 0.9% NaCl was 
injected percutaneously in the TA muscle and this was immediately followed by the 
application o f an electrical field. The mice were given isoflurane inhalation anaesthesia 
for both injection o f  plasmid DNA and application o f the electrical pulse. The injected 
leg was held steady and the 7mm circular electrodes were applied to the medial and 
lateral sides o f the lower hind limb with reasonable pressure to maintain contact with 
the skin surface. Electrode jelly was used on the electrode plates to ensure good 
electrical contact and a voltage o f 175V/cm was applied in ten 20ms square wave pulses 
at 1Hz using a BTX ECM 830 electroporator.
2.2.5.2 Collection of blood samples
Animals were placed in an appropriate restrainer and approximately 1mm of tail was 
removed. Blood (~50/xl) from the tail vein was collected in a capillary and transferred 
to citrated tubes (0.109M sodium citrate was added in 1:10 o f the volume) prior to 
injection and at various times post-injection. At termination, animals were sacrificed in 
a rising concentration o f CO2. The chest cavity was opened up and 0.5 -  1ml blood 
harvested by direct cardiac puncture. The samples were centrifuged twice at 8,000 rpm 
for lOmin at 4°C and the plasma stored at -80°C for further use.
2.2.5.3 Collection of tissue samples
Following exsanguination o f the mice, the TA muscles were excised, snap-frozen in 
liquid nitrogen and stored at -80°C. For removal o f the brachiocephalic arteries, the 
animals were first perfused in situ with 10% formalin. Brachiocephalic arteries were
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excised with a piece o f the aortic arch and the stump o f the right subclavian artery still 
attached to aid orientation during histological analysis and also to avoid any trauma to 
the brachiocephalic artery during removal [126].
2.2.5.4 Brachiochephalic artery sectioning and staining
Brachiocephalic arteries were placed into a pellet o f liquid 2.5% agarose, and orientated 
so that the proximal end o f the artery (with part o f aortic arch attached) was downward, 
and the brachiocephalic artery itself was vertical. Once solidified, the agarose pellets 
were then embedded in paraffin. Sections were cut every 30/-im (starting from the 
proximal end) and mounted onto slides. Serial sections were stained with hematoxylin, 
eosin and Miller’s elastin/van Gieson stain.
The sections were dried in an oven at 35°C for 24h prior to staining. The sections were 
then immersed for 5min in a series o f pots containing Histoclear, 100% alcohol (IMS 
99%), 100% alcohol and 70% alcohol. The slides were rinsed in distilled H2O and 
stained with 0.5% (w/v) potassium permanganate for lOmin. This was followed by a 
3min wash in tap water and a 5min incubation in 1% (w/v) oxalic acid. The sections 
were washed as before in tap water, rinsed in 70% alcohol and stained with M iller’s 
(BDH elastin (Miller) diluted to half strength with water) for 3h. Sections were then 
rinsed by immersion in 70% alcohol, washed in distilled H2O and counterstained with 
van Gieson (saturated aqueous picric acid 450ml + 1% aqueous acid fusion 50ml) for 
lOmin. The sections were finally dried in a 60°C oven for 3h and rinsed in 100% 
alcohol.
2.2.5.5 Plaque morphology and morphometry
Elastin-stained sections were visualised under a microscope and plaques were inspected 
for the presence o f buried fibrous caps, which are characterised by smooth muscle cell- 
rich layers, containing elastin, and overlayed with foam cells. Plaque morphometry was 
performed with a computerised image-analysis program (Image Pro-Plus, Media 
Cybernetics). The internal and external elasticae perimeters were recorded and used to 
derive the media area, which was assumed to be the circumference o f a perfect circle. 
The plaque area was measured and the true lumen size was determined by subtracting 
the plaque area from the area enclosed by the internal elastic lamina (Figure 2-5). 
Plaque lipid content was quantified with the Scion image analysis software program. 
The total number o f pixels in the plaque area o f the brachiocephalic artery was first
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calculated, and the image was then converted into black and white, with the same colour 
threshold set for each image. The white area represents lipid and the black area tissue, 
therefore, the % lipid content could be calculated by subtracting the number o f pixels in 
the plaque area o f the black and white image from the total number o f pixels originally 
determined.
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External elastic lamina
Buried fibrous 
cap
Internal elastic lamina
Plaque area
External Elastic Lamina (EEL)
Internal Elastic Lamina (IEL)
Total vessel area = perimeter of EEL2 4FI
True lumen area = (perimeter of IEL2 + 4IT) -  plaque area
Media area = (perimeter of EEL2 4IT) -  (perimeter of IEL2 411)
Figure 2-5. Brachiocephalic artery.
Microscope image (10*) o f  a 120pm section o f the brachiocephalic artery stained with 
Miller's elastin/van Gieson. The External Elastic Lamina (EEL), Internal Elastic 
Lamina (IEL), plaque area, lumen and a buried cap are indicated.
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2.2.5.6 Protein extraction from muscle tissue
CelLytic MT Mammalian Tissue Lysis/Extraction Reagent containing protease inhibitor 
cocktail was added to the TA muscle samples at a ratio o f 1:20 ( lg  tissue/20ml reagent). 
The mixture was then homogenised using a rotor-stator homogeniser with a 5mm probe 
until complete disruption o f the tissue was observed. The lysed sample was centrifuged 
at 13,000 rpm for lOmin at 4°C to pellet the tissue debris and then the protein- 
containing supernatant was aspirated, transferred to a chilled microcentrifuge tube and 
stored at -80°C.
2.2.5.7 Determination of total plasma cholesterol levels
The use o f enzymes to assay cholesterol is routinely used by many investigators. 
Cholesteryl esters are enzymatically hydrolysed by cholesterol esterase (CE) to 
cholesterol and free fatty acids. Free cholesterol, including that originally present, is 
then oxidised by cholesterol oxidase (CO) to cholest-4-en-3-one and hydrogen peroxide 
(H2O2). The hydrogen peroxide combines with hydroxybenzoic acid (HBA) and 4- 
aminoantipyrine (4AAP) to form a chromophore (quinoneimine dye) which may be 
quantified at 500-550 nm.
1. Cholesteryl Esters ---------- ► Cholesterol + Fatty Acids
2. Cholesterol + O2 ---------- ► Cholest-4-en-3-one + H2O2
3. 2H20 2 + HBA + 4AAP ---------- ► Quinoneimine Dye + 4 H2O
Individual mouse plasma from tail-vein bleeds was added at a ratio o f 1:100 with 
infinity cholesterol liquid stable reagent, for example 2/d o f plasma and 200/d o f 
reagent. The samples and a cholesterol standard with a value o f 4.29mmol/L were 
added in triplicate to a microtitre 96-well plate and incubated at 37°C for 5min. The 
absorbance at 500nm was immediately measured with a Dynex microplate reader. The 
relationship between cholesterol and absorbance is linear, therefore, the cholesterol 
values were calculated using the equation below:
Cholesterol =  (Absorbance o f  unknown + Absorbance o f  cholesterol standard) x cholesterol standard value
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2.2.5.8 Analysis of plasma lipoprotein distribution
The Hydragel Lipo + Lp(a) K20 kit was used to determine the lipoprotein profile o f 
pooled (10/tl) and individual (10/il, diluted 1 in 5 with PBS ) mouse plasma. The 
analysis was performed by electrophoresis on pH 7.5 buffered agarose gels and the 
separated lipoproteins were then stained with a lipid-specific Sudan black stain. The 
Hydragel K20 applicator carrier and gel were set up according to the manufacturer’s 
instructions and lO/il o f each sample was applied into the applicator wells. The sample 
applicator was placed into the correct position on the applicator carrier and left for 7min 
30sec. The gel was then removed and placed into an electrophoresis chamber 
containing 300ml o f Hydragel running buffer and subjected to electrophoreis for 90min 
at 50V. After migration, the gel was dried with hot air (80°C) for at least 45min and 
then immersed in Sudan black stain for 15min. The gel was de-stained for 5min in de­
staging solution (45% pure ethanol and 55% ddH20) and immersed in wash solution 
for 1 min. The gel was washed rapidly with ddH20 and dried once again with hot air. 
The percentage o f lipoprotein fractions were determined by densitometry using the 
Hyrys 2 Hit densitometer with the Phoresis software.
2.2.6 Statistical analysis
Values in text, tables and figures were expressed as the mean±S.D when appropriate. 
Statistical analysis was performed by student’s t-test using Microsoft Excel (Microsoft 
Office XP, 2004). A p<0.05 was considered to be significant.
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Chapter 3:
Plasmid-Mediated ApoE3 Gene Transfer
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3 PLASMID-MEDIATED APOE3 GENE TRANSFER
3.1 Introduction
ApoE is considered an attractive gene transfer candidate to alleviate 
hypercholesterolaemia and atherosclerotic pathology. Indeed, liver-directed gene 
transfer o f human ApoE3 by recombinant adenoviruses (rAd) in ApoE'7' mice lower 
plasma cholesterol and decelerate aortic atherogenesis [308]. The major limitation, 
however, with rAd vectors is their potential to induce immune and inflammatory 
responses, and although these can be reduced using modified vectors, levels o f plasma 
ApoE are often compromised [312;313] (see section 1.9.1 for further details). Such 
considerations and also safety concerns have prompted renewed interest in non-viral 
gene transfer or ‘naked DNA’ delivery [338]. Skeletal muscle has emerged as an 
attractive target for gene transfer: it is highly vascularized and actively secretory, and is 
a stable post-mitotic tissue with little nuclear turnover [261 ;262]. Thus, two studies 
have reported systemic delivery and long-term biological effects o f ApoE following 
intramuscular injection o f plasmid DNA containing the cytomegalovirus (CMV) 
promoter to drive human ApoE expression. One study noted a decrease in plasma 
cholesterol despite very low levels o f plasma ApoE [324], while the other found 
reduced atherosclerotic plaque and xanthoma formation after 9 months [325].
Skeletal muscle fibres are surrounded by a plasma membrane, the sarcolemma, which is 
in turn surrounded by an extracellular matrix (ECM). Groups o f fibres are divided into 
fascicles by a further ECM barrier and finally the entire muscle is surrounded by the 
epimysium. Together these structures form the main barrier to efficient plasmid transfer 
into skeletal muscle. Pre-treatment o f muscle with a sucrose solution has been shown to 
generate spaces between muscle fibres and, thus, improve the distribution o f the 
plasmid [339] and specific enzymes, such as hyaluronidase and collagenase are reported 
to break down components o f the ECM. Physical methods, such as electroporation and 
ultrasound, however, have demonstrated greater plasmid transfection efficiencies and 
studies have shown that when electroporation is used in conjunction with hyaluronidase 
treatment, plasmid transduction into skeletal muscle is significantly improved 
[336;337]. Electrotransfer o f plasmid DNA is dependent on permeabilisation o f the cell 
membrane and the electrophoresis o f the DNA across the membrane and into the cell. 
Hyaluronidase helps to permeabilise components o f the ECM, which could explain why
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it improves electro-transfer. It is speculated that the permeabilisation o f the ECM by 
hyaluronidase increases the effective concentration o f plasmid at the membrane leading 
to increased uptake [296].
This chapter describes the construction and evaluation o f single-stranded (ss) and self- 
complementary (sc) AAV expression plasmids harbouring the human ApoE3 gene, 
driven by the ubiquitous CMV enhancer/chicken p-actin (CAG) promoter [250] and two 
muscle-specific promoters, CK6 and C512. The CK6 promoter was first developed by 
Hauser et al. [257]; they determined the sequence o f a genomic fragment o f the MCK 
regulatory region and using oligomer-mediated site-specific mutagenesis were able to 
modify the enhancer, such that it significantly improved gene expression. They tested a 
series o f small, highly active MCK regulatory cassettes, several o f which contained the 
mutagenised MCK enhancer (2RS5) and a truncated MCK promoter region. The CK6 
cassette, although less than 600bp in length, was found to be sixfold more active than 
the full-length 3.3kb MCK promoter, 8% as active as the CMV promoter in myocytes 
and 12% as active as the CAG promoter in vivo. Transgene expression was 600-fold 
higher in muscle than in liver, thus the CK6 promoter confers very high muscle 
specificity. More importantly, however, human dendritic cells infected in vitro with the 
CK6-driven rAd vectors, do not express significant levels o f transgene; this promoter is, 
therefore, likely to increase the persistence o f transduced muscle cells.
The C512 promoter was first described by Li et al., who designed a simple strategy to 
construct synthetic muscle-specific promoters [258]. The investigators, firstly, 
randomly assembled myogenic control elements from human a-skeletal actin (E-box, 
MEF-2, TEF-1 and SRE) into recombinant synthetic promoter libraries. Then, by 
screening the clones for their transcriptional activity in vitro and in vivo, they were able 
to identify promoters with enhanced activity which greatly exceeded that o f natural 
myogenic and viral gene promoters. Multiple single elements demonstrated low 
activity compared with the natural skeletal a-actin promoter or clones derived from the 
library containing a combination o f regulatory elements. In primary chicken myotubes, 
transgene expression from the C512 promoter was 6-fold and 10-fold greater than the 
CMV and skeletal a-actin promoters, respectively. The synthetic C512 promoter also 
demonstrated higher expression in vivo; transcriptional activity was reported to be 3-4- 
fold higher than the natural skeletal muscle promoter and 6-8-fold higher than the CMV 
promoter. The muscle specific activity o f C512 was also confirmed in several non­
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muscle cell lines and in transgenic animals; this promoter is, therefore, unlikely to drive 
the expression o f transgenes in antigen-presenting cells. In a later study, systemic 
expression o f FIX from the C512 promoter following intramuscular injection o f an 
AAV1 vector was reported to be 50% of that obtained from a CMV immediate-early 
enhancer promoter-driven construct [259]. The small size o f C512 along with its 
capability o f directing robust levels o f transgene expression make this promoter an 
appealing choice for our experiments.
Each plasmid construct was first tested in vitro in murine C2C12 myoblasts and 
myotubes and then injected via electrotransfer into the T. anterior muscles o f ApoE'7' 
mice. I show that each plasmid efficiently secretes ApoE3 protein when transfected into 
cultured mouse C2C12 myotubes and also produces local expression, which is markedly 
enhanced by electropulsing the site, when injected into skeletal muscle o f ApoE'7' mice. 
However, the identical assay methods failed to detect ApoE protein in plasma and the 
hyperlipoproteinaemia was not ameliorated, implying that a more efficient vector and 
delivery system is needed to achieve therapeutic levels in the circulation.
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Figure 3-1. Schematic representation of the C512 and CK6 promoters
(A) The C512 promoter includes minimal muscle-specific elements of the human a-skeletal actin promoter (transcription enhancer factor 1 [TEF-1], 
two SP-1-binding sites and a TATA box). Additional binding sites for muscle transcription factors (TEF-1, serum response element [SRE], myocyte 
enhancer factor 1 [MEF-1, also known as E box], and MEF-2) were cloned upstream of the minimal promoter for optimal expression in myoctes. (B) 
The CK6 promoter contains a mutated MCK enhancer sequence (2RS5), which is composed of the transcription factor binding sites, SRE, activator 
protein-2 (AP-2), Trex, MEF-1 and MEF-2. The left MEF-1 is replaced with a right MEF-1 site (2R) and the sequence is mutated (S5) between the 
second MEF-1 and the MEF-2 sites. The S5 modification was originally created as one of a series of linker-scanner mutants, but was found to 
significantly increase enhancer activity. Downstream from these transcription factor binding sites is a truncated version of the MCK proximal 
promoter.
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3.2 Results
3.2.1 Generation of ssAAV2 and scAAV2 plasmid constructs
Before explaining the construction o f each plasmid, it is necessary to highlight at this
point that plasmids are prefixed with a “p” rather than with “ssAAV2” or “scAAV2” so 
as not to confuse with the viral vectors mentioned in Chapter 4.
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Figure 3-2. Schematic representation of the restriction digests for generation of 
ssAAV2 and scAAV2 plasmid constructs
Schematic representation o f the restriction digests required for the generation o f  
p.CAG.ApoE3, p.CK6.ApoE3 and p.C512ApoE3 plasmid constructs (A) and 
p.C5J2.ApoE3(sc) andp.CK6.ApoE3(sc) plasmid constructs (B).
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3.2.1.1 p.CAG.ApoE3
A multiple cloning site c/s-plasmid [252], with an AAV2 backbone was used to 
generate the plasmid constructs. The multiple cloning site contains unique restriction 
sites that facilitate sub-cloning and also helps to prevent molecular manipulations from 
interfering with the ITRs which could otherwise cause them to form recombinations. 
The plasmid also contains a SV40 polyadenylation signal, which is used to enhance 
transgene expression. To construct p.CAG.ApoE3, full-length human ApoE3 cDNA 
was excised from pshuttle.CMV.ApoE3 and ligated into the multiple cloning site o f the 
CAG-driven plasmid (Figure 3-2A). Following ligation, transformation and selection 
on an ampicillin plate, colonies were picked and grown overnight. Recombinants were 
identified by PCR using specific primers for ApoE3 (TF, TR, Table 2-2), which 
amplified a 270bp product (Figure 3-3A). One fi\ o f each culture was used in the PCR 
reaction along with 2.5/xl o f 100% DMSO; the conditions were 95°C for lOmin, 94°C 
for 30sec, 68°C for 30sec. (25 cycles) and 72°C for 7min. The plasmid minipreps were
dt)purified using the Wizard plus SV Minipreps DNA Purification System and digested 
with Sail in order to verify the presence o f the ApoE3 insert (Figure 3-3B). One o f the 
minipreps was used to make a maxiprep, which was purified the next day using the 
Endofree Plasmid Maxi kit.
3.2.1.2 p.CK6.ApoE3
The CAG promoter in p.CAG.ApoE3 was excised and replaced by the CK6 muscle- 
specific promoter (Figure 3-2A). Recombinants containing the CK6 insert were 
identified by a Sapl/Xhol digest (Figure 3-3C).
3.2.1.3 p.C512.ApoE3
PCR primers were designed with the BsrGI and Xhol restriction sites incorporated in 
their 5’ regions (BSRGIC512F; XHOC512R; Table 2-2). These primers were then used 
in PCR to amplify the C512 promoter. The amplification then generates a C512 target 
fragment whose termini now carry the new restriction sites. The C512 promoter insert 
was then purified using the Qiagen gel extraction kit and digested overnight with 
BsrGI/XhoI to generate the restriction sites. The CAG promoter in p.CAG.ApoE3 was 
removed and replaced with the C512 promoter (Figure 3-2A). Recombinants were 
identified by a BsrGI/XhoI digest (Figure 3-3D).
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3.2.1.4 p.C512.ApoE3 (sc)
As discussed in section 1.7.3, the scAAV vector must be half the length o f wild-type 
AAV so that it can be packaged as a dimer. The length between the two ITRs is, 
therefore, restricted to 2.3 kb, which makes cloning more complex when large 
transgenes and promoters are required. Indeed, it proved to be impossible to clone the 
large CAG promoter into the scAAV plasmid, thus, only scAAV vectors driven by 
muscle-specific promoters are assessed in this study. Full-length human ApoE3 cDNA 
was excised from pshuttle.CMVApoE3 and ligated into the multiple cloning site o f the 
scAAV2 plasmid (Figure 3-2B and Figure 3-3E). Recombinants were identified by the 
use o f PCR with specific primers for ApoE3, which amplified a 270bp product (see 
section 3.2.1.1 for PCR conditions). Following purification, the recombinants were 
verified by an Acc65I/MfeI digest, which produces a 1200bp fragment (Figure 3-3F). 
Next, it was necessary to clone the C512 promoter into the scAAV2.ApoE3 vector. 
NheI/Acc65I restriction sites were incorporated onto the ends o f the C512 promoter 
insert by PCR amplification (C512NheF, C512Acc65R; Table 2-2) and then cloned into 
the scAAV2 plasmid at the 5’ end o f the ApoE3 insert (Figure 3-2B).
3.2.1.5 p.CK6.ApoE3 (sc)
The restriction sites Nhel and BsiW I were incorporated onto the ends o f the CK6 
promoter insert by PCR amplification (CK6NheF; CK6BsiWIR; Table 2-2) and then 
cloned into the scAAV2.ApoE3 plasmid at the 5’ end o f the ApoE3 insert (Figure 
3-2B). Recombinants were identified by the use o f PCR (Figure 3-3G) with specific 
primers for CK6 (CK6F1, CK6R1; Table 2-2) and confirmed by a Nhel/M fel digest 
(Figure 3-3H).
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Figure 3-3. PCR and restriction enzyme digests of ssAAV2 and scAAV2 plasmid 
constructs
(A) PCR to identify p.CAG.ApoE3 recombinants. Lanes 1-11 represent 11
recombinants and lane 12 represents the +ve control. The expected band (270bp) 
representing the ApoE3 insert was amplified in all 11 colonies. (B) Restriction digest o f  
p.CAG.ApoE3 with Sail to verify presence o f ApoE3 insert. Lanes 1-11 represent 11 
recombinants. The expected band (1059bp) representing the ApoE3 insert was present 
in all 11 colonies. (Q  Restriction digest o f p.CK6ApoE3 with Sapl/Xhol to identify 
recombinants containing the CK6 promoter insert. Lanes 1-5 represent 5 separate 
colonies. The expected band (853bp) representing the CK6 promoter insert was present 
in only 1 colony (lane 1). (D) Restriction digest o f  p.C512.ApoE3 with BsrGI/XhoI to 
identify recombinants containing the C512 promoter insert. Lanes 1-3 represent 3 
separate colonies. The expected band (496bp) representing the C512 promoter insert 
was present in only 1 colony (lane 1). (E) PCR to identify scAAV2.ApoE3
recombinants. Lane 1-7 represent 7 colonies. The expected band (270bp) representing 
the ApoE3 insert was present in only 1 colony (lane 2). (F) Restriction digest o f
scAAV2ApoE3 with Acc65I/MfeI to verify the recombinant. Lane 1 represents the 
recombinant. The expected band (~1200bp) representing the ApoE3 insert was present. 
(G) PCR to identifyp.CK6ApoE3(sc) recombinants. Lanes 1-11 represent 11 colonies. 
The expected band (~650bp) representing the CK6 promoter insert was present in only 
1 colony. (H) Restriction digest o f p.CK6.ApoE3(sc) with Nhel/Mfel to verify the 
recombinant. Lane 1 represents scAAV2.ApoE3 and lane 2 represents 
p.CK6.ApoE3(sc). The expected band (~1879bp) representing the CK6/ApoE3 insert 
was present.
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3.2.2 ITR screening
Homologous recombination can occur between the ITRs in E.coli during the 
construction o f the rAAV plasmids. As a result o f this recombination, ITR sequences 
are often rearranged or partially deleted during subcloning. It was essential, therefore, 
to check the intactness o f the 5’ and 3’ ITR sequences in all constructs. They were 
screened by 3 restriction enzymes including BssHII (cuts at the A arm), M scI (cuts at 
the junction o f A and D arms) and Sm al (cuts at the B arm) (Figure 3-4). The ITR 
regions were also sequenced to verify the absence of any mutation.
All the ss and sc plasmid constructs produced the correct size bands when digested with 
the three screening restriction enzymes (Figure 3-5 and Figure 3-8), suggesting that both 
the 3 ’ and 5 ’ ITRs were intact. Sequencing helped to further verify that there were no 
mutations (Figure 3-6A, B, C, D), although the ITR regions proved to be very difficult 
to sequence due to their hairpin structure and high guanine and cytosine content. This 
occasionally resulted in the loss o f sequence and regions that could not be read (Figure 
3-6E).
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Figure 3-4. Structure and sequence of a ssAA V2 vector ITR.
The diagram includes the positions o f  the Terminal Resolution Site (TRS), the Rep 
Binding Element (RBE) and a portion o f  the small internal palindromes within the 
terminal hairpin (RBE'). The diagnostic restriction sites, MscI, BssHII and Smal are 
also indicated
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Figure 3-5. Diagnostic restriction digests of p.CAG.ApoE3, p.CK6.ApoE3 and 
p.C512.ApoE3 with BssHII, MscI, and Smal.
The gel images represent the restriction digests o f  p.C512.ApoE3 (20% TBE gel) (A), 
p. CK6.ApoE3 (20% TBE gel) (B), p.CAG.ApoE3 (20% TBE gel) (Q, andp.CAG.ApoE3 
(D) andp.C512.ApoE3 (E) with BssHII only; on a 1% agarose gel to help resolve the 
larger bands.
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Figure 3-6. Sequencing of p.CAG.ApoE3 ITR
This figure represents the terminal resolution site (trs) (A), the Rep binding element 
(RBE) o f the 5 ’ ITR (B), a portion o f the small internal palindromes within the terminal 
hairpin (RBE) o f the 5 ' ITR (Q, the complementary strand o f  the RBE o f  the 5 ITR 
(D), and the RBE o f the 3' ITR which has high background and is difficult to read (E).
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Figure 3-7. Structure and sequence of a scAAV2 vector 5* ITR
The diagram includes the positions o f the mutated Terminal Resolution Site (TRS), with 
the guanine substitution highlighted, the Rep Binding Element (RBE) and a portion o f  
the small internal palindromes within the terminal hairpin (RBE). The diagnostic 
restriction sites, MscI, BssHII and Smal are also indicated.
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Figure 3-8. A 4-20% TBE gel showing the restriction digests of p.C512.ApoE3(sc) 
and p.CK6.ApoE3(sc) with BssHII, MscI and Smal to screen the ITR regions
The gel images represent the restriction digests o f p.CK6ApoE3(sc) (A), and 
p. C512.ApoE3(sc) (B).
3.2.3 Secretion of recombinant human ApoE3 from transiently transfected 
murine C2C12 myoblasts and myotubes
Having constructed the expression plasmids and established that their ITRs were intact,
it was necessary to check that the vectors were working efficiently and secreting ApoE3 
in vitro. Murine C2C12 myoblasts were transfected with 2/ig o f each rAAV.ApoE3 
plasmid (p.CAG.ApoE3, p.CK6.ApoE3, p.C512.ApoE3, p.CK6.ApoE3(sc) and 
p.C512.ApoE3(sc)) and a control plasmid, p.CK6 (-), identical to the CK6-driven 
expression vector, but lacking ApoE3 cDNA. C2C12 is a rapidly dividing cell line that 
can differentiate into post-mitotic myotubes when exposed to horse serum or low-FBS 
medium. The transfected cultures were left to grow in DMEM containing 10% FBS, 
under normal conditions for 24h, after which the medium was harvested and replaced 
with 5% heat-inactivated horse serum to induce differentiation and fusion into large 
multinucleate myotubes. Following a further 24h incubation, myoblast fusion and 
myotube formation was observed (Figure 3-9B) and the medium was harvested. The 
cells were cultured for a final 24h, at which point mature myotube formation was 
apparent (Figure 3-9C). ApoE3 secretion in the aspired medium was analysed by 
Western Blot and quantified by an ELISA. Western blot analysis (Figure 3-10) 
revealed that p.CAG.ApoE3 transfected cells had secreted ApoE3 at all collection- 
points, whereas cells transfected with plasmids driven by the muscle-specific promoters, 
CK6 and C512, failed to produce ApoE3 until the 24-48h collection, the time-interval in 
which myoblasts start to differentiate into myotubes. An ELISA (Figure 3-11) yielded 
values o f up to 714ng/ml o f ApoE3 in the medium o f cells transfected with 
p.CAG.ApoE3. The ApoE3 content in medium from cells transfected with 
p.CK6.ApoE3 or p.C512.ApoE3 and their respective sc plasmids was lower, ranging 
from 10-80ng/ml for the 48-72h time period. Secreted ApoE3 reached optimum levels 
at 48h and decreased slightly at 72h, which was a trend seen in the majority o f the 
plasmids.
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Figure 3-9. Phase microscope images (10* field) of murine C2C12 myoblast 
differentiation into multinucleate myotubes
(A) myoblasts after 24h incubation (seeded at 1* 10s cells/ml); (B) myoblast fusion and 
myotube formation after 481n incubation; (Q  mature myotubes after 72h incubation.
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Figure 3-10. Secretion of human ApoE3 by C2C12 myoblasts and myotubes 
following transfection with the ApoE3 expression plasmids.
Dishes o f  C2CJ2 myoblasts were transfected with p.CAG.ApoE3 and the muscle- 
specific plasmids, p.CK6ApoE3 and p.C512ApoE3 (A) and their respective sc 
plasmids (B). Culture supernatants were probed for ApoE3 (34 kDa) by Western 
blotting 24, 48 and 72h after transfection, while concentrations were measured by 
ELISA (ng/ml).
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Figure 3-11. ELISA quantification of human ApoE3 secretion from transfected 
murine C2C12 myoblasts.
A graph (A) and a table (B) showing the concentration (ng/ml) with ± standard 
deviation (n = 3) of ApoE3 secreted from C2CJ2 myoblasts transfected with 
ss/scAAV2.ApoE3 plasmids.
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3.2.4 Transient co-transfection of C2C12 myoblasts with p.C512.GFP and 
p.CMV.RFP
The transient transfection study (section 3.2.3) suggests that muscle-specific promoter 
activity is only switched on in differentiated myotubes. To confirm this, C2C12 
myoblasts were co-transfected with 2(xg o f plasmids expressing fluorescent reporter 
genes, one driven by the muscle-specific promoter, C512 (green fluorescent protein 
(GFP)) and the other by the ubiquitous CMV promoter (red fluorescent protein (RFP)). 
As before, cells were incubated in DMEM containing 10% FBS for 24h and then 
switched to medium containing 5% heat-inactivated horse serum for a further 48h. At 
each 24h interval, cells were visualised under a phase-contrast light or fluorescent 
microscope to assess expression levels. Between 24-48h, myoblast fusion and myotube 
formation was observed, while at 72h mature myotube formation was apparent. As 
predicted, RFP was readily detected at all time-intervals, including the 0-24h collection 
when only myoblasts were present, whereas GFP was not detected until later when 
myotube formation was evident (Figure 3-12).
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Light GFP RFP 
24h 
48h 
72h
Figure 3-12. Phase and fluorescent microscope images (20* field) of murine 
C2C12 myoblasts co-transfected with p.C512.GFP and p.CMV.RFP
Cells were observed 24, 48 and 72h after transfection to assess relative expression 
levels.
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3.2.5 Expression of human ApoE3 following intramuscular electrotransfer of 
p.CAG.ApoE3 in ApoE'/_ mice 
A preliminary in vivo experiment was undertaken to assess electroporation-mediated
plasmid transfection. Eight ApoE'A mice were given intramuscular injections o f bovine 
hyaluronidase, an enzyme that breaks down extracellular matrix and connective tissue in 
skeletal muscle fibres to improve plasmid transfer [336;337], followed, 2h later, by 
25/xg p.CAG.ApoE3. For 5 mice an electrical field was applied immediately to the 
single TA muscle injection site, whereas the muscles o f the other 3 mice were not 
electropulsed. Plasma samples were collected prior to injection and at termination, 7 
days post-injection, and were assayed for ApoE3 expression by ELISA and by Western 
blotting. Unfortunately, the levels o f plasma ApoE3 in all eight mice fell below the 
reliable detection limit (~15 ng/ml for the ELISA; data not shown). However, protein 
extracted from excised muscle clearly demonstrated local ApoE3 expression by Western 
blotting, though only in those electropulsed (Figure 3-13A). ELISA quantification of 
ApoE3 expressed in these muscles demonstrated levels between 4.8-20 /ng/TA muscle, 
indicating high variability between each mouse, and much lower amounts in non­
electroporated muscle (Figure 3-13A).
Individual total plasma cholesterol was measured at day 7, but was not significantly 
lower than the day 0 sample for either electroporated or non-electroporated animals 
(Figure 3-13B). The lipoprotein profile o f pooled plasma from each group was also 
analysed. Very-low-density lipoprotein (VLDL), intermediate-density lipoprotein 
(IDL) and low-density lipoprotein (LDL) migrated as a heavily-stained broad prep-band 
in the plasma of A poE7' mice, whereas, high-density lipoprotein (HDL) ran as a fast a - 
migrating minor fraction (Figure 3-13C). In contrast, plasma from wild-type (wt) 
C57BL/6 mice has high levels o f HDL and a relatively low proportion o f clearly 
separated VLDL and LDL. Densitometry o f the lipoprotein profiles did not reveal any 
difference between day 0 and day 7 samples, either in absolute amounts or in the HDL 
to total lipoprotein ratio (Figure 3-13D), which can serve as a sensitive indicator o f 
effective ApoE gene transfer [312;327].
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Figure 3-13. Electroporation enhances local expression of ApoE3 following 
intramuscular injection of the p.CAG.ApoE3 expression plasmid in ApoE' mice.
Tibialis anterior (TAJ muscles o f young ApoE^ mice were injected with p.CAG.ApoE3 
and, when required, immediately electropulsed. (A) Western blot analysis o f  ApoE3 
expression after 7 days in excised TA muscle from electroporated mice (animals 1-5) 
and non-electroporated mice (animals 6-8); ApoE3 concentrations (pg/TA muscle) were 
quantified by an ELISA. (B) Total plasma cholesterol levels were determined for 
individual animals in each group before and 7 days post injection o f  p. CAGApoE3. (Q  
Pooled plasma samples at day 0 and day 7 were subjected to agarose gel electrophesis 
and the separated lipoproteins stained with Sudan black. (D) Graphical representation 
o f the HDL VLDL/IDL/LDL ratio.
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3.2.6 Expression of human ApoE3 following intramuscular electrotransfer of 
plasmids driven by muscle-specific promoters in ApoE'7' mice
Three groups o f ApoE'7* mice (6 mice per group) were given intramuscular injections of 
p.CK6.ApoE3, p.C512.ApoE3 or p.CAG.ApoE3, while a fourth control group was 
uninjected. Since the above combination of hyaluronidase pre-treatment and 
electrotransfer demonstrated enhanced plasmid transfection this technique was used for 
all injections. Blood was collected prior to injection and 7 days post-injection and the 
separated plasma assayed for human ApoE3 protein by Western blotting and our in- 
house ELISA. As in the preliminary experiment, ApoE3 was undetectable in plasma by 
these assay methods, but was again readily measured in the excised muscles o f all 
treated mice (Figure 3-14A). ELISA quantification demonstrated significantly higher 
levels o f muscle ApoE3 in mice injected with p.CAG.ApoE3 (13.38+7.46pg ApoE3/TA 
muscle) compared with animals treated with plasmids driven by the muscle-specific 
promoters, CK6 and C512 (0.61+0.38 and 0.45+0.38pg ApoE3/TA muscle, 
respectively; P<0.001); no ApoE3 was detected in control muscles (Figure 3-14B).
The mean levels of plasma total cholesterol in ApoE'7' mice 7 days post-injection with 
p.CAG.ApoE3, p.CK6.ApoE3 and p.C512.ApoE3, were not significantly reduced 
compared with the negative control group. Furthermore, the lipoprotein profiles in the 
three treatment groups did not obviously differ from the control group at 7 days (Figure
3-14C), and this was confirmed by densitometric analysis.
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Figure 3-14. Muscle ApoE3 levels and plasma lipoprotein distribution in ApoE- 
deficient mice following intramuscular electrotransfer of plasmids driven by 
muscle-specific promoters expressing ApoE3.
Three groups o f ApoE mice were injected intramuscularly with p.CAG.ApoE3, 
p.CK6.ApoE3 or p.C512.ApoE3, while a fourth negative control group received no 
injection. (A) Representative Western blots (2 mice per group) o f ApoE3 expression in 
excised TA muscle; ApoE3 concentrations (pg/TA muscle) were quantified by ELISA. 
(B). Graphical representation o f the average ApoE3 concentration (pg/TA muscle) from 
each group. (Q  Pooled plasma samples at day 7 were subjected to agarose gel 
electrophoresis and the separated lipoproteins stained with Sudan black.
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3.3 Discussion
Although less efficient than viral vectors, plasmids have an excellent safety profile with 
low immunogenicity and minimal risk for insertional mutagenesis, since they are only 
expressed episomally. They may also be manufactured in quantity and to high purity, 
while the use o f DNA vectors devoid o f bacterial sequences can give robust and 
persistent transgene expression [307]. In this chapter, I have evaluated whether the 
electroporation technique in combination with plasmid vectors driven by muscle- 
specific promoters, can deliver sufficient human ApoE3 into the circulation to reverse 
hyperlipidaemia in ApoE'7' mice.
Cultured mouse C2C12 muscle cells transfected with each expression vector efficiently 
synthesised and secreted recombinant human ApoE3. Both Western blotting and 
ELISA revealed that cells transfected with p.CAG.ApoE3 strongly secreted ApoE3 at 
each 24h time-period studied, whereas cells transfected with plasmids driven by the 
muscle-specific promoters, CK6 and C512, failed to produce ApoE3 until after 24h. 
This difference can be explained. As with the endogenous muscle creatine kinase gene 
[257;340], both the CK6 and C512 promoters are transcriptionally inactive in myoblasts 
and only become activated when myoblasts commit to terminal differentiation into 
myotubes [258;340]. In our experiments, C2C12 myoblasts started to differentiate into 
myotubes during the 24-48h interval, in which period muscle-specific promoter activity 
was switched on to drive ApoE3 expression. Co-transfection o f C2C12 myoblasts with 
p.C512 expressing GFP and a CMV-driven plasmid expressing RFP confirmed this 
explanation; as expected, GFP was not detected at the early 0-24h time-interval, 
whereas RFP was readily observed. Although the amount o f ApoE3 protein expressed 
from both muscle-specific promoters in terminally differentiated myotubes was 8-times 
less than from the CAG promoter (Figure 3-11; 48-72h collections), the latter was most 
probably still producing a significant proportion from myoblasts as this was evident for 
p.CMV.RFP (Figure 3-12; 48-72h). Nevertheless, Hauser et al. reported that CK6 had 
only 8% the activity o f the ubiquitous CMV promoter in myocytes in vitro, and 12% of 
the CAG promoter in vivo [257]. On the other hand, the synthetic C512 promoter was 
generally very comparable to the CMV promoter in a series o f in vitro and in vivo 
studies, and often proved superior [258;259].
ApoE’7" mice were used for my preliminary in vivo experiments since they become 
grossly hypercholesterolaemic on normal chow [ 117; 133]. My experiments were
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designed to evaluate hypolipidaemic effects o f nonviral ApoE3 gene transfer and hence 
were confined to a study period o f 7 days. If sufficient ApoE3 was secreted into 
plasma, it was predicted that there would be a rapid reduction in total cholesterol and a 
shift towards an atheroprotective lipoprotein profile, namely decreases in VLDL and 
LDL, and a rise in HDL. These changes were noted, for example, in ApoE'7' mice 5 
days after intravenous injection (liver-directed) administration o f a rAd expressing 
human ApoE3 [312].
In my preliminary in vivo experiment hyaluronidase and electrotransfer-mediated 
plasmid transduction was assessed in 5 mice, with the remaining 3 mice only receiving 
hyaluronidase treatment to enhance plasmid uptake. Unfortunately, our assay methods 
did not detect ApoE3 in plasma o f mice injected with p.CAG.ApoE3. In agreement, I 
found no evidence for reduced total cholesterol or for normalisation o f the lipoprotein 
profile in mice 7 days after treatment. Though disappointing, these results were 
consistent with studies in ApoE'7' mice [325] and Yoshida Wistar rats [341] receiving 
non-electroporated intramuscular injections o f naked plasmids expressing human 
ApoE2 or ApoE3. In both o f these studies, only the receptor binding-defective ApoE2, 
and not wild-type ApoE3, was detected in plasma, although local expression of 
recombinant ApoE3 was measurable in the muscle. A subsequent study did report 
detectable ApoE3 in plasma after an intramuscular injection o f DNA, but the level was 
very low (0.6ng/ml, well below the range o f our own ELISA) [324]. We were also able 
to detect local expression o f human ApoE3 in excised muscles and this was markedly 
increased (50-fold) by electroporation, confirming previous reports that this technique 
significantly enhances plasmid transfer [342].
As with the preliminary in vivo experiment, ApoE3 was not detected in the plasma, but 
readily expressed in the excised muscle o f mice injected with the CK6- and C512- 
driven plasmids. In agreement with the findings in vitro (Figure 3-11), the total amount 
o f ApoE3 expressed in the muscle (~0.5/zg) was much lower compared with that 
observed in mice treated with p.CAG.ApoE3 (6-25/ig). As expected, plasma total 
cholesterol had not reduced and the lipoprotein profile was not normalised in the mice 
after 7 days o f treatment with these ApoE3 expression plasmids.
Interestingly, the levels o f ApoE3 expression in excised, electroporated muscle varied 
from one mouse to another. There are a number o f factors that are likely to cause this 
variation; TA muscles vary in size, therefore, adjustment o f the voltage applied for each
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animal may be important. The distribution o f transduced fibres may be affected 
depending on where the needle is placed within the muscle in relation to the central 
tendon and a precise orientation o f the electrical field is necessary for efficient 
electropermeabilisation [343].
How can we explain this discrepancy between ample local expression o f ApoE3 and 
very low plasma levels? One possibility is that secreted ApoE3 is promptly sequestered 
by the excess of remnant lipoproteins in the plasma o f ApoE'7' mice and, unlike binding- 
defective ApoE2, is rapidly cleared by the liver via interaction with the LDL-R or LRP 
[76;153;344]. Such rapid removal has been reported following injection o f ApoE3 
protein [327;345]. Note too that mouse ApoB-containing lipoproteins (VLDL, IDL and 
LDL) are almost entirely dependent on ApoE for clearance; unlike their human 
counterparts, they contain a very high proportion o f ApoB48, a truncated structural 
protein which lacks the receptor-binding domain present in fully-functional ApoB 100 
[128]. Hence, in our plasmid-treated ApoE'7' mice any lipoprotein particles sequestering 
ApoE3 would be rapidly targeted for hepatic clearance. An alternative explanation is 
that recombinant ApoE3 is successfully expressed by muscle, but the protein is 
inefficiently secreted. An initial appraisal would suggest this possibility is unlikely as 
we readily measured ApoE3 protein in myotube culture medium following in vitro 
transfections, while in vivo skeletal muscle transduced with an ApoE3-expressing rAd 
vector secreted ApoE3 into plasma [312]. However, in the latter study high-dose 
intramuscular injections o f rAd vector were needed to measure ApoE3 in plasma 3 and 
7 days post-injection; low-dose injections did not produce detectable plasma ApoE3. 
As ApoE interacts strongly with glycosaminoglycans (GAGs) in cell-surface 
membranes and extracellular matrix [346], it is conceivable that a threshold level of 
ApoE3 expression is needed to saturate such binding sites before efficient secretion 
occurs. This possibility merits further investigation.
In summary, we have shown that hyaluronidase pre-treatment and electroporation 
significantly enhance ApoE3 transgene expression following injection o f naked DNA 
(plasmids) into skeletal muscle. Our original hope was that these techniques in 
combination with plasmid vectors driven by muscle-specific promoters would produce 
sustained physiological levels o f ApoE3 protein in plasma. Unfortunately, measurable 
levels o f circulating ApoE3 were not attained and consequently hyperlipidaemia was 
not reversed. This does not exclude, however, long-term therapeutic benefits, as
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previous deliveries o f ApoE3 by intramuscular plasmid injection [325] or by a cell- 
based platform [326] have demonstrated reductions in atherosclerotic aortic plaques 
despite a failure to detect ApoE3 in plasma. Notwithstanding, we conclude that a more 
efficient delivery vehicle is needed to fully exploit the benefits o f ApoE3 gene 
therapeutics and that although non-viral gene therapy has made substantial progress it 
still struggles to mimic the efficiency o f recombinant viruses.
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Chapter 4:
rAAV-mediated ApoE3 Gene Transfer
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4 rAAV-MEDIATED APOE3 GENE TRANSFER
4.1 Introduction
Early liver-directed gene transfer studies with ApoE utilised recombinant adenoviruses 
(rAd) and were initially reported to be a success as a lowering in plasma cholesterol and 
a deceleration in aortic atherogenesis was observed in ApoE'7' mice [308]. However, 
the therapeutic effect of these 1st generation vectors was shown only to be transient due 
to an immune response directed against both the transgene and the rAd proteins. 
Nevertheless significant progress has since been made with improved 2nd generation 
rAd vectors which have their E l, E3 and DNA polymerase genes deleted to reduce 
hepatotoxicity [312] and which contain mammalian promoters, for example cellular 
elongation factor l a  (E F-la), to prolong ApoE transgene expression [314]. However, 
with the addition o f the E F -la  promoter, ApoE levels in the plasma and normalisation 
o f the lipoprotein profile were compromised, suggesting that further vectors are needed.
Recombinant adeno-associated virus (AAV) vectors fortunately offer more hope for 
improvement and have emerged as attractive alternatives for achieving stable and safe 
transgene expression in vivo. They are non-pathogenic and require a helper virus for 
productive infection, which ultimately enhances their safety profile. In the first report, 5 
years ago, an AAV2 vector expressing ApoE was used to transduce skeletal muscle o f 
young ApoE'7' mice and although hyperlipidaemia was not reversed, as the levels o f 
ApoE secreted were low, there was a 29% reduction in plaque formation up to 3 months 
later [316]. Since then AAV technology has undergone several advances, the first o f 
which involved the cloning o f additional serotypes (AAV1-AAV11) that have been 
critically evaluated for their tissue tropism. AAV serotype-2, now well-documented to 
be the least efficient in vivo, can be pseudotyped by packaging with capsids from other 
serotypes [200] to achieve the most efficient transduction efficiency in a desired tissue. 
Indeed, intravenous injection o f AAV2/7 and AAV2/8 vectors expressing human 
ApoE3 produced sustained therapeutic levels o f ApoE3 in plasma and cholesterol levels 
were lowered for up to 1 year. Furthermore, atherosclerosis in these mice had been 
completely prevented [318]. Another major development in AAV technology has been 
the discovery o f the self-complementary AAV (scAAV) vector. Conventional single­
stranded AAV (ssAAV) vectors are limited by their requirement for either host-cell 
mediated synthesis of the complementary-strand or annealing of the plus and minus
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strands from two separate viral particles co-infected into the same cell. Molecular 
rearrangement o f the ssAAV vector genome into either circular or linear concatemers is 
an essential event for stable persistence o f the transgene in vivo [177; 178]. A double 
stranded structural intermediate is required for such molecular rearrangements to occur, 
and since this event does not occur immediately after transduction, a rapid 
disintegration o f linear ss vector genome follows. However, it has now been 
demonstrated that when the rAAV genome length is half the wild-type size, two copies 
can be packaged as a dimeric inverted repeat DNA molecule (scAAV). Such scAAV 
molecules should spontaneously re-anneal, bypassing the rate-limiting step o f second- 
strand synthesis and allowing rapid formation o f a transcriptionally active molecule. 
This phenomenon was discovered by Hirata and Russell [284] and manipulated further 
by McCarty et al. [285;286].
In 1996, Kessler et al. first demonstrated the ability o f rAAV vectors to transduce 
skeletal muscle and achieve sustained expression and systemic delivery o f a therapeutic 
protein following a single intramuscular administration [347]. Several studies have 
since used skeletal muscle as a platform for rAAV-mediated gene transfer and their 
success has given us impetus for our study [263;348-350].
This chapter describes the generation o f pseudotyped ssAAV2/7 and scAAV2/7 vectors 
harbouring the human ApoE3 gene, which are driven by the ubiquitous CMV 
enhancer/chicken p-actin (CAG) promoter [250] and two muscle-specific promoters, 
CK6 [257] and C512 [258]. The three-plasmid system was used, which involved the 
triple transfection of 293-T cells with an Ad helper plasmid, a pAAV expression 
plasmid (see section 3.2.1), and a packaging plasmid containing the AAV-serotype 2 
Rep and AAV-serotype 7 Cap genes. AAV7 is reported to have a high transduction 
efficiency in muscle in vivo [194;207] and was, therefore, selected for this study. The 
AAV vectors were first evaluated in vitro and then injected into the TA muscles o f 
ApoE'7' mice to assess their ability to ameliorate hypercholesterolaemia.
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4.2 Results
4.2.1 Construction and characterisation of ssAAV2/7 and scAAV2/7 vectors 
expressing the human ApoE3 transgene
As described in the introduction, when the rAAV genome length is half the wild-type
size, two copies can be packaged as a dimeric inverted repeat DNA molecule (scAAV). 
Here we have used specialised scAAV plasmids, which have a mutation in their 5’ ITR 
(see section 1.7.3) and are, therefore, able to form dimeric inverted repeat forms o f the 
genome efficiently. Initially it was thought that only scAAV2/7 vectors driven by the 
two muscle-specific promoters could be constructed due to the large size o f the CAG 
promoter (see section 3.2.1.4). The replicon size o f the ssAAV2/7.CAG.ApoE3 vector, 
however, is 2499bp, which is just over half the length of the wild-type genome 
(2340bp). The predicted size o f the dimeric replicative form of this vector is 4853bp, 
which is 103.7% o f the wild-type genome and within the optimal size range for efficient 
packaging. It is possible, therefore, that the ssAAV2/7.CAG.ApoE3 vector could 
package either two monomeric copies or dimeric inverted repeat DNA molecules 
(scAAV) (Figure 4-1 A). The replicon size o f the ssAAV2/7.CK6.ApoE3 vector is 
2367bp, which is again close to half the length o f the wild-type genome and has, thus, 
the potential to form a scAAV molecule. The predicted dimeric size o f this vector is 
4589bp, which is 98% of the wt AAV genome length (Figure 4-IB). Both the 
scAAV2/7.CK6.ApoE3 and scAAV2/7.C512.ApoE3 vectors have dimeric sizes of 
4271bp and 3869bp respectively (Figure 4-1C), the latter, however, is below 4.1kb, 
which is the minimal level for efficient functional packaging [351].
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Figure 4-1. The structure of ss- and scAAV genomes during packaging and their 
conformation upon uncoating
When the length o f  the AAV genome is half the wild-type size, two copies can be 
packaged as a dimeric inverted repeat DNA molecule (scAAV) or as diploid monomers. 
Such scAA V molecules should spontaneously re-anneal, bypassing the rate-limiting step 
o f  second-strand synthesis [285J. The predicted conformation that the rAAV vectors 
used in this study adopt upon release from the virion is schematically illustrated. (A) 
Due to the size o f  ssAAV2/7.CAG.ApoE3 (2499bp), this vector can be packaged as a 
single monomer, diploid monomers or a scAAV dimer. (B) As with 
ssAAV2/7.CAG.ApoE3, ssAAV2/7.CK6ApoE3 (2208bp) can be packaged as a single 
monomer, dipoloid monomers or a scAAV dimer. (Q  Both scAAV2/7.CK6.ApoE3 and 
scAAV2/7.C512.ApoE3 are packaged as scAAV dimers and re-fold and form double­
stranded transcriptionally active molecules upon release from the virion.
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A triple-transfection method was used to produce the virus particles (see section 2.2.3.1 
for details), followed by purification by iodixanol step-gradient ultracentrifugation 
(section 2.2.3.2). The virus particle titer was determined by DNA dot-blot hybridisation 
analysis (section 2.2.3.3) and verified by real-time quantitative PCR (Q-PCR) (section 
2.2.1.4). The two quantitative methods produced similar values for each viral 
preparation tested, giving us a high confidence that the titers were accurate. DNA dot- 
blot and Q-PCR estimated viral titers ranged from 1.92x 1011 to 5.96* 1012 and 9.9* 
1010 to 1.4* 1012 vector genomes (vg) respectively (Table 4-1). O f the two methods, the 
DNA dot-blot is the most routinely used and the more reliable for viral titer 
quantification; I decided, therefore, to use the estimated values from this method for 
future experiments.
The rAAV stocks were also assessed for their quality and purity by electrophoresis of 
lx  109vg o f each rAAV preparation on a NuPAGE® Novex 4-12% Bis-Tris 
polyacrylamide gel (see section 2.2.4.1 for details). The viral capsid proteins, VP1, 
VP2 and VP3, which are present in proportions o f 1:1:10 respectively, were readily 
detected in the scAAV2/7.C512.ApoE3 preparation after staining the gel with silver 
nitrate using the PlusOne silver staining kit (see section 2.2.3.4) (Figure 4-2). The viral 
capsid proteins o f the other ssAAV and scAAV preparations were also seen, however, 
the relative proportions were less clear. Unlike scAAV2/7.C512.ApoE3, these viral 
preparations also exhibited the presence o f additional protein bands and were, thus 
impure in comparison.
AAV vector Dot-blot
concentration
(vg/ml)
Total yield 
(vg)
Q-PCR
concentration
(vg/ml)
Total yield 
(vg)
ssAAV2/7.CAG.ApoE3 5.96x 10" 7.15x 10" 1.45x 10" 1.74x 10"
ssAAV2/7.CK6.ApoE3 7.7* 10" 1.54x 10“ 7x 10" 1.4x 10“
scAAV2/7.CK6.ApoE3 9.6* 1010 1.92x 10" 4.96x 10IU 9.9x 10'°
scAAV2/7.C512. ApoE3 2.46x 10" 2.46x 10" 1.51x 10" 1.51x 10"
Table 4-1. A comparison of viral titers obtained by DNA dot-blot hybridisation 
analysis and real-time Q-PCR
NB -  the ssAA V2/7.C512.ApoE3 vector was made but not purified.
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Figure 4-2. The purity profiles of the ss- and scAAV2/7 vectors isolated by 
iodixanol-step gradient ultracentrifugation
The volume equivalent to 1* l( fvg  o f each viral preparation was loaded onto a 4-12% 
Bis-Tris polyacrylamide gel and, following electrophoresis, was stained with silver 
nitrate. The positions o f  the viral capsid proteins, VP1, VP2 and VP2, are indicated.
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4.2.2 Expression of GFP in C2C12 myoblasts and myotubes following infection 
with a scAAV2/7.CMV.GFP vector
Before proceeding to assess the functionality o f my viral preparations in vitro, I carried
out a preliminary experiment to determine the optimal multiplicity o f infection (MOI) 
required for efficient transduction in both murine C2C12 myoblasts and myotubes. 
Mature C2C12 myotubes, prepared by growing for 6 days in DMEM containing 5% 
horse serum, and C2C12 myoblasts were infected with increasing MOI (8x 104 to 3.2* 
105) o f a pseudotyped scAAV2/7 vector, driven by the CMV promoter and expressing 
GFP. Cell culture supernatants in 6-well plates were replaced with 700/d o f serum-free 
DMEM containing scAAV2/7.CMV.GFP viral particles and incubated under normal 
conditions for 3h with gentle rotation o f the plate every 20mins. After the infection 
period, normal growth medium was added to the cells and at each 24h interval, cells 
were visualised under a fluorescent microscope to assess expression levels.
GFP expression levels, in both infected myoblasts and myotubes, increased with an 
increase in MOI and over time, thus, high fluorescence was observed in cell cultures 
infected with a MOI o f 3.2* 105 after 72h. Interestingly, after the first 24h interval, 
GFP was only expressed in myoblasts and not in myotubes, indicating that myoblasts 
were more easily infected by scAAV2/7.CMV.GFP. By 48h expression levels in 
myotubes and myoblasts was equal, however, by 72h the GFP intensity in mature 
myotubes appeared greater (Figure 4-3A). It would seem that the scAAV vector takes 
72h to become transcriptionally active in myotubes, whereas, in myoblasts this process 
occurs earlier.
4.2.3 Secretion of recombinant human ApoE3 from cultured myotubes following 
infection with ssAAV2/7 and scAAV2/7 vectors
Having determined the feasibility o f infection o f both C2C12 myoblasts and mature 
myotubes with a scAAV2/7 vector, I next went on to test the functionality o f the four 
viral preparations that I had produced. As before, myoblasts were seeded at a 
concentration of 2x 105 per well o f a 6-well plate and grown for 6 days in DMEM 
containing 5% horse serum. Mature myotubes, were then infected with 
ssAAV2/7.CAG.ApoE3, ssAAV2/7.CK6.ApoE3, scAAV2/7.CK6.ApoE3 and 
scAAV2/7.C512.ApoE3 at a MOI o f 3.2x 105 (see section 4.2.2 for details o f infection 
protocol). After 24, 48 and 72h, culture supernatant was removed and analysed for 
secretion o f human ApoE3. Western blot analysis demonstrated secretion o f ApoE3 in
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myotubes infected with all viral preparations, although ApoE3 expression was much 
higher following infection o f cells with the CAG-driven ssAAV2/7 vector (Figure
4-3B).
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Figure 4-3. Transduction of C2C12 myoblasts and myotubes with scAAV2/7 and 
ssAAV2/7 vectors
(A) Fluorescent microscope images (20x field) o f murine C2C12 myoblasts and 
myotubes infected with scAAV2/7.CMV.GFP at a MOI o f 3.2x 10s. Cells were 
observed 24, 48 and 72h after infection to assess relative GFP expression levels. (B) 
Human ApoE3 secretion from mature myotubes 48h after infection with 
ssAA V2/7. CAG.ApoE3, scAAV2/7.C512.ApoE3, scAAV2/7.CK6.ApoE3 and 
ssAA V2/7. CK6.ApoE3 at a MOI o f 3.2* I05.
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4.2.4 Human ApoE3 protein present in the plasma of ApoE'7' mice following 
intramuscular injection of the ssAAV2/7.CAG.ApoE3 vector
The ssAAV2/7.CAG.ApoE3 vector was clearly demonstrated to be functional in vitro
(section 4.2.3), I, therefore, proceeded to test this vector in vivo in ApoE 7' mice. It was 
also prudent to re-assess the ApoE3 expression plasmid driven by the CAG promoter 
over a longer time-course, thus, both ssAAV2/7.CAG.ApoE3 and p.CAG.ApoE3 were 
directly compared in this in vivo experiment. One group of young ApoE*7' mice (3 mice 
per group) received intramuscular injections o f 1* 1010vg of ssAAV2/7.CAG.ApoE3 
and another group were injected via electroporation with 25/xg of the CAG-driven 
expression plasmid. Tail vein bleeds were taken prior to injection and at 1, 2 and 4 
weeks post injection and plasma was assayed for ApoE3 secretion by Western Blot 
analysis. Unfortunately, ApoE3 protein levels in the plasma o f all mice injected with 
the CAG-driven expression plasmid remained undetectable, even at 4 weeks post 
treatment. A weak signal can be seen at 1, 2 and 4 weeks, however, this is not greater 
than the 0 time-point and was, therefore, considered as background only (Figure 4-4A). 
In contrast, ApoE3 was readily detected in the plasma o f mice injected with 
ssAAV2/7.CAG.ApoE3 as early as 1 week and the total amount secreted increased over 
time (Figure 4-4A). The concentration o f circulating ApoE3 at each time-point was 
semi-quantified by Western blot analysis; human plasma was serially diluted 1:30, 1:60 
and 1:120 and loaded onto the 4-12% Bis-Tris polyacrylamide gel along side the mouse 
plasma samples for direct densitometric comparison. The level o f ApoE3 in the plasma 
o f all mice injected with the ssAAV2/7.CAG.ApoE3 vector reached an average o f 
1.4±0.35pg/ml at the 4 week time-point (Figure 4-4B).
The TA muscles from all animals in each group were excised at 4 weeks termination 
and protein was extracted for the analysis o f local ApoE3 expression. Interestingly, 
Western blot analysis demonstrated markedly higher levels o f ApoE3 protein in the 
muscles o f mice injected with p.CAG.ApoE3. The total amount o f ApoE3 attained per 
TA muscle from these mice ranged from 1.80 -  4.05pg, while only 0.17 -  0.52pg of 
ApoE3 was present in muscle from mice injected with the ssAAV2/7.CAG.ApoE3 
vector (Figure 4-4C). In addition, I directly compared the level o f ApoE3 expression in 
1 week (obtained from our first in vivo experiment chapter 3, section 3.2.6) and 4 week 
muscle tissue from animals treated with p.CAG.ApoE3. Western blot analysis and an 
ELISA clearly demonstrated a decline in the total amount o f ApoE3 in the muscle over
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time, with an average o f 7.67±3.96|ug/TA muscle and 2.42±0.69 pg/TA muscle in the 1 
and 4 week samples respectively (Figure 4-4D).
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Figure 4-4. Plasma and muscle ApoE3 levels in ApoE A mice following injection of 
both TA muscles with ssAAV2/7.CAG.ApoE3 and p.CAG.ApoE3.
Mice were injected with 1x 10wvg o f ssAAV2/7.CAG.ApoE3 or 25pg o f  the CAG-driven 
ApoE3 expression plasmid and tail vein bleeds were taken before treatment (0 weeks) 
and 1, 2 and 4 weeks post-treatment. (A) Representative Western blot o f  plasma 
ApoE3 levels at each time-point in individual mice from each group. (B) Semi­
quantification by Western blot analysis o f  ApoE3 levels in the 4 week plasma samples o f  
all three mice injected with ssAAV2/7.CAG.ApoE3. (C) Immunodetection o f ApoE3 by 
Western blot analysis in muscle lysate from animals treated with either p.CAG.ApoE3 
(animals 1, 2 and 3) or ssAAV2/7.CAG.ApoE3 (animals 4, 5 and 6). (D) A Western 
blot comparing ApoE3 levels in 1 week (A, B, and C) and 4 week (1, 2 and 3) muscle 
tissue from animals injected with p.CAG.ApoE3.
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4.2.5 The hyperlipidaemic profile of ApoE'7' mice treated with
ssAAV2/7.CAG.ApoE3 and p.CAG.ApoE3 is not ameliorated
Plasma samples from individual animals treated with ssAAV2/7.CAG.ApoE3 and 
p.CAG.ApoE3 were assayed for total cholesterol. Plasma from each time-point was 
analysed, however, no significant reductions were observed after 4 weeks o f treatment 
in mice injected with the expression plasmid (9.58±0.99 vs 9.44±0.71mmol/L at 0 and 4 
weeks, respectively; P>0.05) and with the ssAAV2/7 vector (9.54±1.10 vs. 
9.63±0.97mmol/L at 0 and 4 weeks, respectively; P>0.05) (Figure 4-5A). To determine 
whether the abnormal lipoprotein profile improved in animals injected with 
ssAAV2/7.CAG.ApoE3, individual plasma samples were subjected to agarose gel 
electrophoresis and the separated lipoproteins stained with Sudan black. The resulting 
gel was analysed by densitometry to determine the relative proportions o f lipoprotein 
classes, however, there was no reduction in the absolute amount o f the atherogenic 
VLDL/IDL/LDL lipoproteins, nor was there any increase in the anti-atherogenic HDL 
fraction after 4 weeks o f treatment. Furthermore, there was no change in the HDL to 
total lipoprotein ratio, which can serve as a sensitive indicator of effective ApoE gene 
transfer (Figure 4-5B and C).
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Figure 4-5. Effect of human ApoE3 expression on the total plasma cholesterol 
level and lipoprotein profile in ApoE; mice
(A) Total plasma cholesterol levels (mmol/L) were determined for individual animals 
after intramuscular injection o f either p. CAG.ApoE3 (animals 1, 2 and 3) or 
ssAAV2/7.CAG.ApoE3 (animals 4, 5 and 6). (B) The lipoprotein profiles o f  individual 
mice injected with ssAAV2/7.CAG.ApoE3 (animals 4, 5 and 6), prior to treatment and 4 
weeks post-treatment. (Q  Determination o f HDL.total lipoprotein ratios by 
densitometry o f Sudan black stained lipoprotein fractions (animals 4, 5 and 6).
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4.2.6 Undetectable levels of ApoE3 in the plasma of ApoE'7' mice following 
intramuscular injection of the scAAV2/7.CK6.ApoE3 vector
In parallel with the previous experiment, a direct comparison between the 
ssAAV2/7.CAG.ApoE3 vector and the CK6-driven scAAV2/7.ApoE3 vector was also 
conducted in vivo. Two groups o f older mice (2 mice per group) received intramuscular 
injections o f ssAAV2/7.CAG.ApoE3 and scAAV2/7.CK6.ApoE3 at a dose o f 5* 109 
vg, while two further groups received a higher dose o f each vector (1* 1010 vg). Tail 
vein bleeds were taken at 1, 4, 8, 12 and 27 weeks post injection and plasma was 
evaluated for the presence o f human ApoE3 proteins by Western blot analysis. From 4 
weeks, ApoE3 was detected in the plasma o f mice treated with both high and low doses 
o f ssAAV2/7.CAG.ApoE3. Western blot analysis clearly demonstrated a dose response 
and in animals injected with 5X 109 vg, secreted levels increased over time, while levels 
dropped slightly after 8 weeks in mice injected with the higher dose (Figure 4-6A). 
Semi-quantitative Western blot analysis (see section 4.2.4 for details) was used to 
determine the relative concentrations o f ApoE3 attained in the plasma at each time 
point, with ApoE3 still detectable in the plasma after 27 weeks (Figure 4-6B). In the 
two mice that received the high dose o f ssAAV2/7.CAG.ApoE3, plasma ApoE3 levels 
reached 1.6pg/ml. In contrast, however, our assay methods did not detect ApoE3 in 
plasma of mice injected with both doses o f the scAAV2/7.CK6.ApoE3 vector at all 
time-points (only 4 and 27 week plasma samples are shown, Figure 4-6B).
At 27 weeks termination, the TA muscles were excised from all animals that received 
high vector doses and processed for evaluation o f ApoE3 expression. Protein was 
extracted from excised TA muscles as before (section 2.2.5.6) and ApoE3 expression 
was assessed by Western Blot analysis and the concentration determined by an ELISA. 
Very little ApoE3 was detected in the muscle o f scAAV2/7.CK6.ApoE3-treated 
animals, with levels reaching only 0.1/xg/TA, whilst the total amount o f ApoE3 in 
ssAAV2/7.CAG.ApoE3-injected muscle was 13 fold higher (1.3/ig) (Figure 4-6C).
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Figure 4-6. Secretion of human ApoE3 in the plasma of ApoE7' mice following 
intramuscular injection of the ssAAV2/7.CAG.ApoE3 vector
Tibialis anterior (TA) muscles o f ApoE'' mice were injected with ssAAV2/7.CAGApoE3 
and scAAV2/7.CK6.ApoE3 vectors (2 mice per group) at doses o f  5* JO9 and 7x 1010 
vg. (A) Western blot analysis o f  1, 4, 8 and 12 week plasma samples o f two individual 
mice injected with either 5x 109vg or 7x 1010vg o f the ssAAV2/7.CAG.ApoE3 vector.
(B) The top two Western blots represent 1, 4, 8, 12 and 27 week plasma samples from 
the two mice injected with 7x lCr°vg o f ssAAV2/7.CAG.ApoE3 and the Western below 
shows the 4 and 27 week plasma samples from an individual mouse treated with 1 x 
10wvg o f scAAV2/7.CK6.ApoE3. (Q  Western blot analysis o f local ApoE3 expression 
in the 27 week TA muscles o f  animals injected with ssAAV2/7.CAG.ApoE3 and 
scAA V2/7. CK6ApoE3.
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4.2.7 Undetectable levels of plasma ApoE3 in ApoE'7' following intramuscular 
injection of scAAV2/7.C512.ApoE3 and ssAAV2/7.CK6.ApoE3
From the previous experiment, it was evident that the CK6-driven scAAV2/7 vector
was inefficient in vivo and failed to produce detectable levels o f ApoE3 in the plasma o f 
treated animals. Notwithstanding this disappointing result, it was still necessary to test 
the scAAV2/7.C512.ApoE3 and ssAAV2/7.CK6.ApoE3 vectors in vivo, thus, two 
groups o f young ApoE'7' mice (2 mice per group) were injected intramuscularly with 1 * 
1010vg o f each vector. Tail vein bleeds were taken prior to treatment and 1 and 4 weeks 
post treatment. Unfortunately, plasma ApoE3 levels fell below the detection limit o f 
both the Western blot and ELISA assay (data not shown).
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4.3 Discussion
It was clear from the previous chapter that measurable levels o f circulating ApoE3 with 
a concomitant reversal in hypercholesterolaemia were unattainable with plasmid- 
mediated gene transfer. It was therefore, concluded that that a more efficient delivery 
vehicle is needed to achieve sustainable and therapeutic levels o f ApoE3. AAV has 
been chosen for this study primarily because it has the best safety profile among all viral 
vectors and with the new technological developments, it now reaps even more appeal as 
a gene transfer vehicle. We have taken advantage of the availability o f additional 
serotypes with improved transduction efficiencies and also utilised the scAAV vector 
which has been shown to accelerate and enhance transgene expression [286-288]. It is 
anticipated that these factors, in combination, will improve ApoE3 gene transfer from 
skeletal muscle, with the ultimate goal to reverse hypercholesterolaemia and 
atherosclerosis. This chapter describes the construction, characterisation and the in 
vitro and in vivo evaluation o f both ssAAV2/7 and scAAV2/7 vectors.
Dong et al. previously demonstrated that the optimal size of the ssAAV vector is 
between 4.1 and 4.9 kb. They discovered that, although it was possible for AAV to 
package a vector up to 5.2kb in size, which is larger than its genome, the packaging 
efficiency o f this vector was markedly reduced [351]. A more recent study reported the 
capability of AAV to package and protect recombinant genomes as large as 6.0 kb, 
however, these large genome-containing virions were found to be more susceptible to 
degradation by the proteasome [352]. Whilst evidently improving AAV-mediated 
transduction efficiency, the scAAV vector has proven to be problematic for the 
expression o f large transgenes, since its packaging capacity (~ 2.4 kb) is significantly 
smaller than that of the conventional ssAAV vector. A recent report, however, 
demonstrated the feasibility o f encapsidating a double-stranded (ds) 3.3kb genome into 
the scAAV vector and found that it could still transduce cells with high efficiency [353]. 
With the exception of scAAV2/7.C512.ApoE3, all the AAV vectors generated for this 
study were within the optimal size range for efficient packaging. Although, 
scAAV2/7.C512.ApoE3 was below the minimal level, subsequent in vitro evaluation 
clearly demonstrated it to be a packageable and functional virion. The size o f the vector 
also has a significant impact on the conformation o f the AAV genome upon release 
from the virion. For example, previous studies have found that rAAV DNA o f less than 
half the wtAAV genome length can be packaged either as a dimer or a diploid monomer 
[284;285]. The dimeric DNA molecules are encapsidated in the inverted repeat
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configuration (scAAV) and have the ability to re-fold into ds DNA templates upon 
uncoating. Both the ssAAV2/7.CAG.ApoE3 and ssAAV2/7.CK6.ApoE3 vectors have 
replicative genome lengths that are close to half the length o f the wt genome. Thus, it is 
possible that these AAV preparations had a mixed population o f virions containing 
either monomeric (ss) or dimeric (sc) DNA vectors. Alkaline gel electrophoresis o f the 
viral preparations would in fact confirm whether the genomes had been packaged as 
dimers or not [288]. The conformational constraints, however, o f DNA packaging in 
parvoviruses [354] most likely precludes the encapsidation of double-stranded 
structures. Furthermore, the packaging o f AAV DNA is dependent on the function of 
an active viral helicase, which also suggests that the DNA is single-stranded as it enters 
the capsid [355]. The propensity o f the virion to consist o f either one or two (either +/- 
stands, +/+ strands or -/- strands) copies o f a monomeric genome is also under debate 
and merits further investigation. The packaging o f a single copy o f the viral genome, 
however, corroborates the current model o f AAV DNA encapsidation, in which a single 
pore in the capsid takes up the viral genome, before a conformational change prevents 
further DNA packaging. Interestingly, it has been discovered that when the transgene 
cassette o f the scAAV vector is bigger than 3492bp it can be packaged efficiently, but 
only in single-stranded form. The ssAAV genomes that were generated, however, were 
not a consequence of repair o f the terminal resolution site (trs), but due to high levels of 
Rep proteins provided by the helper plasmid [353].
Assessment o f the integrity and purity o f each viral stock generated for this study was 
essential before any further in vivo experiments could be carried out. It remains unclear 
as to how pure a viral preparation needs to be before it is deemed “safe” for both pre- 
clinical and clinical work, but it is thought that contaminating cellular debris may incite 
an inflammatory response, which could eliminate the vector and the transfected cells, 
thus, limiting sustained transgene expression. Furthermore, cellular proteins can mimic 
true vector-mediated transduction events and produce artifactual results [356]. The 
electrophoresis of AAV preparations on a SDS polyacrylamide gel, followed by silver 
staining is a technique routinely used to assess the purity and integrity o f viral stocks. 
Unfortunately, all the AAV preparations generated for this study, with the exception of 
scAAV2/7.C512.ApoE3 were less pure than anticipated. Although it was re-assuring 
that the viral capsid proteins, VP1, VP2 and VP3, o f each ss and scAAV preparation 
were visible (Figure 4-2), contaminating protein bands were also present. The relative 
staining intensity of the viral capsid profile also varied between the four viral stocks,
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which may indicate differences in the efficiency o f encapsidation o f the AAV2 genome 
into the serotype-7 capsid. Additional purification steps, however, have the effect o f 
reducing the biological potency o f viral preparations, thus, it was decided that since this 
is not a clinical trial, but merely a series o f preliminary experiments to test the 
efficiency o f rAAV in mice, the viral preparations would be satisfactory for our means.
Before proceeding to assess the efficiency o f the scAAV2/7 and ssAAV2/7 vectors in 
vivo, it was first necessary to test their functionality in vitro. From our preliminary 
experiment, in which murine C2C12 myoblasts and myotubes were infected with a 
CMV-driven scAAV2/7 vector expressing GFP, we were able to determine the optimal 
MOI required for efficient transduction. Interestingly, we also discovered that whilst 
the onset o f transgene expression was earlier in myoblasts, a much higher level o f GFP 
expression was observed following infection o f differentiated, mature myotubes (Figure 
4-3). The transduction efficiency o f the scAAV2/7.CMV.GFP vector was clearly 
affected by the cellular state o f differentiation in C2C12 cells. When proliferating 
myoblasts are deprived o f growth factors they enter a terminal differentiation stage and 
expression o f various differentiation factors (myogenin and p21/W AFl) and contractile 
proteins (myosin and troponin) are induced [357]. It is, thus, possible that these factors 
are linked to the high transgene expression observed in differentiated cells. Previous 
studies have also demonstrated that the influence o f myoblast differentiation on 
transduction efficiency is dependent on the AAV serotype. Duan et al. found that a 
pseudotyped rAAV2/5 vector performed better in differentiated C2C12 cells compared 
with those that were undifferentiated, while the complete opposite was found for a 
rAAV-serotype 2 vector [358]. Another study also reported enhanced transgene 
expression from a rAAV-serotype 2 vector in undifferentiated myoblasts, whereas this 
was not the case with pseudotyped AAV2/10 and 11 vectors which were found to 
transduce differentiated cell with a higher efficiency [192]. Differentiation associated 
changes in cell surface receptor expression may contribute to increased binding o f the 
serotype-7 capsid in mature myotubes, although this is difficult to infer since the 
receptor for AAV7 is still unknown. Duan et al. hypothesised, however, that 
differentiation-induced changes in the intracellular processing and/or uncoating o f 
virions might have more o f an influence on the increased transduction efficiency 
observed with pseudotyped vectors [358].
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Having established that AAV serotype-7 transduces differentiated C2C12 cells with a 
much higher efficiency, we proceeded to infect mature myotubes, grown for 6 days, 
with each o f the ss and scAAV2/7 vectors. Western blot analysis demonstrated 
secretion o f human ApoE3 into the medium of cultured myotubes infected with all viral 
preparations, thus verifying their functionality. It was also evident that the 
ssAAV2/7.CAG.ApoE3 vector was more efficient in vitro than both ss- and scAAV2/7 
vectors driven by the muscle-specific promoters. This corroborates our previous 
findings (chapter 3) for the C512 and CK6-driven plasmids; both o f which produced 
markedly less ApoE3 in vitro and in vivo. With the exception of the C512 promoter, 
which is reported to be as active in skeletal muscle and cell cultures as the natural 
myogenic and viral gene promoters [258;259], previous studies have also shown CK6 to 
perform less efficiently than the ubiquitous promoters [257]. The scAAV vector, which 
obviates the need for viral second-strand DNA synthesis, has been reported to perform 
equally as efficient in vitro as in vivo. Studies have used this vector as a helper virus to 
improve the transduction efficiency o f the conventional ssAAV vectors in various 
human cell lines in vitro [359;360]. It was therefore, anticipated that the scAAV vector 
would enhance transgene expression from our less active muscle-specific promoters, 
however, our findings clearly suggest otherwise.
Although it was conclusive from chapter 3, that measurable levels o f plasma ApoE3 
could not be achieved via plasmid-mediated gene transfer, our first in vivo experiments 
were conducted over just 1 week. It was, subsequently, hypothesised that a longer time 
period might be required to achieve maximum secretion o f the protein from muscle. 
We, therefore, re-assessed electrotransfer of p.CAG.ApoE3 over 4 weeks and at the 
same time directly compared this plasmid with the ssAAV2/7.CAG.ApoE3 vector. 
Despite local expression in the muscle, ApoE3 remained undetectable in the plasma of 
p.CAG.ApoE3-treated animals, 4 weeks post-injection (Figure 4-4) and their plasma 
cholesterol levels remained unchanged. Furthermore, a direct comparison o f 1 week 
muscle lysates, from animals previously injected with p.CAG.ApoE3, with the 4 week 
muscle lysates, clearly demonstrated a decline in the levels of ApoE3; suggesting that 
there had been plasmid loss or possibly silencing of gene expression. We can therefore 
infer that plasmid-mediated ApoE3 transfer in skeletal muscle is not sustainable and 
that active secretion o f the expressed protein will not be maintained over a prolonged 
period.
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Fortunately, the complete opposite was observed in animals treated with the 
ssAAV2/7.CAG.ApoE3 vector; ApoE3 was readily detected in the plasma as early as 
one week post-injection and the level steadily increased overtime (Figure 4-4). This 
ultimately reinforces the high tropism of serotype 7 for skeletal muscle, since a previous 
study failed to detect ApoE3 in the plasma o f ApoE'7' mice that had received i.m 
injections o f a rAAV-serotype 2 vector [316]. The basis for this improved efficiency, 
however, is unclear since essential information such as primary attachment receptors, 
co-receptors and trafficking properties to the nucleus remains unknown for serotype 7. 
A pseudotyped A A V 2/1 vector has been shown to transduce skeletal muscle as 
efficiently as AAV1 [191], which is the serotype that confers the highest level of 
transduction in skeletal muscle o f the primate AAVs tested to date. It could therefore be 
inferred that these two serotypes share the same properties required for efficient 
transduction in muscle. The advantage, however, o f using AAV7 over AAV1, is that 7 
is immunologically distinct and sera from humans show less neutralising antibodies to 
this serotype compared with AAV1 [191]. Furthermore, AAV DNA has been identified 
in 17% of normal human muscles [361] which emphasises the importance o f using 
novel AAV serotypes isolated from non-human primates for skeletal muscle gene 
transfer.
Despite measurable levels o f circulating ApoE3, plasma total cholesterol and 
lipoprotein profiles o f ssAAV2/7.CAG.ApoE3-treated animals remained unchanged 
after 4 weeks (Figure 4-5). The concentration o f ApoE reported to normalise plasma 
cholesterol is 2pg/ml [96], albeit endogenous mouse ApoE which is 6-fold more 
efficient than human ApoE3 in clearing remnant particles [137]. The concentrations 
(1.40±0.35pg/ml) of plasma ApoE3 reached in our mice were just below this threshold 
level, thus, we would not expect to observe a reduction in hypercholesterolaemia. 
Unexpectedly, we found local ApoE3 expression in the muscle of 
ssAAV2/7.CAG.ApoE3-treated animals to be lower than that observed in animals 
treated with the CAG-driven plasmid. We can only assume that this is because ApoE3 
is being actively secreted into the plasma from ssAAV-injected muscle, whilst 
expression in plasmid-injected muscle is retained. It is possible that the ssAAV2/7 viral 
vector and plasmid are being taken-up by different cell-types within the TA muscle, 
which could consequently affect their ability to be secreted.
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In parallel with the previous experiment, we directly compared the 
ssAAV2/7.CAG.ApoE3 vector with the CK6-driven scAAV2/7 vector in ApoE7' mice. 
The main objective o f this experiment was to see whether a scAAV vector could 
enhance expression from the less active muscle-specific promoter in vivo. Ultimately, it 
is desirable to use the lowest vector dose possible; hence, animals were injected with 
both high (1* 1010 vg) and low (5x 109 vg) doses. Consistent with our previous 
experiment, mice that received intramuscular injections of ssAAV2/7.CAG.ApoE3 
demonstrated detectable plasma ApoE3 levels, with the concentration reaching its 
highest at 4 and 8 weeks (Figure 4-6). Furthermore, ApoE3 was still detectable in the 
plasma at the 12 and 27 week time-points, albeit the levels having declined slightly, 
suggesting that there may have been a humoral immune response directed against either 
the vector or the transgene. Human ApoE is a neo-antigen to ApoE7' mice, making it 
likely that antibodies against ApoE were produced. In addition, direct intramuscular 
injection per se induces a localised inflammatory immune response mediated by a 
mixed infiltrate o f activated lymphocytes and macrophage/dendritic cells [362]. It was 
anticipated that such immune responses would be circumvented with our muscle- 
specific promoter-driven AAV vectors [254] and we would observe an increase in 
persistence o f transduced muscle cells. However, failure to detect ApoE3 in the plasma 
and very low amounts in the muscle of scAAV2/7.CK6.ApoE3-treated animals (Figure 
4-6), rendered this analysis impossible. We were able to confirm that this observed 
vector inefficiency was not due to the scAAV vector but a result o f the weak activity o f 
the muscle-specific promoter, since both the ssAAV2/7.CK6.ApoE3 and 
scAAV2/7.C512.ApoE3 vectors equally failed to produce ApoE3 in vivo.
Why is transduction efficiency in the skeletal muscle significantly lower with muscle- 
specific promoters? It might be that, while, the ubiquitous promoters drive a high level 
o f expression in virtually all skeletal-muscle fibres, the CK6 promoter has been reported 
to favour only the fast-twitch fibres [363]. A similar expression pattern was also 
observed with both CK1 and CK7, their activity was demonstrated to be low and mosaic 
in predominantly slow muscles, such as the soleus [364]. The TA muscle, however, is 
predominantly made up of fast-twitch fibres [365], which should in theory favour 
expression from the CK6 promoter. Nevertheless, we can be encouraged by the 
development o f novel, muscle-specific promoters with improved transduction 
efficiencies; these include a muscle creatine kinase/SV40 hybrid promoter which is 
reported to yield enhanced and long-term transgene expression [256], while a MHCK7
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(a-myosin heavy-chain enhancer, creatine kinase 7) promoter was shown to direct high- 
level expression comparable to CMV and RSV (Rous sarcoma virus) promoters [364].
Although we are encouraged by our findings that skeletal muscle injected with 
ssAAV2/7.CAG.ApoE3 can secrete pg/ml quantities o f ApoE3, further experiments are 
ultimately needed to determine why therapeutic levels and a reversal in 
hypercholesterolaemia were not achieved. By directly comparing the 
ssAAV2/7.CAG.ApoE3 vector with a scAAV2/7.CAG.ApoE3 vector, we might be able 
to delineate whether the poor outcome was due to the use o f the less efficient ssAAV 
vector or the CAG promoter. Although the CAG promoter has been reported to direct 
high transgene expression in skeletal muscle [252], its potential to provoke an immune 
response is a limiting factor. Another important experiment is to assess liver versus 
muscle transduction. A comparison o f plasma ApoE levels in animals injected either 
intravenously or intramuscularly with ssAAV2/7.CAG.ApoE3, will give a clear 
indication o f whether inadequate secretion by muscle was the cause of low 
concentrations o f circulating ApoE in our study. It would also be worthwhile to 
generate reporter gene constructs; the injection o f both CAG-driven and muscle-specific 
promoter-driven ssAAV2/7 vectors expressing LacZ or GFP into skeletal muscle will 
allow us to accurately evaluate the activity o f each promoter and determine whether 
they target different muscle cell types.
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Chapter 5:
Comparison of ssAAV2/7, ssAAV2/8 and 
ssAAV2/9 Vectors Expressing ApoE3
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5 COMPARISON OF ssAAV2/7, ssAAV2/8 AND ssAAV2/9 
VECTORS EXPRESSING APOE3
5.1 Introduction
As discussed in previous chapters, ApoE has several anti-atherosclerotic properties, 
which are mediated by means that are both dependent [85-87;90] and independent 
[96;147;311] o f plasma cholesterol homeostasis. This is corroborated by earlier studies 
using rAd vectors for liver-directed ApoE gene transfer, which resulted in the correction 
o f hypercholesterolaemia and protection against atherosclerosis in ApoE-deficient mice 
[308;366]. The effect o f these first generation rAd vectors, however, was transient due 
to an associated immune response, which cleared transduced hepatocytes. Nevertheless, 
vector modifications have since resulted in reduced toxicity and prolonged ApoE 
expression in treated animals [310;312;313]. The general safety issues associated with 
rAd vectors, however, have driven our group and others to use rAAV as an alternative. 
This viral vector has emerged as an attractive candidate for gene transfer, firstly because 
it does not appear to cause any human disease and secondly because it remains 
quiescent in the absence o f helper virus. AAV has therefore been labelled as a safe and 
stable gene transfer vehicle and for these reasons has attracted the attention o f many 
researchers.
The first AAV serotype to be identified and fully characterised was AAV2, which has 
therefore, been extensively investigated as a gene transfer vector. Although AAV2 is a 
promising vector in vitro, it is now well documented to perform less efficiently in vivo. 
Fortunately, eleven different serotypes (designated AAV1 to AAV11) and over one 
hundred genomic variants of AAV from human and non-human primate samples have 
now been identified [185; 190; 192; 194]. Furthermore, pseudotyped rAAV2 vectors 
which have been cross-packaged into alternative AAV serotype capsids, exhibit 
serotype-specific tissue or cell-type tropism and/or strikingly improved transduction 
efficiency [ 190; 194;367]. The success of AAV gene therapy is thus essentially 
dependent on finding the optimal AAV serotype for efficient transduction o f specific 
target tissues. Gregorevic and colleagues were first to discover that genes could be 
delivered globally to target tissue(s) by systemic administration o f pseudotyped rAAV 
vectors derived from alternative serotypes [260]. Nakai et al. and Wang et al, 
subsequently demonstrated that transduction of all hepatocytes, all the skeletal muscles
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throughout the body and the entire myocardium in mice could be achieved by 
intravenous injection o f CMV and EFla-driven rAAV8 vectors [211 ;212]. Moreover, 
Inagaki and colleagues have recently discovered that AAV9 is as robust as AAV8 and 
can also cross vascular endothelial cell barriers very efficiently and transduce many 
nonhepatic tissues, especially the heart, following systemic administration [213;214].
AAV vectors for liver-directed ApoE gene transfer have demonstrated promising and 
encouraging results. Thus, intravenous injection o f a pseudotyped AAV2/8 vector, 
expressing ApoE, produced normal human levels (50 to 80/ig/ml) in the plasma o f 
ApoE'7' mice [317], while AAV2/7 and AAV2/8 vectors lowered cholesterol levels for 
up to 1 year and completely prevented atherosclerosis [318].
Here, we have chosen skeletal muscle as the platform for AAV-mediated ApoE gene 
transfer, since it is a stable, post-mitotic tissue, which is highly vascularised and 
actively secretory [261 ;262], Several studies have demonstrated sustained transgene 
expression over several weeks following intramuscular injection of rAAV vectors 
[263;264;347;368]. Xiao et al. in fact, observed maintained expression over 1.5 years 
with no evidence o f an immune response directed against the vector or lacZ reporter 
gene [264]. Intramuscular, AAV-mediated ApoE gene transfer has previously been 
tested in ApoE'7' mice and, achieved a reduction in atherosclerotic plaque density, 
although plasma ApoE levels were low and did not ameliorate hypercholesterolaemia 
[316]. AAV serotype-2 was used in this study, which, as mentioned above, is less 
efficient in vivo and could explain poor secretion o f ApoE protein. Furthermore, in 
chapter 4 , 1 demonstrated that intramuscular injection o f a CAG-driven AAV-serotype 7 
vector in ApoE'7' mice results in detectable ApoE3 levels in the plasma. The ApoE 
concentration attained in the plasma, however, was below the anticipated threshold 
required to correct the hypercholesterolaemic phenotype. Nevertheless, this is still an 
improvement on the aforementioned study and, although, atherosclerotic plaque density 
was not assessed, we would predict that this would be reduced over time.
It was conclusive from the experiments described in chapter 4 that the activities o f the 
two muscle-specific promoters were significantly weaker than that o f the ubiquitous 
CAG promoter in vivo. Even with the aid o f a scAAV vector, both CK6 and C512 
performed inefficiently and failed to drive vigorously ApoE3 expression, as judged by 
local levels of ApoE3 protein in muscle and in plasma. It is, therefore, unlikely that in a
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long-term experiment, these vectors would have an effect on atherosclerotic lesion 
development. Instead, I decided to pseudotype the ssAAV2.CAG.ApoE3 vector with 
the capsids o f alternative serotypes and directly compare these with the 
ssAAV2/7.CAG.ApoE3 vector in vivo. The AAV serotypes 8 and 9 were selected for 
their aforementioned robustness with the main objective o f this experiment to compare 
the abilities o f all three vectors to ameliorate hypercholesterolaemia and inhibit 
progression o f pre-existing early atherosclerotic lesions, following intramuscular 
injection into A poE/_ mice.
5.2 Specific methodology - ELISA quantification of human ApoE3 in 
murine plasma samples
The ELISA, previously described in this thesis (section 2.2.4.2) had only been used for
the determination o f ApoE3 concentrations in cell culture supernatants and muscle 
tissue lysates. Unfortunately, when this assay was used for analysis of human ApoE3 in 
murine plasma samples, an inhibitory effect was observed. The signal appeared to be 
quenched and it was assumed, therefore, that the capture antibody in this ELISA was 
binding additional proteins in the mouse plasma, which blocked human ApoE3 antigen 
binding. Semi-quantitative Western blot analysis had so far been employed to estimate 
ApoE3 levels in our plasma samples; however, for large-scale experiments this would 
be very time consuming. An alternative ELISA was, therefore, used which was 
optimised by Dr Patrick Rensen’s group at Leiden University Medical Centre.
The following buffers were prepared prior to starting the ELISA:
• Wash buffer (1 x PBS with 0.05% Tween-20 (v/v))
• Blocking buffer (1 x PBS with 0.1 % Casein)
• Secondary antibody buffer (Blocking buffer with 0.05% Tween-20 (v/v))
The ELISA plate was prepared by coating each well o f a medium binding (Costar) 
immunoassay plate with 100/xl o f polyclonal goat anti-human ApoE primary antibody 
(Academy Biomedical Company; cat. 50A-Glb), diluted 1:1000 in PBS to give a final 
concentration o f 1/xg/ml. The plate was covered and incubated firstly for lh  at 37°C and 
then overnight at 4°C. The following day, the plate was washed 3 times with wash 
buffer and then blocked by the addition o f 150/xl/well o f blocking buffer and incubating 
for lh  at 37°C. Meanwhile, a human ApoE3 standard (Academy Biomedical Company; 
cat. 50P-103) stock solution was first diluted with wild-type mouse serum to a
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concentration of 0.1 mg/ml and then 9 further dilutions were prepared in blocking buffer 
ranging from lOng/ml -  0.03906ng/ml. After blocking, the plates were washed as 
before and 100/xl o f each sample and standard was added in triplicates to the appropriate 
wells and the plate was incubated for 2h at 37°C in a humidified incubator. The plate 
was then washed a further 3 times and 100/xl of HRP-goat anti-human ApoE (Academy 
Biomedical Company; cat. 50H-Glb) detection antibody, diluted to a concentration o f 
2/xg/ml in secondary antibody buffer was added to each well. The plate was incubated 
for 2h at room temperature and this was followed by a final washing step and the 
addition o f 100/xl o f TMB substrate (equal volumes of 0.004% (v/v) H2O2 and TMB 
dye) to each well. The plate was wrapped in aluminium foil and incubated for 15min on 
a shaker at room temperature, after which the enzymatic reaction was stopped by the 
addition o f 2M H 2 S O 4  (100/* 1/well). The absorbance at 450nm was immediately 
measured using a Dynex microplate reader.
5.3 Results
5.3.1 Construction and characterisation of ssAAV2/8 and ssAAV2/9 vectors 
expressing the human ApoE3 transgene
Both the ssAAV2/8.CAG.ApoE3 and ssAAV2/9.CAG.ApoE3 vectors were generated 
as per the method described in chapter 2, section 2.2.3.1. Briefly, 293-T cells were 
transfected with an Ad helper plasmid, the pAAV2.CAG.ApoE3 expression plasmid, 
and a packaging plasmid containing the AAV-serotype 2 Rep and AAV-serotype 8 or 9 
Cap genes at a ratio o f 3:1:1, respectively. Cell lysates were prepared two days after 
transfection and rAAV particles purified by iodixanol step-gradient ultracentrifugation 
(section 2.2.3.2). The virus particle titer was determined by DNA dot-blot hybridisation 
(section 2.2.3.3) and verified by real-time quantitative PCR (Q-PCR) (section 2.2.1.4). 
The two quantitative methods produced similar values for each viral preparation tested, 
as previously observed in chapter 4 (Table 5-1).
As before, the rAAV stocks were assessed for their quality and purity by electrophoresis 
o f 1* 109vg o f each rAAV preparation on a NuPAGE® Novex 4-12% Bis-Tris 
polyacrylamide gel (see section 2.2.4.1 for details), which was then stained with silver 
nitrate using the PlusOne silver staining kit (see section 2.2.3.4), The capsid proteins, 
VP1, VP2 and VP3, o f both viral preparations were visible on the gel but not well 
defined, thus, it was difficult to confirm whether they were in accordance with the 
1:1:10 stoichiometric ratio (Figure 5-1). Furthermore, both ssAAV2/8 and 9 viral
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stocks exhibited the presence o f additional protein bands, which was also apparent with 
the other AAV vectors described in chapter 4.
AAV vector Dot-blot
concentration
(ve/ml)
Total yield 
(vg)
Q-PCR
concentration
(vg/ml)
Total yield 
(vg)
ssAAV2/8.CAG.ApoE3 2.98* 10" 5.96x 10" 1.57x 10" 3.14x 10"
ssAAV2/9.CAG.ApoE3 2.98x 10" 5.96x 10" 2.61x 10" 5.22x 10"
Table §>1. A comparison of viral titers obtained by DNA dot-blot hybridisation 
analysis and real-time Q-PCR
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VP1 —
VP2—>
VP3“ *
*~VP2
VP3
VP1 = 87 kDa 
VP2 = 73 kDa 
VP3 = 62 kDa
SSAAV2/8.CAG. ssAAV2/9.CAG.
ApoE3 ApoE3
Figure 5-1. Purity profiles of the ssAAV2/8.CAG.ApoE3 and 
ssAAV2/9.CAG.ApoE3 vectors isolated by iodixanol step-gradient 
ultracentrifugation
The volume equivalent to 1* ic f  vg o f each viral preparation was loaded onto a 4-12% 
Bis-Tris polyacrylamide gel and, following electrophoresis, stained with silver nitrate. 
The positions o f the viral capsid proteins, VP1, VP2 and VP3, are indicated.
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5.3.2 Secretion of recombinant human ApoE3 from cultured myotubes and HEK  
293-T cells following infection with ssAAV2/7, 2/8 and 2/9 vectors
Before proceeding to test the viral preparations in vivo, it was first necessary to assess 
their functionality in vitro. HEK 293-T cells were seeded at a concentration o f 5x 105 
cells per well o f a 6-well plate and left overnight to adhere, while C2C12 cells had been 
grown for 6 days to allow differentiation into mature myotubes. The cultured cells were 
infected with ssAAV2/7.CAG.ApoE3, ssAAV2/8.CAG.ApoE3 and 
ssAAV2/9.CAG.ApoE3 at a MOI o f 3.2* 105 (see section 4.2.2. for details o f infection 
protocol). After 24, 48 and 72h, culture supernatant was removed and analysed for 
secretion o f human ApoE3. Western blot analysis demonstrated secretion o f ApoE3 
from 293-T cells (Figure 5-2A) and mature myotubes (Figure 5-2B) infected with all 
viral preparations, although ApoE3 expression was higher following infection o f both 
cell types with ssAAV2/7.CAG.ApoE3 (Figure 5-2A and B). ELISA quantification 
yielded values ranging from 0.34 to 1.33pg o f ApoE3 from 293-T cells infected with 
ssAAV2/7.CAG.ApoE3 over the 24 -  72h time-course, while only 0.13 -  0.4pg and 
0.14 -  0.3pg o f ApoE3 was secreted from cells transduced with ssAAV2/8.CAG.ApoE3 
and ssAAV2/9.CAG.ApoE3 respectively (Figure 5-2A). Mature myotubes infected 
with ssAAV2/7, ssAAV2/8 and ssAAV2/9 vectors produced about 70, 20 and 35ng o f 
ApoE3 per well, respectively, after 48h (Figure 5-2B).
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A: SSAAV2/7.CAG. ssAAV2/8.CAG. ssAAV2/9.CAG.
ApoE3 ApoE3 ApoE3
24 h 48h 72h 24h 48 h 72 h 24h 48 h 72h
ApoE3 
(34 kDa)“
ApoE3
(ng/well) 0.6 1.33 0.34 0.44 0.40 0.13 0.19 0.3 0.14
B: ssAAV 2/7 ssAAV2/8 SSAAV2/9
ApoE3 
(34 kDa)'
ApoE3
(ng/well)
71.2 20.5 35.6
Figure 5-2. Secretion of recombinant human ApoE3 from cultured HEK 293-T 
cells and mature C2C12 myotubes following infection with ssAAV2/7,2/8 and 2/9 
vectors
Viral preparations were added to the cultured cells at a MOI o f 3.2* 105 and 
supernatant was collected at 24, 48 and 72h post infection. ApoE3 expression was 
assessed by Western Blot analysis and quantified by an ELISA assay. (A) ApoE3 
expression from HEX 293-T cells. (B) ApoE3 expression from mature C2C12 myotubes 
after 48h only.
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5.3.3 Human ApoE3 is detectable in the plasma of ApoE'7' mice following
intramuscular administration of the CAG-driven ssAAV2/7, 2/8 and 2/9 
vectors
Having verified that each vector was functional in vitro, I went on to conduct a side-by- 
side experiment with ssAAV2/7, 2/8 and 2/9 vectors delivered via the TA muscle o f 
ApoE-deficient mice. Three groups of 6 week old, female mice (8 mice per group), 
were injected with ssAAV2/7.CAG.ApoE3, ssAAV2/8.CAG.ApoE3 and 
ssAAV2/9.CAG.ApoE3 at a dose o f 1* 1010 vg, while a fourth control group was 
uninjected. One week before treatment all animals were fed a high-fat diet and this 
continued throughout the duration o f the experiment. Tail vein bleeds were taken prior 
to injection and at 1, 2, 4 and 13 weeks post-injection and plasma was assayed for 
human ApoE3 protein by Western blot analysis and ELISA (see section 5.2).
As expected no ApoE3 was found in the plasma o f control animals at all time-points 
(Figure 5-3C), but it was clearly detectable in the plasma of mice treated with 
ssAAV2/7.CAG.ApoE3 and ssAAV2/8.CAG.ApoE3 as early as 1 week and levels were 
sustained for the 13 week time-course (Figure 5-3A and C). After 1 week, circulating 
ApoE3 in these two groups o f animals reached comparable levels (1.9/ig/ml±0.56 and 
2.08/xg/ml±0.43 respectively), however, at 2 weeks the concentration in ssAAV2/7- 
treated mice had markedly declined to 0.87/xg/ml±0.47 (Figure 5-3B, C and D), which 
was significantly lower than that observed in the ssAAV2/8-treated mice 
(1.78±0.64/xg/ml P  = 0.03 Figure 5-3B, C and E). In fact, only 3 animals from the 
ssAAV2/8-injected group demonstrated a decline at 2 weeks, while there were 6 
ssAAV2/7-treated mice that exhibited this trend (Figure 5-3G and H). This decrease is 
most likely due to ApoE3 being sequestered by the excess o f remnant lipoproteins in the 
plasma and rapidly cleared by the liver via interaction with the LDL-R or LRP. 
Furthermore, different trends were observed in both groups after 2 weeks, plasma 
ApoE3 levels in animals injected with the ssAAV2/7 vector appeared to augment 
(Figure 5-3D), while levels declined in ssAAV2/8-treated mice (Figure 5-3E). Thus at 
termination the mean concentration in the ssAAV2/7 group of mice was slightly higher 
(1.4±0.41^g/ml), than that o f the ssAAV2/8 group (1.28±0.2/*g/ml). In contrast, the 
amount o f ApoE3 protein detected in the plasma o f ssAAV2/9-treated animals was 
markedly lower at each time-point (Figure 5-3C and F), with concentrations reaching 
only 0.49±0.18jLig/ml and falling almost below the sensitivity limit o f the Western blot 
(data not shown).
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Figure 5-3. Plasma ApoE3 levels in ApoE7' mice following intramuscular 
injections of ssAAV2/7, ssAAV2/8 and ssAAV2/9 vectors
Three groups of female mice were injected with /x  J010vg of either 
ssAAV2/7.CAG.ApoE3, ssAAV2/8.CAGApoE3 or ssAAV2/9.CAG.ApoE3, while a fourth 
control group was uninjected. Tail vein bleeds were taken prior to injection and at 1, 2, 
4 and 13 weeks post-injection and plasma was assayed for human ApoE3 protein. (A) 
A Western blot ofpooled plasma samples from ssAAV2/7- and ssAAV2/8-treated mice 
over the 13 week time course. (B) Semi-quantitative Western blot analysis of plasma 
ApoE3 levels (pg/ml) in individual animals injected with ssAAV2/7 and ssAAV2/8. (Q  
ELISA quantification of circulating human ApoE3 concentrations (pg/ml), the graph 
represents the mean value at each time-point of all four groups. (D-F) Plasma ApoE3 
levels in individual mice at each time-point is shown (*), with the solid line indicating 
the mean value for animals injected with ssAAV2/7 (D), ssAAV2/8 (E) or ssAAV2/9 (F). 
Individual ssAAV2/7- (G) and ssAAV2/8-treated animals (H) demonstrating a decrease 
in plasma ApoE3 levels at 2 weeks and an increase at 4 weeks.
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5.3.4 The hyperlipidaemic profile of ApoE'/_ mice treated with the CAG-driven 
ssAAV2/7, 2/8 and 2/9 vectors is not ameliorated
Plasma from individual AAV-treated and control animals was assayed for total
cholesterol. Plasma total cholesterol from the control animals rose 2-fold between 0 
(7.7±2mmol/L) and 2 weeks (14±1.6mmol/L) and then sharply declined at 4 weeks 
(10.9±2mmol/L), but by the final 13 week time-point the level had augmented again 
(13.4±2.9mmol/L) (Figure 5-4A). A similar pattern was also observed with ssAAV2/8- 
and ssAAV2/9-treated mice (Figure 5-4A); however, a different trend was displayed 
with animals from the ssAAV2/7 group. These mice demonstrated a steep increase in 
total cholesterol level between the 0 and 2 week time-points, however, the level 
continued to gradually rise thereafter and at 4 weeks (13.9±1.5mmol/L) was 
significantly (P<0.05) different from the negative control group (Figure 5-4A). The 
initial rise in total cholesterol exhibited in all 32 animals within the first two weeks was 
most likely due to the high-fat diet, which was commenced only one week before 
treatment. Nevertheless, none o f the treated groups exhibited a normalisation in 
cholesterol level after 13 weeks or a reduction when compared with baseline levels. It 
is important to emphasise, however, that the increase in total cholesterol observed 
between 4 and 13 weeks might also be due to the ageing o f the mice.
Figure 5-4B represents a comparison of total cholesterol at 2 and 13 weeks in each 
group. Interestingly, the ssAAV2/7- and ssAAV2/8-treated animals demonstrate lower 
levels at 2 weeks, while ssAAV2/9-treated mice, which displayed very low circulating 
ApoE3 concentrations, and negative control animals show very little difference between 
these two time-points. Direct comparisons were also made between total cholesterol 
and plasma ApoE3 levels over time for three individual mice treated with ssAAV2/7 
(Figure 5-4C, D and E) or ssAAV2/8 (Figure 5-4F, G and H). Animals with the highest 
and lowest mean plasma ApoE level over the time-course were selected for comparison 
and two trends were clearly observed. When ApoE3 concentrations were high in these 
two treated groups, the decrease in total cholesterol, which was observed at 4 weeks in 
control mice, was inhibited and the level appeared to reach either a plateau or decline 
after 13 weeks (Figure 5-4C, D, F and G). In contrast, when ApoE3 levels were much 
lower, a marked increase in total cholesterol was observed at termination (Figure 5-4E 
and H).
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To determine whether the abnormal lipoprotein profile o f high atherogenic 
VLDL/IDL/LDL, and low anti-atherogenic HDL, had improved in treated-animals, 
pooled plasma samples from the individual mice in each group were subjected to 
agarose gel electrophoresis. The separated lipoproteins were stained with Sudan black 
and analysed by densitometry to determine the relative proportions o f lipoprotein 
classes. Plasma from wild-type C57BL/6 mice exhibit high levels o f HDL and a 
relatively low proportion o f clearly separated VLDL and LDL; hence their HDL to total 
lipoprotein ratio was greater than 1 (Figure 5-5A, B, C and D). In contrast, the plasma 
of the negative control ApoE7' mice demonstrated mostly VLDL/IDL/LDL lipoprotein 
particles, and a profile was displayed that clearly reflected their total cholesterol levels 
over the time-course. As expected, the high-fat diet resulted in an increase at 1 week in 
the absolute amounts o f HDL and VLDL/IDL/LDL particles; furthermore, between 
baseline and 1 week the HDL to total lipoprotein ratio had increased from 0.05 to 0.09 
(Figure 5-5A and E). At 2 weeks, each individual lipoprotein fraction had markedly 
decreased, but by 13 weeks, VLDL/IDL/LDL levels had risen again, while HDL 
remained low. The HDL to total lipoprotein ratio at termination was, thus, significantly 
lower (0.02) than that observed at 0 and 1 weeks. This lipoprotein profile was also 
exhibited in mice treated with ssAAV2/7, 2/8 and 2/9 vectors (Figure 5-5B, C, D and 
E), however, the 2, 4 and 13 week HDL to total lipoprotein ratios do not appear as 
suppressed (relative to 0 and 1 weeks) in these animals (Figure 5-5E). Although no 
amelioration in the hyperlipidaemic phenotype was observed after 13 weeks, the ApoE 
in the plasma o f treated animals appears to counteract the effect of prolonged fat feeding 
or ageing, especially at 2 and 4 weeks.
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Figure 5-4. Total plasma cholesterol levels in ApoE 7 mice treated with ssAAV2/7, 
ssAAV2/8 and ssAAV2/9 vectors expressing human ApoE3
Total plasma cholesterol levels (mmol/L) were determined for individual control 
animals and animals that received intramuscular injections o f  either 
ssAA V2/7. CAGApoES, ssAAV2/8.CAG.ApoE3, or ssAAV2/9.CAG.ApoE3. (A) 
Represents the mean total cholesterol level (mmol/L) o f  all 8 animals in each group at 
each time-point. (B) Represents the total cholesterol levels o f  individual mice (•) in 
each group at 2 and 13 weeks, with the solid line (-) indicating the mean values. Total 
cholesterol vs plasma ApoE3 concentrations over time for individual animals treated 
with ssAA V2/7 (CJ) and E) and ssAA V2/8 (F, G and H)
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Figure 5-5. The lipoprotein profiles of ApoE'A mice following intramuscular 
injections of ssAAV2/7, ssAAV2/8 and ssAAV2/9 vectors expressing human ApoE3
For each group, pooled plasma samples from individual mice at each time-point (0, 1, 
2, 4 and 13 weeks) were subjected to agarose gel electrophoresis and the separated 
lipoproteins stained with Sudan black. Lipoprotein profiles o f  control animals (A), 
ssAAV2/7.CAGApoE3-treated mice (B), ssAAV2/8.CAGApoE3-treated mice (Q  and 
ssAAV2/9.CAGApoE3-treated mice (D). Graphical representation o f the 
HDL: VLDL/IDL/LDL ratio at each time-point, in all groups (E).
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5.3.5 Progression of atherosclerotic plaque area in the brachiocephalic artery of 
ApoE-deficient mice is not inhibited by intramuscular injections of 
ssAAV2/7, ssAAV2/8 and ssAAV2/9 vectors expressing human ApoE3
To investigate the effect o f human ApoE3 gene transfer on atherosclerotic lesion 
development, brachiocephalic arteries were excised from all control and ssAAV2/7, 
ssAAV2/8 and ssAAV2/9-treated ApoE'7' mice. Brachiocephalic arteries were 
embedded in paraffin and sections were cut every 30/xm and mounted onto slides. 
Serial sections were stained with hematoxylin and eosin and Miller’s elastin/van Gieson 
stain (EVG) (see section 2.2.5.4 for details). Elastin-stained sections were visualised 
under a microscope and plaque morphometry was performed with a computerised 
image-analysis program (Image Pro-Plus). The internal and external elasticae 
perimeters were recorded and used to derive the media area, which was assumed to be 
the circumference of a perfect circle. The plaque area was measured and the true lumen 
size was determined by subtracting the plaque area from the area enclosed by the 
internal elastic lamina (see Figure 2-5 for details). Plaques were also inspected for the 
presence o f buried fibrous caps and their lipid content was quantified.
Plaque sizes varied considerably within each group; some brachiocephalic arteries 
contained very large and unstable plaques (Figure 5-9), while others had very small 
lesions (Figure 5-7B) or none at all (Figure 5-7A). All arteries containing plaques had 
undergone expansive remodelling of the arterial wall in an attempt to preserve blood 
flow down the lumen. Unfortunately, 3 o f the 8 brachiocephalic arteries from the 
negative control group and 1 from both the ssAAV2/7 and ssAAV2/8-treated groups 
could not be analysed due to technical problems during processing. Unexpectedly, 2 of 
the 5 elastin-stained sections from the control group were free o f plaques, whereas only 
3 o f the 21 arteries from the treated groups were “clean”. For these reasons and with the 
anticipation that ssAAV2/9-treated animals might exhibit more plaque area due to their 
very low levels of circulating ApoE, comparisons have only been made between the 
three treated groups.
The plaque area did not differ significantly between ssAAV2/7, ssAAV2/8 and 
ssAAV2/9-treated animals (68.9±69.9xl03/mi2, 72.7±41.5xl03/xm2 and 91.5±20.8x 
103^ m 2 respectively) (Figure 5-6A), although it is important to emphasise here that 
there were plaque-free arteries in ssAAV2/7 and ssAAV2/8-injected mice, while this 
was not observed in animals treated with the ssAAV2/9 vector (Table 5-2). Although
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the mean vessel, lumen and media areas appeared to be generally lower in ssAAV2/7- 
treated animals, the differences were not significant (Figure 5-6A). The plaque lipid 
content was also quantified for individual animals in each group (Figure 5-6B). The 
mean percentage in the brachiocephalic arteries of mice treated with ssAAV2/9 was ~ 
50% higher, although this was not statistically significantly different compared with the 
ssAAV2/7- or ssAAV2/8-injected animals (P>0.05).
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Figure 5-6. The brachiocephalic artery morphometry of ApoE"7* mice treated with 
ssAAV2/7, ssAAV2/8 and ssAAV2/9 vectors expressing human ApoE3
Elastin-stained brachiocephalic artery sections were visualised under a microscope and 
plaque morphometry was performed with a computerised image-analysis program 
(Image Pro-Plus). The plaque, vessel, true lumen and media area were determined for 
individual animals and the mean o f each ssAAV2/7, ssAAV2/8 and ssAAV2/9-treated 
group was calculated (A). The plaque lipid content was also quantified for individual 
animals with the average values for each group represented in the graph (B).
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Plaque area (x \0 3p m 2) Plaque lipid content (% )
Animals ssAAV2/7 ssAAV2/8 ssAAV2/9 ssAAV2/7 ssAAV2/8 ssAAV2/9
1 124.3 72.9 101.7 21.5 16.4 29.3
2 90.4 122.5 97.8 35.1 38.8 11.6
3 0 119.4 51.7 0 18.1 29
4 186 71.4 77.3 51.6 16.9 40.4
5 63.9 0 98.8 2.6 0 26.2
6 18 69 115.2 15.4 27.8 41.7
7 0 53.8 98.2 0 17.6 18.3
Average 68.9±69.9 72.7±41.5 91.5±20.8 18.0±19.7 19.4±11.9 28.1±10.9
Table 5-2. Plaque area and lipid content for individual animals in each treated 
group
N.B A 0 was assigned fo r  brachiocephalic arteries without a plaque
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Figure 5-7. EVG stained sections of brachiocephalic arteries (10* magnification)
(A) A 30pm section from a brachiocephalic artery with no visible plaque. The artery 
was excised from a mouse treated with ssAAV2/7.CAG.ApoE3. (B) A 120pm section 
with a small, stable plaque. The artery was from an animal treated with 
ssAA V2/8. CAG.ApoE3.
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Figure 5-8. EVG stained sections of brachiocephalic arteries (10* magnification)
(A) A 120pm section showing an intermediate, stable plaque with small lipid deposits. 
This artery was excised from an animal treated with ssAAV2/9.CAG.ApoE3. (B) A 
120pm section showing an intermediate, unstable plaque with visible buried fibrous 
caps and lipid deposits. The artery was taken from an animal injected with 
ssAA V2/8. CAG.ApoE3.
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Figure 5-9. An EVG stained section (150pm) of a brachiocephalic artery (10x 
magnification) containing a large, unstable plaque.
This artery was excised from an animal treated with ssAAV2/7.CAG.ApoE3. The 
section shows numerous lipid deposits in the plaque area.
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5.4 Discussion
The overall aim of the large-scale in vivo experiment described in this chapter was to 
identify the AAV capsid best suited for gene delivery to skeletal muscle and it was for 
the aforementioned qualities that we selected AAV serotypes 8 and 9. Here we have 
directly compared pseudotyped, CAG-driven ssAAV2/8 and 2/9 vectors with our 
previously tested ssAAV2/7.CAG.ApoE3 vector. The functionality o f each vector was 
first confirmed in vitro, in both HEK 293-T cells and mature, differentiated myotubes. 
Secretion o f human ApoE3 from both cell-types was discovered to be markedly higher 
following infection with ssAAV2/7.CAG.ApoE3 (Figure 5-2). From these results, it 
can be inferred that in vitro gene transfer to muscle cells by AAV7 is more efficient 
than that by AAV8 and AAV9. Currently there are no published reports that have 
carried out the same comparisons in vitro, which could corroborate our findings.
Having verified that all three vectors function efficiently in vitro, we then went on to 
perform a head-to-head comparison o f each vector in vivo, injecting the TA muscle of 
ApoE'7' mice. These mice are a valuable model o f human atherosclerosis. The animals 
become grossly hypercholesterolaemic on normal chow, exhibit spontaneous xanthoma 
formation and develop atheroma in coronary arteries from 2 months [117; 133]. For the 
purpose of this experiment, the mice were fed a high-fat diet which has been shown to 
advance the progression of atherosclerosis by at least 6 weeks with lesions developing 
more rapidly throughout the vascular tree [121]. Our 13 week experiment was designed 
to evaluate the hypolipidaemic effects o f each vector and also their ability to inhibit the 
progression of early atherosclerotic lesion development.
Human ApoE3 was detected in the plasma o f all animals treated with both 
ssAAV2/7.CAG.ApoE3 and ssAAV2/8.CAG.ApoE3 as early as 1 week post-injection 
(Figure 5-3A) and levels were sustained for the entire 13 week period. After the first 
week levels had reached 2pg/ml and above in both groups. However, at 2 weeks the 
level had fallen, possibly suggesting secreted ApoE3 had been sequestered by the 
excess of remnant lipoproteins in the plasma and rapidly cleared by the liver. 
Interestingly, mean circulating concentrations had significantly declined in ssAAV2/7- 
treated animals (1.9±0.56pg/ml to 0.87±0.47pg/ml p <0.005), but the decrease was 
much less in mice that had received ssAAV2/8 injections. This ultimately highlights 
differences in vector efficiency, as ssAAV2/8 must be producing more ApoE3 to
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compensate for its rapid removal. Nevertheless, by 13 weeks, plasma ApoE3 levels had 
declined in ssAAV2/8 animals, whereas in ssAAV2/7-treated mice concentrations had 
augmented compared with the 2 and 4 week time-points (Figure 5-3C). From these 
findings, it could be speculated that both vectors function differently over time; it is 
possible that ssAAV2/8 transduces skeletal muscle more rapidly, while transduction is 
slower with ssAAV2/7, with peak expression occurring later on. Gao et al. have 
previously used AAV7 and AAV8 for skeletal muscle gene transfer and directly 
compared and evaluated their relative performances [191]. Both serotypes were 
discovered to transduce the muscle with a high efficiency, although AAV7 performed 
slightly better and demonstrated efficiencies o f transgene expression equivalent to that 
observed with AAV1. These findings were confirmed in a subsequent study, which 
quantitatively compared the transduction efficiencies of pseudotyped AAV vectors in 
both slow and fast muscle fibres. Here, however, the performance o f AAV2/8 was also 
comparable to that o f AAV2/1 [207].
Unfortunately, plasma ApoE3 levels in mice injected with ssAAV2/9.CAG.ApoE3 were 
very low and fell below the detection limit o f the Western blot. This was disappointing, 
however, as it was predicted that this vector would function relatively well; substantial 
transduction o f AAV9 in skeletal muscle has previously been reported following 
systemic delivery [213]. Nevertheless, our knowledge o f the biology o f AAV9 in vivo 
is currently limited and there are no studies so far that have assessed transgene 
expression following direct injection o f AAV9 into skeletal muscle.
Total plasma cholesterol in ssAAV2/7-, ssAAV2/8- and ssAAV2/9-treated mice was 
not reduced after 13 weeks, despite there being detectable circulating levels o f ApoE3 in 
these animals. Due to the high-fat diet, plasma total cholesterol from both control and 
treated animals significantly augmented between 0 and 2 weeks; this was followed by a 
sharp decline at 4 weeks in all animals apart from those that were treated with 
ssAAV2/7.CAG.ApoE3. In ApoE'/_ mice, ApoBlOO naturally becomes the principle 
ligand mediating hepatic remnant clearance through the LDL-R; as a result plasma from 
these mice normally has only traces o f ApoBlOO-VLDL, but contains very high levels 
o f the binding-defective ApoB48-VLDL [129]. The sudden decrease in total cholesterol 
observed at 4 weeks suggests that alternative mechanisms for the hepatic uptake o f 
remnant lipoproteins were initiated in response to their excessive accumulation in the 
plasma. It has been hypothesised that lipoprotein lipase and hepatic lipase, when
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present on the surface o f VLDL, IDL and LDL, can act as ligands for the LDL-R and 
LRP and, thus, mediate the endocytosis o f these lipoprotein particles [369]. The HDL 
receptor, SR-BI, is also believed to mediate the hepatic removal o f ApoB48-carrying 
lipoproteins in the absence o f ApoE [370]. It is possible that SR-BI binds to anionic 
phospholipids, for which it has high affinity, on the surface o f cholesterol-rich 
lipoproteins. Furthermore, inhibition of SR-BI expression in the liver o f ApoE-deficient 
mice results in accumulation o f remnants in the plasma and this can be reversed by the 
restoration o f hepatic SR-BI [371], Interestingly, chylomicrons and VLDL in the 
plasma o f ApoE'7' are also enriched in ApoAI, which could also mediate their removal 
via the SR-BI receptor [372]. Initiation of such mechanisms, however, might not occur 
when a certain level of ApoE in the plasma is restored; indeed, in wild-type mice 
lipoproteins are readily cleared from the circulation even when their hepatic SR-BI is 
absent [373]. It is also speculated that SR-BI does not bind remnants until their 
concentration in the plasma becomes sufficiently high to efficiently compete with other 
lipoproteins that also bind to this receptor [371]. Two trends were observed in our 
study that are consistent with these reports; high levels o f ApoE3 in ssAAV2/7 and 
ssAAV2/8-treated animals appeared to prevent the decline in total cholesterol at 4 
weeks, and suppress any further increase at 13 weeks, while low circulating 
concentrations resulted in a marked increase in total cholesterol at termination (Figure 
5-4C to H). It is possible to speculate, therefore, that the small amount o f ApoE3 
secreted in the plasma of ssAAV2/7 and ssAAV2/8-treated animals was sufficient to 
inhibit the induction of alternative mechanisms that clear remnant lipoproteins, but 
insufficient to mediate effective clearance via LRP.
In accordance with the observed decrease in total cholesterol at 4 weeks in control, 
ssAAV2/8- and ssAAV2/9-treated mice, there was also a visible reduction in both the 
HDL and VLDL/IDL/LDL fractions (Figure 5-5). By 13 weeks, however, the absolute 
amount of VLDL/IDL/LDL had augmented and reached levels equivalent to that 
observed at 0 and 1 week; thus there was no amelioration in the hyperlipidaemic 
phenotype of treated animals after 13 weeks. Interestingly, the suppression o f the HDL 
to total lipoprotein ratio at 2, 4 and 13 weeks was much less in treated compared with 
control animals (Figure 5-5E). It could therefore, be speculated that the presence o f 
ApoE3 in the plasma counteracted the effect o f prolonged fat feeding or ageing in these 
mice, especially at 2 and 4 weeks post-treatment. The concentration o f ApoE reported 
to normalise plasma cholesterol is 2/xg/ml [96], however, this threshold level was
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derived from a study using mouse and not human ApoE. Mouse ApoE is in fact 6-fold 
more efficient than human ApoE3 in clearing remnant particles and transgenic mice 
expressing the human ApoE isoform in place of the mouse protein are more susceptible 
to diet-induced hypercholesterolaemia and atherosclerosis [137]. Furthermore, in a 
study comparing hypomorphic mice, which express reduced levels o f Arg-61 ApoE (an 
isoform resembling human ApoE4), with ApoE'7' mice expressing similar levels o f Arg- 
61 ApoE after bone marrow transplantation, hepatocyte ApoE was demonstrated to be 
more efficient than extrahepatic ApoE in promoting clearance of remnant lipoproteins 
[374]. Although this contradicts findings by Thomgate et al. whom demonstrated that 
only low levels of ApoE expressed specifically in the adrenal gland o f ApoE-/- was 
sufficient to inhibit atherosclerosis [96]. Nevertheless, the aforementioned factors along 
with increased plasma total cholesterol, induced by a high-fat diet, might explain why 
the circulating ApoE in our treated mice could not prevent the accumulation o f VLDL- 
size lipoproteins o f abnormal conformation and enriched in unesterified cholesterol.
The brachiocephalic artery, which is the first branch from the aortic arch, is a well- 
defined area in which to study plaque stability and rupture. The lesion characteristics in 
this artery o f a fat-fed ApoE 7' mouse are similar to those associated with plaque 
instability in humans and it was for this reason that we selected this site to investigate 
the anti-atherosclerotic effect o f ectopically expressed human ApoE. ApoE'7' mice, 
when fed a high-fat diet for only 8 weeks, exhibit a high frequency o f plaque rupture in 
these arteries and at later times buried fibrous layers within the plaque can be seen, 
which may represent previous healed ruptures [125]. The layered appearance o f the 
brachiocephalic artery plaques has also been observed in human coronary arteries 
[375;376]. Consistent with these reports, our mice, which had also been fed a high-fat 
diet for a short period o f 13 weeks, demonstrated unstable plaques with visible buried 
fibrous caps. Plaque sizes, however, varied considerably within each group; some 
arteries contained very large and unstable plaques, while in others the lesions were very 
small and less developed. Surprisingly, two o f our control animals had arteries that 
were “clean”, the reason for this, however, cannot be explained. Plaque progression in 
the brachiocephalic artery, however, was not attenuated in ssAAV2/7, 2/8 and 2/9- 
treated animals and no significant reductions in lumen and media size were observed. 
An increase in lipid core size has been linked to vulnerability o f human plaques [376], 
which is also true in mouse brachiocephalic arteries; Williams et al. reported ruptured 
plaques to have a much greater lipid content than intact plaques [125]. We, therefore,
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measured the plaque lipid content in our treated animals, and although the lesions from 
mice injected with ssAAV2/9 demonstrated a higher percentage, consistent with their 
lower levels o f plasma ApoE3, the difference was not significant.
Previous deliveries o f ApoE3 by intramuscular plasmid [325] and AAV injection [316] 
have demonstrated reductions in atherosclerotic aortic plaques despite a failure to detect 
ApoE3 in plasma. Given that in this study we have detected circulating levels o f human 
ApoE3, we considered an inhibition in atherosclerotic lesion development highly 
feasible. The failure to observe such inhibition, however, was not due to the AAV 
serotypes used since liver-directed ApoE gene transfer mediated by AAV2/7 and 
AAV2/8 vectors completely prevented atherosclerosis in ApoE deficient mice [318]. 
The method previously used for plaque quantification, en face  lipid staining, could be 
considered as more sensitive, although plaque lipid content in the brachiocephalic artery 
demonstrated a trend towards a reduction in ssAAV2/7- and ssAAV2/8-treated animals. 
It is possible that differences in aortic and brachiocephalic artery plaque development 
could be responsible. In the aortic sinus the lesions remain as fatty streaks for an 
extended period, and it is months before a fibrous cap can be discerned, while lesions 
develop rapidly in the brachiocephalic artery, especially under conditions o f  high-fat 
feeding, when advanced plaques are present after as little as 5 weeks [126]. It is 
conceivable that the small amount o f ectopically expressed ApoE becomes limiting in 
the face o f the challenge o f such rapidly growing lesions in the brachiocephalic artery 
and a much higher level of circulating ApoE is required to inhibit their development. 
Furthermore, ApoE has been shown to inhibit progression, rather than reverse 
established atherosclerotic plaques. Based on these findings, it would be more 
advantageous to carry out the experiment for a longer period without feeding the 
animals a high-fat diet, and in order to reinforce plaque quantification, en-face lipid 
staining o f the aorta should be performed.
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Chapter 6:
General Discussion
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6 GENERAL DISCUSSION
Atherosclerosis, the leading cause of death in industrialised countries, is increasingly 
recognised as an inflammatory disease [2] and has multiple genetic and environmental 
contributions [10]. Atherosclerosis is characterised by the accumulation o f lipids and 
foam cells in the artery wall and the eventual development of a fibrous plaque. ApoE is 
a 34-kDa circulating glycoprotein synthesised in liver and macrophages, which has been 
demonstrated to be highly anti-atherogenic. This is evidently displayed in ApoE- 
deficient mice which develop severe hypercholesterolaemia and atherosclerosis on a 
normal chow diet [117; 118]. ApoE was initially described to play a major role in 
plasma lipoprotein metabolism and cholesterol homeostasis, specifically its ability to 
facilitate the removal o f remnant lipoproteins in the liver. There is now, however, a 
substantial amount o f evidence suggesting that ApoE has anti-atherosclerotic properties 
that are independent of lipid lowering [96;97;147;311]. These include anti-oxidant 
[110], anti-platelet [99] and anti-inflammatory [103-105] actions that are all unrelated to 
lipid transport and metabolism and contribute to the anti-atherogenic effect.
Circulating proteins are attractive targets for genetic manipulation and, unsurprisingly, 
ApoE has emerged as a strong candidate for treating hypercholesterolaemia and 
cardiovascular disease. Indeed, viral ApoE gene transfer studies have shown some 
encouraging results. In particular, liver-directed adenoviral gene transfer of ApoE 
ameliorates hyperlipidaemia and inhibits atherogenesis in ApoE-deficient mice 
[310;312;313;366]. Nevertheless, safety considerations and the option o f repeat 
administrations have prompted renewed interest in alternative vectors, including non- 
viral (plasmid or “naked DNA”) constructs [338] and rAAV [239]. Two studies have 
reported systemic delivery and long-term biological effects o f ApoE following 
intramuscular injection o f plasmid DNA containing the cytomegalovirus (CMV) 
promoter to drive human ApoE expression. One study noted a decrease in plasma 
cholesterol despite very low levels o f plasma ApoE [324], while the other found 
reduced atherosclerotic plaque and xanthoma formation after 9 months [325]. 
Similarly, a rAAV vector derived from serotype-2 inhibited the development o f 
atherosclerosis in ApoE'/_ mice, although their hyperlipidaemia was unchanged [316]. 
These aforementioned studies have all used skeletal muscle as an alternative therapeutic 
target to liver, since it is a stable post-mitotic tissue with little nuclear turnover, which is 
highly vascularised and actively secretory [261;262].
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The main objective o f this study was to assess the potential o f muscle-based expression 
of the human ApoE3 gene for ameliorating hypercholesterolaemia and preventing 
atherosclerosis in the ApoE'7' mouse, by plasmid and AAV-mediated delivery. With the 
aim to improve on previous studies, plasmids were injected via electrotransfer, which is 
a technique that has been demonstrated to significantly enhance uptake o f naked DNA 
by skeletal muscle [336;337]. Furthermore, our plasmids contained muscle-specific 
promoters, which, unlike viral promoters, avoid cellular shutdown by DNA 
methyltransferases and, importantly, prevent transgene expression in antigen-presenting 
cells. Although rAAV vectors derived from serotype-2 have underperformed, 
alternative serotypes are showing great promise and markedly improve transduction 
efficiency in vivo. Here, we have used AAV serotypes 7 [194;207], 8 and 9 [212-215] 
which are all reported to have a high tropism for skeletal muscle. In addition, we also 
constructed scAAV vectors, which obviate the need for viral second-strand DNA 
synthesis and are, therefore, more efficient than the contemporary ssAAV vector 
[285;286]. Hence, it was anticipated that these alterations to plasmid and AAV- 
mediated delivery would improve intramuscular gene transfer of human ApoE3, with 
the ultimate goal to reverse hypercholesterolaemia and protect against atherosclerosis.
6.1 Hyperlipidaemia in ApoE-deflcient mice is not reversed following 
intramuscular electrotransfer of plasmids expressing human 
Apolipoprotein E3
Chapter 3 described the construction and evaluation o f single-stranded and self-
complementary AAV expression plasmids harbouring the human ApoE3 gene, driven 
by the ubiquitous CAG promoter [250] and two muscle-specific promoters, CK6 [257] 
and C512 [258]. Each plasmid construct was first tested in vitro in murine C2C12 
myoblasts and myotubes and then injected via electrotransfer into the T. anterior 
muscles of ApoE'7' mice. I demonstrated that cultured mouse C2C12 muscle cells 
transfected with each expression plasmid efficiently synthesise and secrete recombinant 
human ApoE3, albeit plasmids driven by the muscle-specific promoters failed to 
produce ApoE3 until after 24h, when the myoblasts had differentiated into myotubes. 
This, however, could be explained as, similar to the endogenous muscle creatine kinase 
gene [257;340], both the CK6 and C512 promoters are transcriptionally inactive in 
myoblasts and only become activated when myoblasts commit to terminal 
differentiation into myotubes [258;340]. Significantly, less ApoE3 was secreted from
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cell cultures transfected with muscle-specific promoter-driven plasmids, which clearly 
implied that they were less active than the CAG promoter.
All ssAAV plasmids were then injected with or without electrotransfer into TA muscles 
of ApoE'7' mice. Unfortunately, after 1 week our assay methods did not detect ApoE3 
in plasma o f mice injected with p.CAG.ApoE3 or with the muscle-specific plasmids, 
p.CK6.ApoE3 and p.C512.ApoE3. In agreement, we found no evidence for reduced 
total cholesterol or for normalisation o f the lipoprotein profile in mice 7 days after 
treatment with any o f the ApoE3 expression plasmids. Though disappointing, these 
results were consistent with studies in ApoE'7' mice [325] and Yoshida Wistar rats [341] 
receiving non-electroporated intramuscular injections o f naked plasmids expressing 
human ApoE2 or ApoE3. In both o f these studies, the binding-defective ApoE2, but not 
ApoE3, was detected in plasma, although local expression of recombinant ApoE3 was 
measurable in the muscle. Likewise, we were able to measure local expression of 
human ApoE3 in excised muscles and this was markedly increased (50-fold) by 
electroporation, confirming previous reports that this technique significantly enhances 
plasmid transfer [342]. In agreement with our findings in vitro, the two plasmid vectors 
driven by the C512 and CK6 muscle-specific promoters appeared to produce much less 
ApoE3 protein (~ 0.5/ig per muscle) than the CAG-driven plasmid (6-25/xg).
These first in vivo experiments were conducted over just 1 week and it was, 
subsequently, hypothesised that a longer time period might be required to achieve 
maximum secretion o f the protein from muscle. In chapter 4, we re-assessed 
electrotransfer o f p.CAG.ApoE3 over a one month period; however, despite local 
expression in the muscle, ApoE3 remained undetectable in the plasma o f treated 
animals. Furthermore, a direct comparison o f 1 week muscle lysates, from animals 
previously injected with p.CAG.ApoE3, with the 4 week muscle lysates, clearly 
demonstrated a decline in the levels o f ApoE3, suggesting that there had been plasmid 
loss or possibly silencing o f gene expression. It was therefore concluded that plasmid- 
mediated ApoE3 transfer in skeletal muscle, is not sustainable and active secretion o f 
the expressed protein will not be maintained over a prolonged period.
It was speculated that human ApoE3 secreted into plasma is rapidly cleared by the liver 
due to the excess of remnant lipoproteins in the plasma o f ApoE'7' mice, which has 
previously been suggested following injection o f ApoE3 protein [327;345].
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Alternatively, recombinant ApoE3 could be successfully expressed by muscle, but the 
protein be inefficiently secreted, although this is unlikely as we readily measured 
ApoE3 protein in myotube culture medium following in vitro transfections, while in 
vivo skeletal muscle transduced with an ApoE3-expressing rAd vector secreted ApoE3 
into plasma [312]. Nevertheless, failure to detect circulating levels o f ApoE3 does not 
exclude long-term therapeutic benefits, as previous deliveries o f ApoE3 by 
intramuscular plasmid injection [325] or by a cell-based platform [326] have 
demonstrated reductions in atherosclerotic aortic plaques, without measurable levels of 
ApoE3 in the plasma. However, the aim was to attain full therapeutic levels o f plasma 
ApoE3 in order to achieve a reduction in total cholesterol, hence, we went on to try 
rAAV-mediated ApoE gene transfer.
6.2 Detectable levels of human ApoE3 in the plasma of ApoE'7' mice 
following intramuscular injection of the ssAAV2/7.CAG.ApoE3 
vector
Chapter 4 described the construction, characterisation and the in vitro and in vivo 
evaluation of both ssAAV2/7 and scAAV2/7 vectors expressing human ApoE3. 
Western blot analysis demonstrated secretion o f human ApoE3 into the medium of 
cultured myotubes infected with each viral preparation; thus, their functionality was 
verified. It was also evident from an ELISA that the ssAAV2/7.CAG.ApoE3 vector 
was more efficient in vitro than both ss and scAAV2/7 vectors driven by the muscle- 
specific promoters. This corroborated our previous findings (Chapter 3) for the C512 
and CK6-driven plasmids, both o f which produced markedly less ApoE3 in vitro and in 
vivo.
We next went on to inject the TA muscles o f A poE7* mice with the 
ssAAV2/7.CAG.ApoE3 vector. Fortunately, in distinct contrast to the previous in vivo 
plasmid injections, ApoE3 was readily detected in the plasma as early as one week post­
injection and the level steadily increased over time. This begs the question as to why 
ApoE3 is secreted from skeletal muscle following AAV, but not plasmid-mediated 
delivery? ApoE interacts strongly with glycosaminoglycans (GAGs) in cell-surface 
membranes and extracellular matrix [346], and it is conceivable that a threshold level of 
ApoE3 expression is needed to saturate such binding sites before efficient secretion 
occurs. Nevertheless, we have, ultimately, reinforced evidence showing the high 
tropism of serotype-7 for skeletal muscle, since an earlier study failed to detect ApoE3
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in the plasma o f ApoE'7' mice that had received i.m. injections o f a rAAV serotype-2 
vector [316]. Unfortunately, we did not observe a hypocholesterolaemic effect in our 
treated animals since the concentrations o f circulating ApoE3 attained were just below 
the reported threshold level required to normalise plasma cholesterol. Nevertheless, our 
finding that skeletal muscle injected with ssAAV2/7.CAG.ApoE3 can secrete pg/ml 
quantities o f ApoE3 is very encouraging and offers hope that an optimised rAAV vector 
will reverse hyperlipidaemia.
Chapter 4 also describes a direct comparison of the ssAAV2/7.CAG.ApoE3 vector with 
the CK6-driven scAAV2/7 vector in ApoE*A mice. As before, mice that received 
intramuscular injections o f ssAAV2/7.CAG.ApoE3 demonstrated detectable plasma 
ApoE3 levels, which were sustained in the plasma for 27 weeks. Levels, however, had 
declined slightly, suggesting that there may have been a humoral immune response 
directed against either the vector or the transgene. Unfortunately, we failed to detect 
ApoE3 in the plasma o f scAAV2/7.CK6.ApoE3-treated animals and expression in 
muscle was very low. We were able to confirm that this observed vector inefficiency 
was not due to the scAAV vector but a result o f the weak activity o f the muscle-specific 
promoter, since both the ssAAV2/7.CK6.ApoE3 and scAAV2/7.C512.ApoE3 vectors 
equally failed to produce ApoE3 in vivo.
6.3 The transduction efficiencies of the ssAAV2/7 and ssAAV2/8 
vectors in skeletal muscle show different patterns over time.
Chapter 5 describes a large-scale in vivo experiment directly comparing pseudotyped,
C AG-driven ssAAV2/8 and 2/9 vectors with our previously tested 
ssAAV2/7.CAG.ApoE3 vector. The functionality o f each vector was first confirmed in 
vitro, in both HEK 293-T cells and mature, differentiated myotubes. Secretion o f 
human ApoE3 from both cell-types was discovered to be markedly higher following 
infection with ssAAV2/7.CAG.ApoE3. It was therefore inferred that in vitro gene 
transfer to muscle cells by AAV7 is more efficient than that by AAV8 and AAV9.
In vivo human ApoE3 was detected in the plasma o f animals treated with each ssAAV 
vector, however, significantly lower levels were exhibited in ssAAV2/9.CAG.ApoE3- 
treated mice. In animals injected with ssAAV2/7.CAG.ApoE3 and 
ssAAV2/8.CAG.ApoE3, circulating ApoE3 was detected as early as 1 week and was 
sustained for the entire 13 week period. By 2 weeks, levels had markedly declined in
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ssAAV2/7-treated mice, which was most likely due to ApoE3 being sequestered by the 
excess o f remnant lipoproteins in the plasma and rapidly cleared by the liver. By 
contrast, the ssAAV2/8 vector appeared to be functioning much more efficiently at this 
early time-point as high ApoE3 levels were sustained, thus counteracting its rapid 
removal. The ssAAV2/7 vector, however, outperformed ssAAV2/8 at the later 13 week 
time-point; it was, therefore, speculated that transduction of the former vector in skeletal 
muscle is much slower.
Total plasma cholesterol and the atherosclerotic VLDL/IDL/LDL lipoproteins in 
ssAAV2/7-, ssAAV2/8- and ssAAV2/9-treated mice were not reduced after 13 weeks, 
despite there being detectable circulating levels o f ApoE3 in these animals. A sharp 
decline in total cholesterol was observed at 4 weeks in the control and ssAAV2/8 and 
ssAAV2/9-treated animals, which suggests that alternative mechanisms for the hepatic 
uptake o f remnant lipoproteins were initiated in response to their excessive 
accumulation in the plasma. However, when plasma ApoE3 levels in ssAAV2/7 and 
ssAAV2/8 animals were high, this decrease was prevented and total cholesterol 
appeared to either plateau or decline at 13 weeks. By contrast, low ApoE3 resulted in a 
marked increase in total cholesterol at termination. Although the small amount of 
ApoE3 secreted into the plasma o f ssAAV2/7- and ssAAV2/8-treated animals was 
sufficient to inhibit the induction o f SR-B1-mediated removal o f remnant lipoproteins, 
it was insufficient to mediate effective clearance via LRP.
Plaque progression in the brachiocephalic artery was not attenuated in ssAAV2/7, 2/8 
and 2/9-treated animals and no significant reductions in lumen and media size were 
observed. It was speculated that the rapid development o f lesions in the brachiocephalic 
artery, under conditions of high-fat feeding, might be responsible for this outcome. 
ApoE has been shown to inhibit progression, rather than reverse established 
atherosclerotic plaques; therefore, it is conceivable that the small amount o f ectopically 
expressed ApoE is overwhelmed by the challenge o f such rapidly growing lesions.
6.4 Conclusions and future considerations
In summary, we have shown that plasmid-mediated ApoE3 gene transfer in skeletal 
muscle of ApoE7' mice is not sustainable and active secretion of the expressed protein is 
unlikely to be maintained over a prolonged period. We concluded that a more efficient 
delivery vehicle is needed to exploit the benefits o f ApoE3 gene therapeutics fully and
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that although non-viral gene therapy has made substantial progress it still struggles to 
mimic the efficiency o f recombinant viruses. We, therefore, went on to investigate 
rAAV-mediated ApoE3 gene transfer and found that by utilising serotypes with a high 
tropism for skeletal muscle (AAV7 and AAV8), we could enhance transduction 
efficiency and obtain measurable circulating levels. The concentration attained in the 
plasma, however, was not sufficient to ameliorate hypercholesterolaemia, thus we have 
clearly demonstrated that more than 2pg/ml of human ApoE3 is required to reduce total 
cholesterol. Plaque quantification by aortic en face  lipid staining has previously shown 
that very low amounts o f circulating ApoE can inhibit atherosclerotic lesion 
development. In our study, despite, observing higher plasma levels, we failed to see the 
same effect in the brachiocephalic artery. It could be speculated that lesion 
quantifiation in the brachiocephalic artery is less sensitive, however, plaque lipid 
content at this atherosclerotic site demonstrated a trend towards a reduction in 
ssAAV2/7- and ssAAV2/8-treated animals Our findings are somewhat negative in 
terms o f treating hyperlipidaemia and atherosclerosis, however for the first time we 
have reported pg levels o f circulating human ApoE3 following intramuscular injection 
of rAAV. This has given us the confidence that a further optimised AAV vector for 
muscle-based delivery would undoubtedly have long-term therapeutic effects.
There are several aspects o f this current study that could be changed which may 
improve the results o f future studies and there are ways in which the AAV vector itself 
could be modified to enhance ApoE3 gene transfer to the skeletal muscle. It is perhaps 
unadvisable to use ApoE'A mice that have been fed a high-fat diet for only a short period 
before the start of the experiment, since this clearly masked the effects o f plasma 
ApoE3 during the early stages o f treatment. Rapid development o f lesions in the 
brachiocephalic artery is also a consequence o f this diet, thus we were unlikely to see an 
effect with low levels of circulating ApoE3. Ideally, we would carry out the experiment 
for a longer period, thus a high-fat diet would not be required. Although we must bear 
in mind that towards the end o f the 13 week in vivo experiment plasma ApoE3 in 
ssAAV2/8-treated animals had significantly declined, suggesting that there may have 
been a humoral immune response directed against either the vector or the transgene. 
This could have been assessed by screening the plasma for antibodies against human 
ApoE and rAAV capsid proteins, and in future studies this should be a routine 
procedure. The possibility o f an immune response ultimately highlights the importance 
o f using muscle-specific promoters; sustained transgene expression may have been
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achieved with our CK6 and C512-driven AAV vectors, had they proven to be more 
active in our preliminary in vivo experiments. Fortunately, novel, muscle-specific 
promoters with improved transduction efficiencies have recently been developed; these 
include the muscle creatine kinase/SV40 hybrid promoter which is reported to yield 
enhanced and long-term transgene expression [256], while a MHCK7 (oc-myosin heavy- 
chain enhancer, creatine kinase 7) promoter was shown to direct high-level expression 
comparable to CMV and RSV (Rous sarcoma virus) promoters [364].
Another means by which we could improve ApoE expression in the skeletal muscle is 
by using the full-length human ApoE gene (5.8-kb, including 5’- and 3’-flanking 
regions) or a mini-gene in which introns 2 and 3 are deleted (3.4-kb); genomic-based 
transgenes are substantially more effective than cDNA-based vectors [377]. 
Unfortunately, in this study we were unable to take full advantage of the scAAV vector, 
due to the inefficiencies o f our muscle-specific promoters. However, the new AAV 
serotypes 7 and 8 and a scAAV vector driven by either MHCK7 or MCK/SV40 appears 
an optimum combination to achieve sustained therapeutic levels of ApoE.
The general safety issues associated with other viral vectors, e.g. rAd, have driven our 
group and others to use rAAV as an alternative. This viral vector has emerged as an 
attractive candidate for gene transfer; firstly, because it does not appear to cause any 
human disease and, secondly, because it remains quiescent in the absence o f helper 
virus. AAV is, thus, considered a safe and stable gene transfer vehicle and for these 
reasons continues to attract considerable interest. Our choice o f using skeletal muscle 
as a platform for ApoE gene transfer is, however, more questionable since ApoE is 
naturally synthesised and secreted by the liver. Indeed, the majority o f ApoE gene 
therapy studies have targeted the liver (Table 1-2). Nevertheless, there is clear evidence 
for the ability of muscle to secrete recombinant therapeutic proteins and this fully 
justifies the long-term goal o f the current investigation: a single intramuscular injection 
as a safe, non-invasive and effective gene therapy protocol to supply atheroprotective 
plasma ApoE. Indirect support includes the efficient secretion o f FIX [266], IL-12 
[297], TIMP-4 [298], and IL-IRa [299] proteins to therapeutic plasma levels, in some 
cases sustained for weeks, following either viral vector delivery to muscle or 
electrotransfer-mediated plasmid injections. There is also direct support that muscle is 
able to secrete ApoE, since injection o f a rAd vector into the skeletal muscle o f ApoE'7' 
mice produced measurable levels o f human ApoE3 in the plasma [312].
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Emerging evidence also suggests that ectopic expression o f ApoE via the skeletal 
muscle is a safer option than liver-directed gene transfer. Muscle represents a non- 
invasive route for vector delivery, with only a single injection needed, and 
chromosomal integration o f rAAV has not been detected following transduction o f 
muscle, albeit only one study has yet assessed this possibility [181]. By contrast, in 
liver rAAV integration has been reported with a preference for transcriptionally active 
genes, although this occurs at a low frequency compared with episomal retention [180]. 
On the other hand, the sustained systemic expression of several therapeutic proteins 
after intramuscular administration o f rAAV, has been limited by a neutralising antibody 
response. Examples include FIX [368], ai-antitrypsin [378] and erythropoietin [347] 
and these responses were typically observed if  a neo-antigen was expressed, such as a 
human protein in a mouse or a species-specific transgene product harbouring a 
mutation.
Further investigation revealed the generation o f a local inflammatory immune response 
in AAV transduced muscle fibre. The response was specific to the transgene product 
and characterised by the activation o f transgene-specific T-helper cells in the draining 
lymph nodes of the muscle. This was followed by an inflammatory immune response 
and clearance o f transgene-expressing muscle fibres by CD8+ T-cells [243]. More 
importantly, the inflammatory response was discovered to be vector dose-specific, 
which is consistent with a previous study in haemophilia dogs that suggested T- and B- 
cell activation at high levels o f local FIX production in skeletal muscle [379]. This 
highlights the necessity for highly-efficient AAV vectors that produce adequate levels 
of secreted protein, as these abrogate the need for high vector doses. Notwithstanding, 
very high levels o f systemic FIX transgene expression achieved by intramuscular 
injection o f high-dose AAV1 vector is reported not to cause an immune response 
[205;380]. As with the liver, which promotes tolerance induction and sustained 
systemic transgene expression, it is possible that tolerogenic antigen presentation at 
sites outside the transduced muscle could be a factor for the observed stable expression.
A recent report has shown that hepatic AAV-mediated gene transfer in humans induces 
a CD8+ T cell immune response directed against the AAV capsid, which is not observed 
in animals [381]. Capsid-derived peptides are presented by MHC class I molecules that 
then become targets for lysis by AAV capsid-specific CD8+ T cells. Fortunately, the
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muscle expresses only discreet levels o f MHC class I molecules, while in the liver they 
are highly expressed, suggesting that AAV-mediated delivery to liver will be more toxic 
than to muscle. It may, however, be viewed that the benefits attained from the higher 
efficacy following AAV administration to the liver outweighs the disadvantage o f 
increased toxicity. If the same efficiency could be achieved via the muscle, then the 
risks associated with the liver would appear higher and this would allow us to 
confidently advocate the muscle as a safer tissue to target for gene therapy.
Although the effectiveness o f AAV vectors for muscle-based ApoE gene transfer can 
undoubtedly be improved, as I have discussed above, the results from liver-directed 
administration are most promising and encouraging; recent reports demonstrate 
sustained therapeutic levels o f ApoE3 in plasma, which normalised the lipoprotein 
profile in ApoE'7’ mice and completely prevented atherosclerosis after one year [318]. 
Alternative animal models, other than the ApoE'7' mouse, however are required to assess 
whether ApoE gene augmentation can be a generic treatment for hyperlipidaemia and 
atherosclerosis. Such models might include the LDLR'7' mouse, fat-fed hamsters or the 
Watanabe heritable-hyperlipidaemic rabbit, all o f which could help evaluate treatment 
regimes. In some cases, for example, only low but sustained levels o f plasma ApoE3 
may be required in patients at an early age to protect against atherosclerosis and reverse 
hypercholesterolaemia, while high levels are possibly needed to regress established 
lesions. ApoE3 gene transfer might also be used as a short-term treatment to 
complement surgical procedures, such as coronary angioplasty for preventing restenosis 
and carotid endarterectomy for removing harmful plaque. A relatively narrow 
therapeutic range of plasma ApoE3, however, is required to achieve normolipidaemia, 
since very low levels will fail to ameliorate hyperlipidaemia, but supraphysiological 
concentrations promote hypertriglyceridaemia [152]. Ultimately, further research is 
needed to obtain optimal vectors for ApoE delivery, whether intramuscular or liver- 
targeted; however, in terms o f bringing ApoE gene therapeutics into the clinic, we are 
now closer than ever.
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